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Advancements in medicine and technology have led to an increasing number of cancer survivors.  
The development of a second primary cancer is one of the most severe sequelae of a cancer diagnosis, 
particularly for cancers that lack an effective screening tool as with ovarian cancer.  Breast and ovarian 
cancer are major causes of morbidity and mortality in women; in the U.S., breast cancer has the highest 
incidence in women and ovarian cancer is the most fatal of gynecological cancers.  Further, these two 
cancers have been found to co-occur.  Along with possible treatment effects of the first cancer, shared 
risk factors, shared genetics, and interactions between these two have been hypothesized to contribute to 
their co-occurrence.  Research on shared risk factors for second cancers is lacking and being able to 
identify potentially modifiable factors associated with second primary cancer could improve clinical 
recommendations for cancer survivors.  Therefore, this dissertation examined risk factors for the 
development of double primary breast and ovarian cancer (DPBOC) in three parts 1) a comprehensive 
review of the literature to identify studies assessing risk factors for DPBOC, 2) a case-control study 
assessing the association between three potentially-modifiable risk factors (oral contraceptive (OC) use, 
parity, and breastfeeding), and risk of second primary ovarian cancer following breast cancer (BR-OV), 
second primary breast cancer following ovarian cancer (OV-BR), single primary ovarian cancer (OV), and 
single primary breast cancer (BR), and 3) a cohort study assessing OC use, parity, and breastfeeding and 
risk of BR-OV, OV, and BR. 
The comprehensive review identified few studies assessing epidemiologic risk factors for the 
development of DPBOC and most of the findings were not statistically significant.  The majority of studies 
focused on treatment of breast cancer and risk of second primary ovarian cancer.  While most of the 
findings on chemotherapy, radiotherapy, and Tamoxifen were heterogeneous and lacked statistical 
significance, hormone therapy for breast cancer may be associated with an increased risk of second 
primary ovarian cancer.  The majority of studies on genetic risk factors for DPBOC looked at BRCA1/2 
 
 
mutations or a crude measure of family history.  Both BRCA1/2 and family history were consistently 
associated with risk of DPBOC, but studies varied on the extent of this risk due to differences in study 
design, exposure and outcome definition, and statistical power.  No studies were identified examining 
DNA methylation and risk of DPBOC. 
The case-control study used data from the three clinic-based sites of the Breast Cancer Family 
Registry (BCFR) which consisted of women from breast and ovarian cancer families.  We observed an 
inverse association with both OC use (OR=0.38, 95% CI: 0.22, 0.60) and breastfeeding (OR=0.52, 95% 
CI: 0.31, 0.87) and risk of DPBOC, but a positive association with parity (≥2 full-term pregnancies: 
OR=5.78, 95% CI: 2.82, 14.58), regardless of diagnosis order (BR-OV or OV-BR).  We found similar 
associations for our OV and BR outcomes as well.  When we examined differences between high and 
average risk women (using BRCA1/2 mutation status and predicted lifetime risk of breast or ovarian 
cancer), the inverse association with OC use only remained in women at average risk while the inverse 
association with breastfeeding only remained in women at high risk.  As the positive association with 
parity and all of our outcomes disagreed with our hypothesis we conducted several sensitivity analyses to 
explore this finding.  Survivor bias may have influenced our results as we observed differences in our 
findings between cases diagnosed ≤2 or ≤5 years before the baseline interview (pseudo-incident) and 
cases diagnosed >2 or >5 years before the baseline interview (prevalent).  Specifically, the inverse 
association with OC use and all of our outcomes, and the positive association with parity and all of our 
outcomes were attenuated in the pseudo-incident group. 
To address concerns of selection and information bias in our case-control study, we conducted a 
cohort study using data from The Breast Cancer Prospective Family Study Cohort (ProF-SC).  In contrast 
to our case-control findings, we observed a suggestive positive association between OC use and risk of 
BR-OV (HR=1.62, 95% CI: 0.91, 2.90) which became stronger in women at high risk, and an inverse 
association between having two or more full-term pregnancies compared to nulliparous and risk of BR-OV 
(HR=0.47, 95% CI: 0.22, 0.97) which did not vary by underlying risk of breast and ovarian cancer.  
However, our BR-OV results may have similarly been influenced by survivor bias as we observed 
 
 
differences in our results between our pseudo-incident and prevalent BR-OV cases; the association 
between OC use and BR-OV only remained in the prevalent cases. 
In summary, the results of this dissertation highlight the methodological challenges in the study of 
second primary cancers and the importance of considering survivor bias in a cohort of cancer survivors 
being followed for second cancers.  Further, our results are suggestive of a discordant effect of OC use 
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Chapter 1. Introduction 
 
1.1. Breast and Ovarian Cancer Burden 
In the U.S. it is estimated that 246,660 women will be diagnosed with breast cancer and 22,280 
women will be diagnosed with ovarian cancer in 2016.  The relative 5-year survival of breast cancer is 
98.4%, 83.9%, and 23.8% when diagnosed localized, regional, and after metastasis, respectively; the 
corresponding relative 5-year survival for ovarian cancer is 92.1%, 73.1%, and 28.8% [1,2].  In contrast to 
established population-based screening methods for breast cancer, there are currently no effective 
population-based screening methods for ovarian cancer [3]; thus the majority of breast cancers (93%) are 
diagnosed localized or regional where survival is high [1], whereas the majority of ovarian cancers (>60%) 
are diagnosed after metastasis when survival is low and treatments are not effective [1,2]. 
1.2. Subtypes of Breast and Ovarian Cancer 
Breast cancer is a heterogeneous disease defined by multiple characteristics, including 
histological (Table 1.1) and molecular (Table 1.2) subtypes, and research has revealed many differences 
between these tumor subtypes, including etiology, incidence, and survival [4-10].  Ductal carcinoma is the 
most common histologic subtype ranging from 68 to 74% of all invasive breast cancers.  For the 
molecular subtypes, Luminal A tumors tend to be slower-growing and have better survival which is in part 
due to the hormone receptors being responsive to hormone therapy.  Compared to Luminal A tumors, 
Luminal B tumors are typically higher grade and more aggressive.  Her2+ tumors tend to be more 
aggressive as well but targeted therapies have improved the prognosis for women with this breast cancer 
subtype.  Lastly, triple negative tumors are commonly found in pre-menopausal women and women with 










Table 1.1. Histological subtypes of 
breast cancer [11‐13] 
Subtype Percent of invasive 











Table 1.2. Molecular subtypes of breast cancer [7,9,10] 
Subtype Percent of invasive breast 
cancer cases 
Luminal A (ER and/or PR+, HER2-) 51-73% 
Luminal B (ER and/or PR+, HER2+) 6-16% 
HER2+ (ER-, PR-, HER2+) 5-8% 
Triple Negative (ER-, PR-, HER2-) 12-20% 
 
Ovarian cancer is also a heterogeneous disease characterized by histologic and molecular 
characteristics.  There are three main categories of ovarian cancer based on where the tumors originated: 
surface epithelial-stromal tumors, sex cord-stromal tumors, and germ cell tumors.  Epithelial ovarian 
cancer is the most common histology accounting for approximately 90% of all malignant ovarian cancers 
[14].  Within invasive epithelial ovarian cancers, serous is the most common subtype (Table 1.3).  Ovarian 
tumors have further been classified into two main types based on their histology, clinicopathologic 
features, and genetics.  Type 1 ovarian tumors include low-grade serous carcinomas, borderline serous 
tumors, low-grade endometriod, and mucinous and clear-cell carcinomas, and account for 25% of ovarian 
cancers and 10% of ovarian cancer deaths.  Type 2 ovarian tumors include high-grade serous 
carcinomas, carcinosarcomas, and undifferentiated cancers, and account for 75% of ovarian cancer and 
90% of ovarian cancer deaths [15,16] (discussed further in section 1.7).  Type 1 tumors are thought to 
originate from borderline tumors and endometriosis, while Type 2 tumors are thought to originate from 
intraepithelial carcinomas in the fallopian tube [16].  Work by The Cancer Genome Atlas (TCGA) has 
identified molecular commonalities between serous ovarian cancer and basal-like breast cancer which is 




Table 1.3. Histological subtypes of 
ovarian cancer [17‐20] 










1.3. Breast and Ovarian Cancer in High Risk Families 
The National Comprehensive Cancer Network (NCCN) uses the same criteria to identify women 
at high risk of breast and ovarian cancer: 1) known family mutation in breast cancer susceptibility genes, 
2) ≥2 primary breast cancers in the same individual, 3) ≥2 primary breast cancers in individuals from the 
same family line, 4) ≥1 primary ovarian cancer in individual(s) from the same family line, 5) first or second 
degree relative with breast cancer ≤45 years, 6) ≥1 family member from the same family line with ≥1 
breast cancer and ≥1 other cancer with an early onset, and 7) male breast cancer [21].  Although familial 
cancers make up a small percent of all breast (5%) [22] and ovarian (5-10%) [23] cases, women with a 
mutation in BRCA1/2 and women with a family history of the disease are at a much greater risk than the 
general population.  However, most women with a family history of breast or ovarian cancer do not carry 
mutations in BRCA1/2 (approximately 75% for breast [24-26] and 56% for ovarian [27]); women with a 
family history alone confer a much higher risk of breast and ovarian cancer than the general population 
[24,28].  For breast cancer, having one affected first degree relative increases a woman’s risk two-fold 
and having three or more affected first degree relatives increases a woman’s risk four-fold [29].  For 
ovarian cancer, having one affected first degree relative increases a woman’s risk three-fold and having 
multiple affected relatives (first or second degree) increases a woman’s risk up to eleven-fold [30].  Since 
the majority of breast and ovarian cancers that occur in high risk families are not due to mutations in 




1.4. Screening for Breast and Ovarian Cancer 
Breast and ovarian cancer have asymptomatic phases when screening tools would be beneficial 
in detecting early stage cancer that could be more successfully treated.  Mammography has been an 
established screening tool for breast cancer with many randomized controlled trials (RCTs) showing a 
survival benefit.  A meta-analysis was conducted of 8 RCTs and summarized the findings for breast 
cancer mortality by age group [31].  For women aged 39-49 years there was a non-statistically significant 
12% reduced risk of breast cancer mortality (RR=0.88, 95% CI: 0.73, 1.003) which corresponds to 4 
deaths prevented per 10,000 women over 10 years.  For women aged 50-59 years there was a 
statistically significant 14% reduced risk of breast cancer mortality (RR=0.86, 95% CI: 0.68, 0.97) which 
corresponds to 5 to 8 deaths prevented per 10,000 women over 10 years.  For women aged 60-69 years 
there was a statistically significant 33% reduced risk of breast cancer mortality (RR=0.67, 95% CI: 0.54, 
0.83) which corresponds to 12 to 21 deaths prevented per 10,000 women over 10 years.  For women 
aged 70-74 years, results were not statistically significant but the sample size was limited by low events.  
While mammography is generally accepted as a beneficial screening tool for breast cancer, many 
aspects of it are still being debated, such as optimal ages to begin and end screening, optimal screening 
interval, balancing the benefits with potential harms of screening, and how these factors are considered 
based on individual risk [31].   
There is currently no established screening tool for ovarian cancer.  The Prostate, Lung, 
Colorectal and Ovarian (PLCO) cancer screening trial was established to evaluate potential screening 
tools for these four cancers.  For ovarian cancer, the PLCO trial evaluated the efficacy of transvaginal 
ultrasound and serum cancer antigen 125 (CA-125) as screening tools to reduce ovarian cancer mortality.  
They found no reduction in ovarian cancer mortality in the screening group receiving transvaginal 
ultrasound and CA-125 testing compared to the usual care group (RR=1.21, 95% CI: 0.99, 1.48) [3].  In 
contrast, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), found statistically 
significant reduced ovarian cancer mortality in years 7 to 14 in women screened annually with CA-125 
compared to no screening when they excluded prevalent cases using the risk of ovarian cancer algorithm 
(ROCA) which considers both past and current CA-125 levels [32].  However, investigators re-examined 
data from the PLCO trial using ROCA, and still observed no reduction in ovarian cancer mortality in the 
screening group [33].  Given these contradictory results, continued follow-up and replication will be 
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Figure 1.1. Cumulative incidence of developing 
a second cancer among women with a prior 
breast cancer diagnosis, SEER 1973-2000 [42] 
needed to establish the efficacy and cost-effectiveness of CA-125 as a universal screening tool for 
ovarian cancer.  As ovarian cancer is asymptomatic until late stages when treatment is less effective and 
mortality is high, establishing an effective screening tool is critical.  
1.5. Double Primary Breast and Ovarian Cancer 
Women who have breast cancer have an increased risk of developing ovarian cancer [34-39] and 
women with ovarian cancer have an increased risk of developing breast cancer [40,41].  Using SEER 
data for the time period 1973 to 2000, Curtis et 
al. report that the cumulative incidence of 
developing any second cancer after breast 
cancer was 17.6% within 25 years.  The most 
common second cancer reported was a second 
primary breast cancer, followed by colon 
cancer, uterine cancer and ovarian cancer 
(Figure 1.1).  Overall, the estimated relative risk 
of ovarian cancer in women with a prior breast 
cancer diagnosis was 1.27 (observed/expected 
(O/E), p<0.05) [42].  However, other studies 
have shown that women with breast cancer have an approximate two-fold increased risk of developing 
ovarian cancer [34,35,39,43].  Further, in women diagnosed with breast cancer at a young age, this risk 
increases to more than 5-fold if they have a family history of breast cancer and 17-fold if they have a 
family history of ovarian cancer [34].  Also using SEER data for the same time period, Freedman and 
colleagues report that the cumulative incidence of developing any second cancer after ovarian cancer 
was 9.4% within 25 years.  Second primary cancers following ovarian cancer included acute leukemia, 
breast cancer, colon cancer and bladder cancer.  Overall, the estimated relative risk of breast cancer in 
women with a prior ovarian cancer diagnosis was 1.09 (O/E, p<0.05) [44].  However, a study by van 
Niekerk et al. in the Netherlands observed a greater than two-fold increased risk of developing breast 
cancer within the same year of an ovarian cancer diagnosis [41].  Further research is needed to clarify the 
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etiology of double primary breast and ovarian cancer (DPBOC) which may include shared risk factors, 
genetics, and epigenetics. 
1.6. Shared Risk Factors for Breast and Ovarian Cancers 
A number of established and suspected risk factors are similar for both breast and ovarian cancer 
and include advanced age, reproductive factors, family history, and height (reviewed in [45]); the majority 
are non-modifiable.  This dissertation evaluated three potentially modifiable shared risk factors: OC use, 
parity, and breastfeeding (Tables 1.4 and 1.5).  One of the few modifiable preventive options for ovarian 
cancer is oral contraceptive (OC) use; a 50% lower ovarian cancer risk has been observed in women who 
use OCs for 10 years or more [46].  Further, this protective effect of OC use has been observed in high 
risk women with a BRCA1/2 mutation  [47].  However, OC use has been suspected to increase breast 
cancer risk [48], although results have been inconsistent [47].  Given these potential discordant effects of 
OC use on breast and ovarian cancer, research is needed to support clinical recommendations for 
women from cancer families who are at an increased risk of developing both cancers.  
Table 1.4. Reproductive and Hormonal Risk Factors for Breast and Ovarian Cancer in the 
General Population 
Risk Factor Breast Ovarian Comments/Reference 
Parity ↓↑ ↓ 
A lower risk of breast cancer after the age of 40 years has been 
observed for parous women with increasing protection for 
additional full-term pregnancies; however, a greater risk of very 
early-onset breast cancer has been observed for parous women 
compared to nulliparous (reviewed in [45,49,50]). A decreased 
risk of ovarian cancer has been observed for parous women 
compared to nulliparous and with each additional full-term 
pregnancy (reviewed in [45,46]). 
Later age at 
first birth ↑ ↓↑ Ø 
A greater risk of breast cancer has been observed for later age at 
first parity and may be stronger for pre-menopausal breast cancer 
compared to post-menopausal [45,49]. The association between 
age at first parity and ovarian cancer is less clear with studies 
showing positive, inverse, and null associations [45,46]. 
Later age at 
last birth ↑ Ø ↓ 
Most studies have reported a positive association between later 
age at last parity and breast cancer, while one found no 
association [49]. An inverse association has been observed 
between later age at last parity and ovarian cancer [51-54]. 
Breastfeeding ↓ ↓ Ø 
An inverse association between breastfeeding and risk of breast 
cancer has been observed with a decreasing trend for increasing 
duration (reviewed in [45,49]). A lower risk of ovarian cancer has 
been observed for women who ever breastfed vs. never 
breastfed, although some literature shows no association 
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(reviewed in [45,46]).  
Earlier age at 
menarche ↑ ↑ Ø 
Early age at menarche is associated with a greater risk of breast 
cancer [45,49]. While many studies have observed a modest 
increased risk of ovarian cancer with an earlier age at menarche, 
several studies have also reported a null association [45,46]. 
Later age at 
menopause ↑ ↑ Ø 
Later age at menopause is associated with a greater risk of 
breast cancer [45,49]. While many studies have observed a 
greater risk of ovarian cancer with later age at menopause, 
several studies have also reported a null association [45,46]. 
OC use ↑ ↓ 
OC use has been associated with a greater risk of breast cancer; 
however this association is more prominent in younger women 
(25-34 years) and lasts for 10 years after stopping use. A lower 
risk of ovarian cancer has been observed with OC use and this 
protection lasts up to 20 years after stopping use (reviewed in 
[45]). 
HRT use ↑ ↑ Ø 
There is a positive association between HRT use and breast 
cancer [45]. While many studies have observed a greater risk of 
ovarian cancer with HRT use, several studies have also reported 
a null association [45,46]. 
 
Table 1.5. Reproductive and Hormonal Risk Factors for Breast and Ovarian Cancer in BRCA1/2 
Mutation Carriers 
Risk Factor Breast Ovarian Comments/Reference 
Parity ↓↑ Ø ↓↑ Ø 
There have been mixed results for the effect of parity on 
breast and ovarian cancer in high risk women. For breast 
cancer, some studies have observed no association in 
BRCA1 carriers and a positive association in BRCA2 carriers 
(reviewed in [50]). For ovarian cancer, some studies have 
reported no association with ovarian cancer [55], while others 
have reported either positive associations [56-58] or inverse 
associations [57,59,60]. 
Later age at 
first birth ↑Ø ↓ 
Studies have reported no association [61,62] or a positive 
association [63,64] between later age at first parity and 
breast cancer; whereas an inverse association has been 
reported with ovarian cancer [58,62]. Type of mutation 
(BRCA1 vs. BRCA2) may modify the results. 
Later age at 
last birth - - 
No studies were found assessing age at last birth and breast 
and ovarian cancer in BRCA1/2 carriers. 
 
Breastfeeding ↓ Ø ↓ Ø 
A lower risk of breast cancer has been observed with 
breastfeeding for BRCA1 carriers, but not BRCA2 carriers 
(reviewed in [50]). Similarly, a lower risk of ovarian cancer 
has been observed for BRCA1 carriers, but not BRCA2 
carriers [57]; however others have observed no association 
with BRCA1/2 carriers [56]. 
Earlier age at 
menarche ↑Ø ↑ 
Earlier age at menarche has been shown to have a positive 
association (reviewed in [50]) [55] and null association with 
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breast cancer [65]. There has been a suggestion of a greater 
risk of ovarian cancer with an earlier age at menarche [55]. 
Later age at 
menopause Ø ↑ 
No association has been observed between age at 
menopause and breast cancer in BRCA1/2 carriers [65]. One 
study observed a positive association between later age at 
menopause and ovarian cancer in BRCA1/2 carriers [66].  
OC use Ø ↑ ↓ 
Case-control studies have showed no association between 
OC use and breast cancer risk in BRCA1/2 carriers; however 
cohort studies have suggested a positive association in 
BRCA1 carriers [47]. A reduced risk of ovarian cancer has 
been observed in BRCA1/2 carriers [47].  
HRT use Ø Ø 
One study observed no association between HRT use and 
breast cancer in BRCA1 mutation carriers [67]. Similarly, one 
study observed no association between HRT use and ovarian 
cancer in BRCA1/2 mutation carriers [68]. 
 
1.7. Genes and Breast and Ovarian Cancers 
Many breast and ovarian cancer susceptibility genes have been identified in the literature.  Table 
1.6 lists the established breast cancer susceptibility genes with high, moderate, and low-penetrance [69] 
and Table 1.7 shows groups of genes that have been identified for Type 1 (low-grade serous carcinomas, 
borderline serous tumors, low-grade endometriod, and mucinous and clear-cell carcinomas) and Type 2 
(high-grade serous carcinomas, carcinosarcomas, and undifferentiated cancers) ovarian tumors [15].  
Many genes have been found to be involved in both breast and ovarian cancer including BRCA1, BRCA2, 
TP53, and PTEN which may contribute to the development of DPBOC. 




High BRCA1, BRCA2, TP53, PTEN, LKB1, CDH1 
Medium ATM, CHEK2, BRIP1, PALB2 










Type 1 KRAS, BRAF, ERBB2, PTEN, PIK3CA, CTNNB1, ARID1A, and 
PPP2R1A 
Type 2 BRCA1, BRCA2, and TP53 
 
The Cancer Genome Atlas (TCGA) was established as a collaboration between the National 
Cancer Institute and National Human Genome Research Institute to comprehensively identify key 
molecular changes across 33 types of cancer, including breast and ovarian.  In their breast cancer study 
using 510 breast tumors, TCGA identified 35 significantly mutated genes (Table 1.8).  They analyzed 
normal tissue on a select group of genes and observed deleterious germline variants in the following 
genes in approximately 10% of the samples: ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PTEN, 
RAD51C and TP53 [70].  In their ovarian cancer study using 316 high-grade serous ovarian cancer 
samples and matched normal samples, TCGA identified 9 significantly mutated genes from each 
individual (Table 1.8) [71].  Genes found to be involved in both breast and ovarian cancer, identified in the 
TCGA, are highlighted in grey. 
Table 1.8. Statistically significant mutated genes in 
breast and ovarian tumor samples, TCGA 



























The TCGA also identified molecular commonalities between basil-like breast tumors and high-grade 
serous ovarian cancers, including BRCA1 inactivation, RB1 loss and cyclin E1 amplification, high 
expression of AKT3, MYC amplification and high expression, and a high frequency of TP53 mutations, 
suggesting that these are shared molecular events in the development of these two cancers [70]. 
1.8. Breast and Ovarian Cancer Inherited Susceptibility Syndromes 
There are a few established inherited susceptibility syndromes associated with an increased risk 
of breast and/or ovarian cancer.  The most common inherited susceptibility syndrome is hereditary breast 
and ovarian cancer (HBOC).  HBOC is caused by a mutation in BRCA1 or BRCA2 and is characterized 
by an increased risk of breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer.  Having 
DPBOC in an individual or family is one of the characteristics identified as indicating high risk of this 
syndrome.  Other characteristics include breast cancer diagnosed before the age of 50, ovarian cancer at 
any age, multiple primary breast cancers, male breast cancer, triple-negative breast cancer, pancreatic 
cancer with breast or ovarian cancer in the same individual or on the same side of the family, Ashkenazi 
Jewish heritage, two or more relatives with breast cancer with one diagnosed before the age of 50, three 
or more family members with breast cancer at any age, and previously-identified BRCA1 or BRCA2 
mutation in a family [72].  In addition to HBOC there are several other inherited susceptibility syndromes 






















Table 1.9. Inherited susceptibility syndromes of breast and ovarian cancer 
Name Gene Cancer Association 
Breast                     Ovarian                   Other 
Li Fraumeni 
syndrome 
TP53 Breast Although ovarian 
cancer is not often 
found in families 
with this syndrome, 






















Breast (male and 
female) 
 Prostate, colon, 
thyroid, and kidney 






















STK11 Breast Ovarian (often non-
epithelial) 
Colon and rectum, 
stomach, small 
intestine, pancreas 
Bloom syndrome BLM 
(RECQL3) 
Breast  Skin, head, neck, 
esophagus, and 
gastrointestinal tract 
Werner syndrome WRN 
(RECQL2) 







XP genes A 
through G 
Breast  Cutaneous and 
ocular malignancies, 








Figure 1.2. Venn diagram showing the 
overlap in hypermethylated genes 
between breast and ovarian cancer 
(adapted from Heichman 2012 [76]) 
1.9. DNA Methylation and Breast and Ovarian Cancer 
Alterations in DNA methylation patterns, one common type of epigenetic event, can activate or 
silence key genes involved in carcinogenesis.  Specifically, hypermethylation can result in the silencing of 
tumor suppressor genes while hypomethylation can activate 
oncogenes [73-75].  Aberrant DNA methylation is thought to 
be one of the earliest markers of carcinogenesis [74].  
Numerous genes involved in DNA repair, cell cycle regulation 
and apoptosis have been found to be hypermethylated in 
breast and ovarian cancer.  Further, breast and ovarian 
cancer share a large number of hypermethylated genes 
which may contribute to the development of DPBOC.  In a 
review, Heichman et al. reported the most common genes 
hypermethylated in six solid cancers and displayed the 
cancer pairs with the most overlap.  Breast and ovarian 
cancer have approximately 38% overlap (Figure 1.2) and 
some of these genes include APC, BRCA1, E-cadherin, 
CDKN2A/P16INK4A, DAPK1, ESR1, H1N1, IGFPB3, MLH1, RARβ and RASSF1 [76]; despite this overlap a 
large number of genes are unique to both.  This overlap has yet to be robustly tested in higher risk 










1.10. Specific Aims 
In order to further our understanding of risk factors for the development of DPBOC, this dissertation 
addressed the following three aims: 
AIM 1: To carry out a comprehensive review of the literature on double primary breast and ovarian 
cancer (DPBOC) and identify studies that examine risk factors for developing DPBOC, including 
epidemiologic, genetic, and epigenetic. 
AIM 2: To examine the association between hormonal and reproductive risk factors (OC use, parity, and 
breastfeeding) and risk of 1) second primary ovarian cancer following a breast cancer diagnosis (BR-
OV), 2) second primary breast cancer following an ovarian cancer diagnosis (OV-BR), 3) DPBOC (BR-
OV and OV-BR combined), 4) single primary breast cancer (BR), and 5) single primary ovarian cancer 
(OV) in a retrospective case-control study design. 
Hypothesis: Parity and breastfeeding will be inversely associated with DPBOC, regardless of 
diagnosis order, while the net associations with OC use will depend on the underlying genetic/familial 
risk of breast or ovarian cancer. 
AIM 3: To examine the association between hormonal and reproductive risk factors (OC use, parity, and 
breastfeeding) and risk of: 1) BR-OV, 2) OV-BR, 3) BR, and 4) OV in a prospective cohort study design. 
Hypothesis: Parity and breastfeeding will be inversely associated with DPBOC, regardless of 
diagnosis order, while the net associations with OC use will depend on the underlying genetic/familial 
risk of breast or ovarian cancer. 
With enhancements in screening technology and treatment for cancer, leading to better cancer 
survival, risk of secondary cancer has become a greater public health issue.  Being able to precisely 
predict whether a woman with breast cancer will go on to develop ovarian cancer, and whether a 
woman with ovarian cancer will go on to develop breast cancer, is critical for appropriate clinical 
management and screening of cancer patients, including prophylactic surgery options.  However, 
because of the limitations of current screening methods (i.e., mammography is limited in its screening 
ability, particularly for women under the age of 50, and no current effective ovarian cancer screening 
tool exists), primary prevention is critical.  This dissertation examined the association between 
potentially modifiable reproductive and hormonal risk factors and DPBOC in a family-based cohort of 
breast and ovarian cancer families enriched for increased familial risk. 
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Chapter 2. Comprehensive Review of Current Literature on Risk Factors for Double Primary 
Breast and Ovarian Cancer 
 
2.1 Introduction 
With enhancements in screening methods for some cancers leading to earlier detection of cancer 
and improvements in cancer treatment, the number of people living with a prior cancer diagnosis has 
increased.  In the U.S. there are approximately 15 million people who have been diagnosed with cancer 
and while the incidence of cancer has been declining, the absolute number of people with cancer has 
been increasing [77].  With improved prognoses and longer survival for individuals with cancer, it is critical 
to study the risk of a second primary cancer [78].   
Second primary cancers may develop from treatment effects of the first cancer, as well as shared 
host factors such as age or genetics, shared lifestyle or environmental risk factors such as tobacco or 
contaminants, and interactions between factors, such as gene-environment interactions (Table 2.1).   
   Table 2.1. Etiology of second primary cancers (Adapted from [79,80]) 
Shared Risk factors for first primary and second primary cancers 
Lifestyle Environmental Host Factors 
Tobacco Contaminants Age and Sex 
Alcohol Occupation Genetics 
Diet Viruses Immune Function 
Other Other Hormonal, Other 
Treatment of first primary cancer 
 
Travis and colleagues categorized second primary cancers into three non-mutually exclusive groups 
based on etiology: 1) treatment-related cancers, 2) syndronomic cancers, and 3) cancers due to shared 
etiologic exposures [81].  While radiotherapy and chemotherapy have improved the survival for many 
cancers, research over the past several decades has supported the association between these 
treatments and the development of second cancers [82].  Syndronomic cancers (discussed in Chapter 1) 
are associated with major susceptibility genes and are often identified in families.  Although syndronomic 
cancers only account for a small proportion of all second cancers, individuals with mutations in these 
major susceptibility genes are at a much higher risk of developing multiple primary tumors [81,83].  
Tobacco is one of the established environmental exposures associated with the risk of multiple primary 
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cancers [81,84].  For cancers that share etiologic exposures, the contribution of genetic factors alone may 
be less and penetrance may be influenced by gene-environment and gene-gene interactions [81].  As 
second cancers may develop from any of these pathways, including interactions between these 
pathways, comprehensive research is needed to identify patterns of multiple cancers and to identify 
individuals at greatest risk. 
In the U.S., breast cancer has the highest cancer incidence in females and ovarian cancer is the 
most fatal of gynecological cancers [85].  Breast and ovarian cancer share many commonalities including 
some forms of treatment, genes, and epidemiologic risk factors which could contribute to the 
development of a second primary breast cancer in women with ovarian cancer and a second primary 
ovarian cancer in women with breast cancer.  As developing a second primary cancer is a leading cause 
of morbidity and mortality in cancer survivors, identifying potentially-modifiable risk factors is critical to 
reduce its occurrence.  My first dissertation aim is to comprehensively review the literature on DPBOC 
and identify studies that examine risk factors for developing these two primary cancers, including 
epidemiologic, genetic, and epigenetic. 
2.1. Methods 
 This comprehensive literature review of DPBOC was divided into three parts: 1) epidemiologic, 2) 
genetic, and 3) epigenetic risk factors.  For epidemiologic risk factors a Pubmed search using the 
following medical subject headings (MeSH) yielded 4,610 results as of February 2018:  ("Neoplasms, 
Second Primary"[MeSH] OR "Neoplasms, Multiple Primary"[MeSH]) AND ("Breast Neoplasms"[MeSH] 
OR "Ovarian Neoplasms"[Mesh]) Filters: English, Human.  After reviewing the titles for relevance and 
removing studies that did not assess epidemiologic  risk factors, including lifestyle, reproductive, and 
treatment factors, or both breast and ovarian cancer, 143 abstracts were selected for review, yielding 18 
studies assessing epidemiologic risk factors for DPBOC. 
For genetic risk factors we used the same search terms used for the epidemiologic risk factors 
which yielded 4,610 results as of February 2018: ("Neoplasms, Second Primary"[MeSH] OR "Neoplasms, 
Multiple Primary"[MeSH]) AND ("Breast Neoplasms"[MeSH] OR "Ovarian 
Neoplasms"[Mesh]) Filters: English, Human.  After reviewing the titles for relevance and removing studies 
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that did not assess genetic factors or both breast and ovarian cancer, 18 abstracts were selected for 
review, yielding 13 studies assessing genetic risk factors for DPBOC.   
For epigenetic risk factors a Pubmed search using the following terms yielded 82 results as of 
February 2018: ("Neoplasms, Second Primary"[MeSH] OR "Neoplasms, Multiple Primary"[MeSH]) AND 
"DNA methylation "[MeSH] Filters: English.  After reviewing the titles for relevance, no abstracts were 
identified assessing DNA methylation and DPBOC. 
2.2. Results 
The results from the comprehensive review on epidemiologic risk factor associations with DPBOC 
are summarized in Tables 2.2 to 2.5 and discussed below. 
2.2.1. Reproductive risk factors: Parity 
Two studies suggested a lower risk of second primary cancer for parous versus nulliparous 
women; however there were no statistically significant findings.  Specifically, in a study examining risk of 
second primary ovarian cancer following breast cancer (BR-OV) versus breast cancer only (BR) there 
was a non-statistically significant lower risk with four or more children compared to nulliparous women 
(HR=0.67, 95% CI: 0.22, 2.03) [86] and in a study examining the risk of second primary breast cancer 
following ovarian cancer (OV-BR) versus ovarian cancer only (OV) there was a non-statistically significant 
greater risk for nulliparous women compared to parous women (RR=1.41, 95% CI: 0.78, 2.56) [87].  In 
contrast, a study examining DPBOC versus ovarian cancer only observed no statistically significant 
difference in parity and number of live births; however they only examined bivariable differences [88]. 
2.2.2. Reproductive risk factors: Age at First Birth 
Two studies suggested a greater risk of second primary cancer for women with an older age at 
first parity versus women with a younger age at first parity; however there were no statistically significant 
findings.  Specifically, in a study examining risk of BR-OV versus BR there was a non-statistically 
significant greater risk for women with an age at first birth of 35 years and greater compared to less than 
25 years of age (HR=2.32, 95% CI: 0.55, 9.72) [86] and in a study of OV- BR versus OV there was a non-
statistically significant greater risk for age at first birth greater than or equal to age 30 compared to less 
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than 30 years (RR=1.43, 95% CI: 0.52, 3.91) [87].  In contrast, a study examining DPBOC versus OV 
observed no statistically significant difference in age at first birth between groups [88]. 
2.2.3. Reproductive risk factors: Breastfeeding 
 A study examining DPBOC versus OV observed no statistically significant difference in length of 
breastfeeding between groups [88]. 
2.2.4. Reproductive risk factors: Age at Menarche 
A study examining risk of BR-OV versus BR reported a non-statistically significant lower risk for 
women with an age at menarche of 12 or 13 versus <12 years, but no association for 14 versus <12 
years [86].  A study examining risk of OV-BR versus OV observed a non-statistically significant lower risk 
for women with an age at menarche less than or equal to 13 years compared to greater than 13 years 
(RR=0.60, 95%CI: 0.29, 1.28) [87].  Cvelbar et al. observed no statistically significant difference in age at 
menarche between women with DPBOC and women with OV [88]. 
2.2.5. Reproductive risk factors: Menopausal Status 
One study observed no association with menopausal status at breast cancer diagnosis and risk of 
second primary ovarian cancer [86].  Similarly, a study examining DPBOC versus OV observed no 
statistically significant difference in menopausal status between groups [88].  In contrast, one study 
observed an increased risk of second primary ovarian cancer for women with pre-menopausal breast 
cancer versus post-menopausal breast cancer  [89].  No studies were identified that examined 





Table 2.2. Summary of reproductive risk factors for double primary breast and ovarian cancer 
Author Pub Date Study Design Data source Study Details Summary 
Parity 
Trentham-Diaz 
[86] 2007 Cohort 
Washington 
State 
9,356 women with breast cancer 
followed for second cancer, including 
ovarian cancer (n=36) 
Non-statistically significant inverse 
association for 4+ births vs. nulliparous 
(HR=0.67, 95% CI: 0.22, 2.03) 
Cvelbar [88] 2005 Case-Control Slovenia Women with DPBOC (n=31) vs. OV (n=62) 
No statistically significant difference 
between cases and controls for nulliparous 
vs. parous and number of births (p=0.51) 




Women with OV-BR (n=72) vs. OV 
(n=177) 
Non-statistically significant positive 
association for nulliparous vs. parous 
(RR=1.41, 95% CI: 0.78, 2.56) 
Age at First Parity 
Trentham-Diaz 
[86] 2007 Cohort 
Washington 
State 
9,356 women with breast cancer 
followed for second cancer, including 
ovarian cancer (n=36) 
Non-statistically significant positive 
association for ≥35 vs. <25 years with risk 
of BR-OV (HR=2.32, 95% CI: 0.55, 9.72) 
Cvelbar [88] 2005 Case-Control Slovenia Women with DPBOC (n=31) vs. OV (n=62) 
No statistically significant difference 
between cases and controls for age at first 
birth (p=0.38) 




Women with OV-BR (n=72) vs. OV 
(n=177) 
Non-statistically significant positive 
association with ≥30 vs. <30 years for risk 
of OV-BR (RR=1.43, 95% CI: 0.52, 3.91) 
Breastfeeding 
Cvelbar [88] 2005 Case-Control Slovenia Women with DPBOC (n=31) vs. OV (n=62) 
No statistically significant difference 
between cases and controls for length of 
breastfeeding (p=0.69) 
Age at Menarche 
Trentham-Diaz 
[86] 2007 Cohort 
Washington 
State 
9,356 women with breast cancer 
followed for second cancer, including 
ovarian cancer (n=36) 
Non-statistically significant inverse 
associations for 12 vs. <12 years 
(HR=0.53, 95% CI: 0.18, 1.55) and 13 vs. 
<12 years (HR=0.50, 95% CI: 0.18, 1.41) 
but not 14 vs. <12 years (RR=0.60, 95% 




Cvelbar [88] 2005 Case-Control Slovenia Women with DPBOC (n=31) vs. OV (n=62) 
No statistically significant difference 
between cases and controls for age at 
menarche (p=0.51) 




Women with OV-BR (n=72) vs. OV 
(n=177) 
Non-statistically significant inverse 
association between  ≤13 vs. ≥14 years 




[86] 2007 Cohort 
Washington 
State 
9,356 women with breast cancer 
followed for second cancer, including 
ovarian cancer (n=36) 
No association between menopausal 
status and risk of second primary ovarian 
cancer 
Cvelbar [88] 2005 Case-Control Slovenia Women with DPBOC (n=31) vs. OV (n=62) 
No statistically significant difference 
between cases and controls for age at 
menopause (p=0.96) 
Langballe [89] 2011 Cohort Denmark 
14,151 women with breast cancer 
followed for second primary non-
breast cancer, including ovarian 
cancer (n=38) 
Increased risk of second primary ovarian 
cancer in women diagnosed with pre-
menopausal (SIR=1.8, 95% CI: 1.2, 2.4) 
but not post-menopausal breast cancer 





2.2.6. Lifestyle risk factors: OC Use 
In a study examining risk of BR-OV versus BR there was no association with OC use (HR= 0.76, 
95% CI: 0.34, 1.65) [86]. 
2.2.7. Lifestyle risk factors: HRT Use 
In a study examining risk of BR-OV versus BR there was no association with recent HRT use 
(HR= 1.36 95% CI: 0.49, 3.73) [86].  Similarly, another study observed no statistically significant 
difference in HRT use between women with DPBOC and women with only ovarian cancer [88]. 
2.2.8. Lifestyle risk factors: Smoking 
A study examining risk of BR-OV versus BR found current smoking to be associated with a non-
statistically significant lower risk (HR= 0.33, 95% CI: 0.10, 1.13) [86]. 
2.2.9. Lifestyle risk factors: Alcohol Use 
In a study examining risk of BR-OV versus BR, any alcohol intake was associated with a 






Table 2.3. Summary of lifestyle risk factors for double primary breast and ovarian cancer 
Author Pub Date Study Design 
Data 
source Study Details Summary 
OC use 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
No association with ever OC use for risk of BR-OV  
(HR= 0.76, 95% CI: 0.34, 1.65) 
HRT Use 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
No association for recent and ever use for risk of 
BR-OV (HR= 1.36 95% CI: 0.49, 3.73) 
Smoking 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
Non-statistically significant inverse association with 
current smoking for risk of BR-OV  
(HR= 0.33, 95% CI: 0.10, 1.13) 
Alcohol 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
Statistically significant inverse association with 
current alcohol use for risk of BR-OV (HR=0.45, 





2.2.10. Body size risk factors: Weight 
In a study examining risk of BR-OV versus BR, having a larger BMI was not associated with risk 
(HR= 0.80, 95% CI: 0.28, 2.29), for a BMI of greater than or equal to 28.9 kg/m2 compared to less than 
22.5 kg/m2.  Similarly, more adult weight gain was not associated with risk (HR= 1.35, 95% CI: 0.31, 
5.84), for gaining more than 36.29kg compared to 0-9.06kg [86].  
2.2.11. Body size risk factors: Height 
A study examining risk of BR-OV versus BR found no association with height greater than or 







Table 2.4. Summary of body size risk factors for double primary breast and ovarian cancer 
Author Pub Date Study Design 
Data 
source Study Details Summary 
Weight 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
No association with overweight for risk of BR-OV  
(HR= 0.80, 95% CI: 0.28, 2.29) 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
No association with adult weight loss (HR=1.49, 
95%  CI: 0.26, 8.47) and high adult weight gain 
(HR= 1.35, 95% CI: 0.31, 5.84) for risk of BR-OV  
Height 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
No association with greater adult height for risk of 
BR-OV 






2.2.12. Treatment risk factors: Chemotherapy 
Most of the studies identified examined the risk of ovarian cancer following chemotherapy 
treatment for breast cancer.  Only one study observed a non-statistically significant lower risk of ovarian 
cancer following stage 1 or 2 breast cancer with chemotherapy treatment (RR=0.59, 95% CI: 0.29, 1.21) 
[90].  The remaining studies observed either no association [91,92] or a suggestive non-statistically 
significant increased risk of ovarian cancer following chemotherapy treatment for breast cancer [43,93].  
However, when chemotherapy was given in combination with radiotherapy, one study showed a 
statistically significant higher risk of ovarian cancer following breast cancer treatment [43].  Only one 
study examined risk of breast cancer following chemotherapy treatment for ovarian cancer and they 
observed no association (RR=0.76, 95% CI: 0.39, 1.46) [87].   
2.2.13. Treatment risk factors: Radiotherapy 
Most of the studies identified examined the risk of ovarian cancer following radiotherapy 
treatment for breast cancer.  Four studies observed no association between radiotherapy treatment for 
breast cancer and risk of second primary ovarian cancer [37,92,94,95], two observed non-statistically 
significant increased risks [93,96], and two observed statistically significant increased risks [43,97].  Two 
studies examined the risk of breast cancer following radiotherapy treatment for ovarian cancer and both 
observed no association [87,98].   
2.2.14. Treatment risk factors: Tamoxifen 
One study observed a non-statistically significant increased risk of ovarian cancer following 
Tamoxifen treatment for breast cancer (OR=1.79, 95% CI: 0.79, 4.06) [90], and one observed a non-
statistically significant increased risk of second primary ovarian cancer following Tamoxifen + 
radiotherapy treatment for breast cancer (SIR=2.8, 95% CI: 0.2, 149.0) compared to radiotherapy only or 
surgery only groups (SIR=0.8, 95% CI: 0.1, 3.2) [94].  In contrast, three studies observed no association 
[92,99,100]. 
2.2.15. Treatment risk factors: Hormone Therapy 
Two studies observed an increased risk of second primary ovarian cancer following hormone 




studies differed because one of them (Yadav and colleagues [93]) examined second primary ovarian and 





Table 2.5. Summary of treatment association with double primary breast and ovarian cancer 
Author Pub Date Study Design Data source Study Details Summary 
Chemotherapy 






449 women with stage 1/2 breast 
cancer with BRCA1/2 followed for 
ovarian cancer (n=40) 
Non-statistically significant inverse association with 
chemotherapy for risk of BR-OV  
(OR=0.59, 95% CI: 0.29, 1.21) 





Women with OV-BR (n=72) vs. OV 
(n=177) 
No association with chemotherapy treatment of 
ovarian cancer for second primary breast cancer  
(HR= 0.76, 95% CI: 0.39, 1.46) 




2,786 women with breast cancer 
followed for second primary 
cancers, including ovarian cancer 
(n=8) 
Non-statistically significant increased risk of second 
primary ovarian cancer with chemotherapy for 
breast cancer (SIR=2.8, 95% CI: 0.9, 6.6) 
Andersson [92] 2008 Cohort Denmark 
31,818 women with early breast 
cancer followed for second primary 
cancers, including ovarian cancer 
(n=181) 
No association between chemotherapy for breast 
cancer and second primary ovarian cancer in 
multivariable model (RR=1.28, 95% CI: 0.79, 2.07) 
Iwasa [91] 2006 Cohort Japan 
47,005 women with breast cancer 
followed for second primary 
cancers, including ovarian cancer 
(n=27) 
No association with chemotherapy for breast cancer 
and second primary ovarian cancer (p>0.05) 




16,705 women with breast cancer 
followed for second primary 
cancers, including ovarian cancer 
(n=74) 
No association with chemotherapy treatment alone 
for breast cancer and risk of second primary ovarian 
cancer; increased risk for chemotherapy + 
radiotherapy (SIR=3.06, 95% CI: 2.07, 4.53) 
Radiotherapy 





Women with OV-BR (n=72) vs. OV 
(n=177) 
No association with radiotherapy treatment of 
ovarian cancer and second primary breast cancer  
(HR=0.70, 95% CI: 0.39, 1.25) 
Reimer [98] 1978 Cohort SEER 
18,764 women with ovarian cancer 
followed for second primary 
neoplasms, including breast cancer 
(n=121) 
No association with risk of breast cancer following 
ovarian cancer in irradiated (SIR=1.1, 95% CI: 0.8, 






Gonzalez [97] 2010 Cohort SEER 
182,057 women with breast cancer 
followed for second primary solid 
cancers, including ovarian cancer 
(n=219) 
Increased risk of second primary ovarian cancer 
following breast cancer in Surgery only (SIR=1.27) 
and Surgery + radiotherapy (SIR=1.43) groups, 
p<0.05 for both 




2,786 women with breast cancer 
followed for second primary 
cancers, including ovarian cancer 
(n=8) 
Non-statistically significant increased risk of ovarian 
cancer following breast cancer with radiotherapy 
(SIR=3.0, 95% CI: 0.1, 16.7) 





4,416 women with breast cancer 
followed for second primary cancer 
Non-statistically significant increased risk of second 
primary ovarian cancer with radiotherapy for breast 
cancer (SIR=1.8, 95% CI: 0.9, 3.2) 
Andersson [92] 2008 Cohort Denmark 
31,818 women with early breast 
cancer followed for second primary 
cancers, including ovarian cancer 
(n=181) 
No association between radiotherapy treatment for 
breast cancer and second primary ovarian cancer in 
the multivariable model (RR=1.31, 95% 0.85, 2.01) 
Harvey [37] 1985 Cohort Connecticut 
41,109 women with breast cancer 
followed for second primary 
cancers, including ovarian and 
fallopian tube cancers (n=183) 
No statistically significant difference in risk of 
second primary ovarian and fallopian tube cancers 
between irradiated and non-irradiated breast cancer 
patients overall, but risk was greater in the 
radiotherapy group for second cancers diagnosed 
within one year of the breast cancer (SIR=3.6) 
compared to the non-radiotherapy group (SIR=1.2)  
Grantzau [95] 2013 Cohort Denmark 
46,176 women with early breast 
cancer followed for second primary 
cancers, including ovarian, fallopian 
tube and broad ligament cancers 
(n=204) 
No association between radiotherapy for early 
breast cancer and second primary ovarian, fallopian 
tube and broad ligament cancers in multivariable 
model (HR=1.11, 95% CI: 0.82, 1.51) 
Andersson [94] 1991 RCT Denmark 
3,538 women with breast cancer 
receiving surgical treatment. 
Women at low risk of recurrence 
received no further treatment while 
women at high risk were randomly 
assigned to either radiotherapy or 
radiotherapy + tamoxifen and 
followed for new primary cancers, 
including ovarian cancer (n=3) 
No association with radiotherapy for early breast 
cancer and second primary ovarian cancer 
(SIR=0.3, 95%CI: 0.0, 1.9)  




16,705 women with breast cancer 
followed for second primary 
cancers, including ovarian cancer 
(n=74) 
Increased risk of ovarian cancer following 
radiotherapy alone (SIR=1.46, 95% CI: 1.07, 1.98) 
and radiotherapy + chemotherapy (SIR=3.06, 95% 













449 women with stage 1/2 breast 
cancer with BRCA1/2 followed for 
ovarian cancer (n=40) 
Non-statistically significant positive association with 
Tamoxifen for ovarian cancer following breast 
cancer (OR=1.79, 95% CI: 0.79, 4.06) 
Cook [99] 1995 Nested case-control 
Washington 
State 
Women with breast cancer who 
develop ovarian (n=39), 
endometrial (n=42) or contralateral 
breast cancer (n=234) vs. Random 
sample of women from the cohort 
who did not develop a second 
primary cancer (n=146 controls for 
ovarian comparison) 
No association with Tamoxifen therapy for breast 
cancer and risk of second primary ovarian cancer  
(OR=0.6, 95% CI: 0.2, 1.8) 
Andersson [92] 2008 Cohort Denmark 
31,818 women with early breast 
cancer followed for second primary 
cancers, including ovarian cancer 
(n=181) 
No association between Tamoxifen treatment for 
breast cancer and second primary ovarian cancer in 
multivariable model (RR=0.78, 95% CI: 0.41, 1.47) 
Curtis [100] 1996 SEER Cohort 
87,323 women with early breast 
cancer followed for second primary 
cancers, including ovarian cancer 
(n=223) 
No association between Tamoxifen therapy for 
breast cancer and second primary ovarian cancer  
(SIR=0.97, 95% CI: 0.59, 1.50) 
Andersson [94] 1991 RCT Denmark 
3,538 women with breast cancer 
receiving 1) surgery only or 
randomly assigned to 2) 
radiotherapy or 3) radiotherapy + 
tamoxifen and followed for new 
primary cancers, including ovarian 
cancer (n=3) 
Non-statistically significant increased risk of second 
primary ovarian cancer following Tamoxifen + 
radiotherapy treatment for breast cancer (SIR=2.8, 
95% CI: 0.2, 149.0) compared to radiotherapy only 
or surgery only groups (SIR=0.8, 95% CI: 0.1, 3.2) 
Hormone Therapy 






1,084 women with breast cancer 
followed for non-breast second 
cancers, including ovarian cancer 
(n=7) 
Statistically significant positive association with 
hormone therapy for breast cancer and risk of 
second primary ovarian cancer (RR=1.14, 95% CI: 
1.03, 1.26) 




2,786 women with breast cancer 
followed for second primary 
cancers, including ovarian cancer 
(n=8) 
Non-statistically significant increased risk of ovarian 
cancer following breast cancer treatment with 






The results from the comprehensive review on genetic associations with DPBOC are summarized 
in Table 2.6 and discussed below.  The majority of studies examining the association between genetic 
mutations and DPBOC have focused on BRCA1/2 mutations and family history.   
2.2.16. Genetic risk factors: BRCA1/2 
The studies evaluating BRCA1/2 mutations in women with DPBOC are diverse making it 
challenging to compare results across studies.  Some of the studies have shown the proportion of women 
with DPBOC with a BRCA1/2 mutation to range from 19% to 85% [102-108]; however, one study did not 
find a statistically significant greater proportion of BRCA1/2 carriers in the case group (DPBOC) than in 
the control group (women with single primary breast or ovarian cancer) [106].  In a study by Domchek et 
al. examining women with ovarian, peritoneal, or fallopian tube cancer who had BRCA1/2 mutations, 
breast cancer free survival was 97% at 5 years and 91% at 10 years [109].  A small study by Gangi and 
colleagues observed 8.9% of ovarian cancer cases with a BRCA1 or BRCA2 mutation developed 
subsequent breast cancer [110].  A study by Metcalfe et al. showed that BRCA1 may contribute to the 
development of DPBOC more than BRCA2.  Specifically, they observed that women with a BRCA2 
mutation had a lower risk of ovarian cancer following stage 1 or 2 breast cancer than did those with a 
BRCA1 mutation (RR=0.41, 95% CI (0.19, 0.90)) [90].  In contrast to the studies showing the contribution 
of BRCA1/2 to second primary cancers, Vencken and colleagues observed that the 2-year, 5-year, and 
10-year risk of breast cancer was greater among BRCA1/2 mutation carriers with no prior cancer (BR) 
(6%, 16%, and 28%, respectively) than among those with prior ovarian cancer (OV-BR) (3%, 6%, and 
11%, respectively) (p=0.03) [111]. 
2.2.17. Genetic risk factors: Other Genes 
In addition to BRCA1/2, a few other genes have been examined with DPBOC.  Bruchim and 
colleagues examined p53 expression as a marker for p53 mutations in cases with DPBOC compared to 
OV and BR controls. They observed no statistically significant differences in p53 expression between the 
ovarian tissue of cases (68%) and controls (71.9%) or the breast tissue of cases (19.4%) and controls 
(21.3%) [106].  Pilarski et al. observed a higher proportion of the KRAS-variant in women with DPBOC 
who are non-BRCA1/2 mutation carriers (27.2%) compared to women with DPBOC who are BRCA1 




2.2.18. Genetic risk factors: Family History 
In addition to looking at specific genes, a few studies examined the association between family 
history and DPBOC.  Bergfeldt et al. observed a non-statistically significant increased risk of OV-BR for 
women with a family history of breast and/or ovarian cancer (RR=1.50, 95% CI (0.52, 4.28)) and a 
statistically significant increased risk with a family history of any cancer (RR=1.94, 95% CI (1.01, 3.72)) 
[87].  Trentham-Dietz and colleagues observed an increased risk of BR-OV with two or more relatives 
with breast cancer (HR= 4.28, 95%CI (1.25, 14.6)) [86].  Lastly, two Swedish studies examined the risk of 
second primary ovarian cancer in women with breast cancer and found contradicting results.  Prochazka 
et al. reported an increased risk of BR-OV for women with a family history of breast cancer (SIR=2.32, 
95% CI: 1.66, 3.10) compared to women with no family history (SIR=1.38, 95% CI: 1.25, 1.51) [112].  
While Hemminki et al. also reported an increased risk of BR-OV for women with a family history of breast 
cancer (SIR=2.0, 95% CI: 1.20, 3.22), it was not statistically significantly different from women with no 
family history (SIR=1.7, 95% CI: 1.47, 2.03), (p=0.27) [113].  One difference in the studies was their 
definition of family history.  Prochazka et al. defined family history as breast cancer in any first degree 





Table 2.6. Summary of genetic associations with double primary breast and ovarian cancer 
Author Pub Date Study Design Data Source Outcome Summary 
BRCA1/2 





Women with ovarian cancer 
(n=435) followed for breast cancer 
(n=12) 
8.9% of patients with ovarian cancer with a BRCA 
mutation developed breast cancer after receiving an 
ovarian cancer diagnosis 








Breast Cancer Free Survival 
(BCFS) in women with ovarian, 
peritoneal, or fallopian tube 
cancer with a BRCA1/2 mutation 
(n=164) 
BCFS was 97% (95% CI: 0.92, 0.99) at 5 years and 
91% (95% CI: 0.82, 0.95) at 10 years. In a pseudo-
incident cohort where the BRCA1/2 test was before 
or within 1 year after diagnosis (n=64), BCFS was 
100% at 5 years and 87% (95% CI: 0.56, 0.96) at 10 
years. 




Women with ovarian cancer (OV) 
and a BRCA1/2 mutation (n=79) 
followed for second primary breast 
cancer (OV-BR) compared to 
unaffected BRCA1/2 mutation 
carriers (n=351) 
The 2-year, 5-year, and 10-year risk of breast 
cancer was greater for cancer-free women with a 
BRCA1/2 mutation compared to women with ovarian 
cancer and a BRCA1/2 mutation (p=0.03) 






449 women with stage 1/2 breast 
cancer with BRCA1/2 followed for 
ovarian cancer (n=40) 
Statistically significant inverse association with 
BRCA2 vs. BRCA1 for second primary ovarian 
cancer following breast cancer (OR=0.41, 95% CI: 
0.19, 0.90) 
Cvelbar [88] 2011 Cross-sectional Slovenia 
Women with DPBOC (n=167) who 
agreed to have BRCA1/2 testing 
(n=20) 
60% of women with DPBOC had a BRCA1/2 
mutation; however only 12% of the cases had 
genetic testing. 





100 women with DPBOC 
screened for BRCA1/2 mutations 
49% of women with DPBOC tested positive for a 
BRCA1/2 mutation; however only about 20% of 
women with DPBOC and no family history had a 
mutation. 
Fishman [102] 2000 Cross-sectional 
Jewish Israel 
Women 
Women with ovarian cancer with a 
prior breast cancer (BR-OV) 
(n=59) 
The prevalence of BRCA1/2 mutations was 57% in 












Women with ovarian cancer 
following breast cancer (BR-OV 
with an ovarian cancer paraffin 
block (n=43) vs. women with only 
ovarian cancer (OV) (n=64) 
The proportion of p53 expression was similar 
between BR-OV cases (69.8%) and OV controls 
(71.9%). 
KRAS 
Pilarski [107] 2012 Cross-sectional 
Eight 
institutions 
across the US 
and Ireland 
Women with breast cancer and 
ovarian or fallopian tube or 
primary peritoneal cancers 
(DPBOC) with a BRCA1 mutation 
(n=75), BRCA2 mutation (n=33), 
and no BRCA1/2 mutation 
(n=124) 
KRAS-variant was found in 21% of the entire 
DPBOC cohort.  Prevalence of the KRAS-variant 
was significantly higher in women with DPBOC who 
were non-BRCA1/2 mutation carriers (27.2%) 
compared to women with DPBOC who were BRCA1 
carriers (16.0%) and BRCA2 carriers (18.2%) 
Family History 
Trentham-Diaz [86] 2007 Cohort Washington State 
9,356 women with breast cancer 
followed for second cancer, 
including ovarian cancer (n=36) 
Statistically significant increased risk of BR-OV with 
≥2 relatives with breast cancer (HR=4.28, 95% CI: 
1.25, 14.6) 





Women with OV-BR (n=72) vs. 
OV (n=177) 
Non-statistically significant increased  risk of OV-BR 
with family history of breast or ovarian cancer 
(RR=1.50, 95% CI: 0.52, 4.28) and statistically 
significant increased risk of OV-BR with family 
history of any cancer (RR=1.94, 95% CI: 1.01, 3.72) 
Prochazka [112] 2006 Cohort Sweden 
152,600 women with breast 
cancer followed for second 
primary cancer, including ovarian 
cancer (n=712) 
Statistically significant increased risk of BR-OV with 
family history of breast cancer (SIR=2.32, 95% CI: 
1.66, 3.10) compared to no family history (SIR=1.38, 
95% CI: 1.25, 1.51) 
Hemminki [113] 2008 Cohort Sweden 
43,398 women with breast cancer 
followed for second primary 
cancers, including ovarian cancer 
(n=174) 
No statistically significant difference in risk of BR-OV 
for women with a family history (SIR=2.0, 95% CI: 
1.20, 3.22) compared to women with no family 
history (SIR=1.7, 95% CI: 1.47, 2.03) 
Fishman [102] 2000 Cross-sectional 
Jewish Israel 
Women 
Women with ovarian cancer with a 
prior breast cancer (BR-OV) 
(n=59) 
The prevalence of having a family history of breast 
or ovarian cancer in a 1st degree relative was 25.5% 






2.2.19. Epigenetic risk factors 
  No studies were identified examining DNA methylation and DPBOC.  
2.3. Discussion 
This comprehensive review highlights the overall lack of research examining risk factors for the 
development of DPBOC.  There were few statistically significant findings evaluating epidemiologic risk 
factors and risk of DPBOC which may be due to a small number of events within the cohort studies, and 
small overall sample size in the case-control studies.  For reproductive and lifestyle risk factors there was 
a suggestion of a greater risk of DPBOC for nulliparity, older age at first birth, younger age at menarche, 
and being pre-menopausal at first primary cancer diagnosis.  There was a suggestion of a lower risk of 
DPBOC with cigarette smoking, and alcohol use.  However, with the exception of alcohol use, there were 
no statistically significant associations with these epidemiologic risk factors and risk of DPBOC. Overall, 
the majority of studies identified in this literature search assessed cancer treatment as a risk factor for 
second primary cancer and overall the findings were quite mixed for chemotherapy, radiotherapy and 
Tamoxifen treatment, while two studies suggested a positive association between hormonal therapy for 
breast cancer and subsequent ovarian cancer.  However, most of these large national database studies 
assessing the association between treatment of breast cancer and risk of second primary cancers lacked 
risk factor and family history data and only examined unadjusted associations. 
Most studies examining genetic associations with DPBOC have focused on the BRCA1/2 genes 
and family history.  While most of these studies confirmed an association between mutations in BRCA1/2 
and risk of DPBOC, the contribution of these genes varied greatly between studies and may differ by type 
of mutation (BRCA1 vs. BRCA2).  For other genes, one study observed no association between p53 
expression and DPBOC, while another study observed enrichment of the KRAS oncogene in women with 
DPBOC, but it was only enriched in non-BRCA1/2 mutation carriers.  Having a family history of breast and 
ovarian cancer was associated with an increased risk of DPBOC.  No studies were found examining DNA 





This comprehensive review has revealed several study limitations and gaps in the literature on 
DPBOC that Aims 2 and 3 will address. First, few studies have evaluted the association between 
epidemiologic risk factors and DPBOC; even more limited is research evaluating differences in these 
associations by cancer diagnosis order (BR-OV versus OV-BR).  The studies that have been done are 
limited by a small sample size for women with both primary cancers, resulting in low power to detect 
statistically significant associations, and have used different reference groups making comparisons 
across studies challenging.  Further, with many breast and ovarian cancer studies showing differences in 
risk factor associations between average and high risk women [56-58,65,114,115], it is critical to also 
evaluate these associations with DPBOC across the risk spectrum.  Aims 2 and 3 will address these gaps 
by evaluating hormonal and reproductive risk factors and risk of DPBOC using a larger sample of cases 
and evaluating differences by cancer diagnosis order and risk profile using a consistent referent group.  
Aim 2 will utilize a retrospective case-control study design while Aim 3 will utilize a prospective cohort 
study design.  Evalutating this important research question using two different study designs will allow us 
to overcome some of the limitations specific to any one study design. 
Research on the genetics and epigenetics of DPBOC is sparse. The studies examining genetic 
associations with DPBOC have mostly focused on BRCA1/2 mutations and have not assessed genetic 
differences by cancer diagnosis order.  Further, comparison across these studies is challenging due to 
their diversity in study design and sample selection.  Aims 2 and 3 will assess reproductive and hormonal 
risk factors for DPBOC across the risk spectrum which is important as most women with a family history 
of breast or ovarian cancer do not carry mutations in BRCA1/2.  No studies were found evaluating DNA 
methylation and DPBOC.  While this dissertation will not examine DNA methylation and DPBOC, my 
future research will examine DNA methylation patterns in women who develop first primary ovarian 
cancer (OV) and women who develop second primary ovarian after breast cancer (BR-OV), and I have 





Chapter 3. Hormonal and Reproductive Risk Factors for Double Primary Breast and Ovarian 




Background: Few studies have examined hormonal and reproductive risk factors for double primary 
breast and ovarian cancer (DPBOC).  While oral contraceptive (OC) use has been associated with a 
reduced risk of ovarian cancer, data have been less consistent with breast cancer.  Parity has been 
consistently associated with a reduced risk of breast and ovarian cancer in average risk women; however 
results have been conflicting in high risk women.  Given these potential discordant effects between 
cancers and between average and high risk women, we conducted a study to examine the influence of 
these factors on DPBOC in women across the risk spectrum. 
Methods: Using the resources of the Breast Cancer Family Registry, we conducted a case-control study 
to examine OC use, parity, and breastfeeding and risk of breast cancer prior to ovarian cancer (BR-OV) 
(n=68), ovarian cancer prior to breast cancer (OV-BR) (n=18), breast cancer only (BR) (n=2,136), ovarian 
cancer only (OV) (n=214), and controls (n=3,573).  We estimated odds ratios (OR) and 95% confidence 
intervals (CIs) using polytomous logistic regression with a clustered bootstrap approach. 
Results: We observed similar associations for BR-OV and OV-BR.  Combining these groups into one 
overall double primary breast and ovarian cancer (DPBOC) group we observed an inverse association 
with ever OC use (OR=0.38, 95% CI: 0.22, 0.60) and later age at first birth (OR=0.28, 95% CI: 0.05, 
0.64), but a positive association with 1 child (OR=2.50, 95% CI: 0.58, 7.56) and ≥2 children (OR=5.78, 
95% CI: 2.82, 14.58).  There was an inverse association between ever breastfed and DPBOC.  When we 
stratified by BRCA1/2 mutation status, the inverse association between OC use and all of our case 
groups only remained in the BRCA1/2 mutation negative group, while the positive association with parity 
remained regardless of BRCA1/2 mutation status.  We observed similar findings in our BR and OV 
groups. 
Conclusion: We observed inverse associations between both OC use and breastfeeding and risk of 
DPBOC and a positive association with parity; however survivor bias may have influenced these results.  







Effective screening methods that lead to earlier detection of cancer coupled with enhanced 
cancer treatments have resulted in improved prognoses and longer survival for some cancers.  With the 
growing prevalence of people living with a prior cancer diagnosis, the incidence of second primary 
cancers has increased [78,81] requiring research on the causes of and treatment for these cancers.  
Women with breast cancer have an increased risk of developing ovarian cancer [34-39,78] and women 
with ovarian cancer have an increased risk of developing breast cancer [40,41].  Specifically, research 
has shown the risk of ovarian cancer following a breast cancer diagnosis to be up to two-fold; however, in 
women with a family history of breast or ovarian cancer this risk has been shown to be 5-fold and 17-fold, 
respectively [34].  In addition, the risk of breast cancer following an ovarian cancer diagnosis has been 
shown to be up to two-fold [41,44]; however having a first-degree family  history of breast or ovarian 
cancer or any malignant disease does not appear to further increase this risk [87].  
The etiology of double primary breast and ovarian cancer (DPBOC), and the development of 
multiple primary tumors in general, may include shared risk factors, genetics, and epigenetics.  The 
Cancer Genome Atlas has shown commonalities between basal-like breast tumors and high-grade 
serous ovarian cancer, including BRCA1 inactivation, RB1 loss and cyclin E1 amplification, high 
expression of AKT3, MYC amplification and high expression, and a high frequency of TP53 mutations 
[70].  Limited studies have evaluated the contribution of shared risk factors to the development of 
DPBOC.  A number of established and suspected risk factors are similar for both breast and ovarian 
cancer and include advanced age, reproductive and hormonal factors, family history, and genetics [45]; 
the majority are non-modifiable. One of the few modifiable preventive options for ovarian cancer is oral 
contraceptive (OC) use; a 50% lower ovarian cancer risk has been observed in women who use OCs for 
10 years or more [46].  Further, this protective effect of OC use has been observed in high risk women 
with a BRCA1/2 mutation [47] and in women with a familial risk of breast and ovarian cancer [58].  
However, OC use has been suspected to increase breast cancer risk [47,48,116,117], although results 
have been inconsistent with some studies observing no association [47,118-121].  Given these potential 
discordant effects of OC use on breast and ovarian cancer, research is needed to support clinical 





parity and breastfeeding are potentially modifiable factors that have also been shown to be associated 
with both breast and ovarian cancer.  In average risk women, parity and breastfeeding have been 
inversely associated with both cancers (reviewed in [46]); however findings have been less consistent in 
high risk women for both breast [50,115,122-124] and ovarian cancer [55-60].  Given these potential 
differences in risk factor associations between average and high risk women, further research is needed 
across the risk spectrum to clarify these associations and to provide accurate clinical information to 
women for prevention. 
In contrast to the abundance of research examining associations between risk factors and breast 
and ovarian cancer, studies examining risk factors for DPBOC are sparse.  Further, the few studies that 
have been done are inconsistent regarding cancer diagnosis order (i.e., breast cancer prior to ovarian 
cancer or ovarian cancer prior to breast cancer) or the control group (i.e., women with breast cancer only, 
or ovarian cancer only, or women with no cancer) making direct comparisons challenging.  A limited 
number of studies have evaluated the association between OC use, parity, and breastfeeding and 
DPBOC and the results have been inconsistent.  A study by Trentham-Diaz et al. observed no 
association between ever OC use and the development of ovarian cancer after breast cancer compared 
to breast cancer only [86].  For parity, Trentham-Diaz et al. observed a non-statistically significant inverse 
association between 4 or more live births and risk of ovarian cancer after breast cancer compared to 
breast cancer only [86] and Bergfeldt and colleagues observed a non-statistically significant positive 
association between nulliparity and risk of breast cancer after ovarian cancer compared to ovarian cancer 
only [87].  These two studies both found a non-statistically significant positive association between later 
age at first birth and DPBOC [86,87].  In contrast, a study by Cvelbar et al. observed no association 
between parity, age at first birth, or breastfeeding and DPBOC compared to ovarian cancer only and no 
family history; however they did not conduct multivariable regression and only examined bivariable 
differences [88]. 
As research examining risk factors for the development of DPBOC is sparse, and little to no 
research has compared risk factor associations by cancer diagnosis order or risk profile, we conducted a 
study to examine the association between modifiable hormonal and reproductive factors and the 







We conducted a case-control study using participants from the three clinic-based sites of the 
Breast Cancer Family Registry (BCFR) (New York, Philadelphia, and Utah).  Further details on the 
methodology of the BCFR are published elsewhere [125-135].  Briefly, the New York site of the BCFR 
enrolled affected and unaffected probands with a family history of breast and/or ovarian cancer from local 
hospitals, organizations, and breast cancer support groups. The Philadelphia site of the BCFR enrolled 
affected probands with a family history of breast and/or ovarian cancer from the Fox Chase Network of 
community hospitals, and Cooper Hospital/University Medical Center in Camden New Jersey, and 
unaffected probands with a family history of breast cancer from the Family Risk Assessment programs at 
these centers.  The Utah site of the BCFR recruited families with three or more cases of breast or ovarian 
cancer from local clinicians, the Family Cancer Assessment Clinic at Huntsman Cancer Institute, and an 
ongoing research study.  Institutional review boards at each BCFR site approved the study protocol and 
all participants provided written informed consent at enrollment.  Eligibility criteria included one or more of 
the following: having two or more relatives affected with breast or ovarian cancer, being a female 
diagnosed with breast or ovarian cancer at a young age, being a female diagnosed with breast and 
ovarian cancer at any age, being a male with breast cancer, or being a BRCA1/2 mutation carrier 
[126,136].  For this analysis, cases were individuals with a personal history of breast and/or ovarian 
cancer at baseline and controls were family members unaffected at baseline with no personal history of 
breast or ovarian cancer.  
The BCFR administered an epidemiologic questionnaire to participants at baseline which 
collected information on demographics, environment, and behavior, including race/ethnicity, height, 
weight, physical activity, and smoking and alcohol consumption; reproductive factors including menstrual 
and pregnancy history, breastfeeding, and hormone use; cancer history including breast and ovarian 
cancer; and surgical procedures of the breast and ovaries. We administered proxy questionnaires to 
relatives of deceased participants (26.0% of cases (n=753) and 4.9% of controls (n=189)) [126].  
 The BCFR tested probands affected with breast and/or ovarian cancer for BRCA1 and BRCA2 





family with an available blood sample. If a deleterious mutation was found then other family members with 
an available blood sample were tested for the same mutation. Myriad Genetic Laboratories, Inc., 
conducted the genetic tests using full sequence analysis and self-identified Ashkenazi Jewish participants 
were screened for the three founder mutations, 185delAG and 5382insC in BRCA1 and 6174delT in 
BRCA2 [126,136].  
 Cancer confirmation was sought at each BCFR site through review of medical records, pathology 
reports, or tumor samples by local pathologists.  Pathologists at each BCFR site used standard pathology 
review forms and were found to have good to excellent agreement between sites [126].  The use of 
proxies for deceased cases and lack of availability of old tumor samples limited the number of cancers 
that were able to be confirmed.  Among non-proxy cases, 60.0% of breast cancer only (BR) cases and 
43.9% of ovarian cancer only (OV) cases were confirmed.  For women with both cancers, 35.9% of breast 
prior to ovarian cancer (BR-OV) cases and 9.1% of ovarian prior to breast cancer (OV-BR) cases had 
both cancers confirmed; 60.4% of BR-OV cases and 36.4% of OV-BR cases had at least one cancer 
confirmed. 
3.3.1. Statistical Analysis 
 We examined mean and percent differences between our exposures of interest (OC use, parity, 
and breastfeeding) and potential confounding variables with our outcomes of interest (BR-OV, OV-BR, 
BR, OV, and controls with neither breast nor ovarian cancer).  We examined multivariable associations 
between our exposures and outcomes of interest using unordered polytomous logistic regression with a 
clustered bootstrap [137] to adjust our standard errors given the correlated nature of our family-based 
data.  For our main analyses, the same control group was used for each of our case groups.  However, 
as a sensitivity analysis, we ran case-case analyses where we compared our double primary groups (BR-
OV and OV-BR) to our single primary groups (OV and BR, respectively).  We examined the following 
variables for possible confounding: age, race/ethnicity, age at menarche, BMI (kg/m2), height (m), 
education, cigarette use, alcohol use, menopausal status, and BCFR site.  We included age as an a priori 
confounder and evaluated the other variables for confounding based on the 10% change-in-beta criterion.  
All exposures and potential confounders were truncated to one year prior to diagnosis for cases and to 





attempted to impute mutation data based on BOADICEA BRCA1/2 carrier probabilities [138].  We used 
the BOADICEA software package (https://pluto.srl.cam.ac.uk/cgi-bin/bd3/v3/bd.cgi) to calculate a 
woman’s probability of being a BRCA1 or BRCA2 carrier.  Specifically, if a woman had a BRCA1 or 
BRCA2 carrier probability of ≥0.5 then we categorized her as being BRCA1/2 mutation positive; otherwise 
they were categorized as BRCA1/2 mutation negative.  We chose this cutpoint based on our data 
comparing known genetic test results to the BOADICEA predicted carrier probabilities. Using a BRCA1 or 
BRCA2 carrier probability of 0.5 as the cutoff, the sensitivity and specificity were 70.9% and 99.3%, 
respectively.  In addition, we used this software package to determine a woman’s 10-year risk of breast 
and ovarian cancer starting one day prior to diagnosis for cases and at the age at interview for controls.  
There was a high correlation between the 1-, 5-, and 10-year risks (>95%) in a cohort including non-proxy 
participants from this study (personal communication, Dr. Terry); therefore if the 10-year risk was missing 
we imputed using the next available preceding risk score.  As a sensitivity analysis, we stratified our 
analyses by a 20% risk of breast or ovarian cancer as this defines a woman as being at increased risk 
according to the National Comprehensive Cancer Network guidelines for breast cancer screening [139].  
We stratified our analyses by an age 40 cutpoint (Table 3) to examine differences between early and late 
onset cancers.  Menopausal status was determined based on a pre-defined algorithm involving time of 
last menstrual period, prior bilateral oophorectomy, hormone replacement therapy use, pregnancy, 
hysterectomy, and age.  For individuals missing menopausal status due to missing variables in the 
algorithm, we imputed the data based on the 90th percentile of age at natural menopause in the controls 
for smokers (54 years) and non-smokers (55 years) [140]. 
Overall, we had 106 DPBOC, 2,504 BR, and 285 OV cases, and 3,825 controls eligible for the 
study; however cases and controls were excluded if they were missing any of the final covariate data.  
Therefore, our study included 86 DPBOC (81.1%), 2,136 BR (85.3%), and 214 OV (75.1%) cases, and 
3,573 controls (93.4%).  We had 29 DPBOC, 636 BR, and 74 OV cases from Philadelphia, 36 DPBOC, 
1,202 BR, and 100 OV cases from New York, and 21 DPBOC, 298 BR, and 40 OV cases from Utah 
eligible for the analysis.  We had 11 participants with the same diagnosis date for breast and ovarian 
cancer and kept these participants as a separate group in our initial analyses.  However, the direction and 





groups to enhance statistical power.  Interaction was assessed on the multiplicative scale using cross-
product terms and either the Wald Test or Likelihood Ratio Test and on the additive scale using the 
relative excess risk due to interaction (RERI) [141]. 
We performed the following sensitivity analyses to test the robustness of our results: 1) excluded 
women with any other cancer diagnosis (non-breast and non-ovarian cancer) prior to the breast or 
ovarian cancer diagnosis for cases and prior to the date of interview for controls (Supplemental Table 
3.1); 2) excluded proxy data (Supplemental Table 3.2); 3) excluded imputed menopausal status data 
(Supplemental Table 3.3); 4) excluded imputed BRCA1/2 mutation data (Supplemental Table 3.4); 5) 
excluded women with a prior bilateral oophorectomy or bilateral mastectomy (Supplemental Table 3.5); 6) 
excluded unconfirmed cases (Supplemental Table 3.6); 7) excluded non-epithelial ovarian cancers 
(Supplemental Table 3.7); 8) excluded in situ breast cancers (Supplemental Table 3.8); 9) excluded 
synchronous cancers (breast and ovarian cancers diagnosed within 12 months of each other) 
(Supplemental Table 3.9).  Women who have a bilateral oophorectomy are still at risk for breast cancer 
and women who have a bilateral mastectomy are still at risk for ovarian cancer.  Since minimal 
differences were observed when we excluded these participants (193 cases (6.7%) and 330 controls 
(8.6%) with prior bilateral oophorectomy; 18 cases (0.6%) and 18 controls (0.5%) with prior bilateral 
mastectomy), we chose to include them in the final analyses given our multinomial outcome.  Further, we 
observed minimal differences in our results for each of these sensitivity analyses and therefore kept all 
participants and imputed data in our main analyses to enhance our statistical power.  Statistical 
significance was determined using a p-value cutpoint of 0.05. All analyses were conducted using SAS 
version 9.3. 
3.4. Results 
 Table 3.1 reports demographic, reproductive, and behavioral differences between the 
breast/ovarian case groups and controls. Women with OV-BR tended to be older than controls and BR-
OV cases. While the majority of our sample was white, women with BR-OV had the highest percentage of 
whites compared to non-whites.  Compared to controls, all of our case groups were more likely to be post-





oral contraceptives.  The median time between cancer diagnoses was 7 and 8 years for women with BR-
OV and OV-BR, respectively. 
Table 3.2 reports our multivariable results assessing the association between OC use, parity, and 
breastfeeding and risk of BR-OV, OV-BR, and DPBOC (combined groups).  OC use was associated with 
a statistically significant 62% lower risk of DPBOC overall, a 60% lower risk of BR-OV, and a 70% lower 
risk of OV-BR.  For all of our case groups, parity was positively associated with risk of cancer.  Having 
two or more children was statistically significantly associated with a more than 5-fold higher risk of 
DPBOC, a more than 6-fold higher risk of BR-OV, and a nearly 4-fold higher risk of OV-BR.  Having an 
older age at first birth (>29 years) was associated with a statistically significantly 72% lower risk of 
DPBOC overall and a 71% lower risk of BR-OV.  We observed no association between age at last birth 
and any of our case groups.  For breastfeeding, we observed a 48% lower risk of developing DPBOC and 
a 51% lower risk of BR-OV.  We further examined the impact of parity and breastfeeding using a 
combined variable on our outcome groups.  While we still observed a positive association between parity 
and DPBOC, regardless of breastfeeding status, the association was attenuated in parous women who 
ever breastfed compared to parous women who never breastfed (Supplemental Table 3.10). 
 Table 3.3 reports our multivariable model stratified by BRCA1/2 mutation status and age at 
diagnosis (cases) or interview (controls).  For these analyses we did not assess cancer diagnosis order 
and only present the DPBOC group to enhance our statistical power.  Overall, there were minimal 
differences in risk between the case groups for parity and breastfeeding.  However, the inverse 
association between OC use and DPBOC was only observed in the BRCA1/2 mutation negative group 
and we observed multiplicative interaction between OC use and BRCA1/2 mutation status for our DPBOC 
group (p=0.02).  There was no multiplicative or additive interaction between parity or breastfeeding and 
BRCA1/2 mutation status for our DPBOC group.  There were minimal differences in the results between 
the women aged less than or equal to 40 years and the women aged greater than 40 years and no 
multiplicative or additive interaction was observed for our DPBOC group. 
To further explore differences across the risk spectrum, we stratified our results by 10-year risk of 





positive association between parity and DPBOC was greater in women with a risk of 20% or more (high 
risk) compared to women with a less than 20% risk (average risk).  While we did not observe a 
statistically significant interaction between parity and risk score on either the additive or multiplicative 
scale, we would expect interaction on at least one scale as both parity and risk score were associated 
with DPBOC.  Therefore, it is likely we did not have sufficient power to detect this interaction.  Further, the 
inverse association between breastfeeding and DPBOC was attenuated and no longer statistically 
significant in average risk women and we observed additive interaction (RERI = -5.33 (-10.55, -0.12)).  
Lastly, the inverse association between OC use and risk of DPBOC was attenuated and no longer 
statistically significant in the high risk group (multiplicative interaction: p=0.04). 
Since our parity results disagreed with our hypothesis of an inverse association between parity 
and risk of DPBOC, and disagrees with much of the breast and ovarian cancer literature showing an 
inverse association between parity and risk of BR and OV, we conducted additional post hoc analyses in 
which we assessed differences by number of first and second degree relatives as a proxy for family size 
(Supplemental Table 3.12), BCFR site (Supplemental Table 3.13), time since last parity, defined as the 
time between age at last parity and age at diagnosis for cases and age at interview for controls 
(Supplemental Table 3.14), time between age at menarche and age at first parity (Supplemental Table 
3.15), and birth cohort (Supplemental Table 3.16).  The positive association between parous women with 
two or more children and DPBOC and BR remained regardless of family size and BCFR site; however, 
we were limited by a small sample size in some of the groups.  Compared to women with 20 years or 
more since last parity, women with 10 to less than 20 years since last parity had an increased risk of 
DPBOC.  We also observed an increased risk of BR for women with 10 to less than 20 years and less 
than 10 years compared to 20 years or more since last parity.  We observed no association between time 
between menarche and first parity and any of our case groups.   Lastly, we evaluated differences by birth 
year, stratifying by being born before 1930, between 1930 and 1960, and after 1960.  We chose these 
cutpoints to examine differences between women exposed to OC formulations with high levels oestrogen 
(pre-1975) and low levels of oestrogen (post-1975) and to examine potential differences in reproductive 
habits.  In contrast to our main OC findings, for women born prior to 1930 there was no association 





no longer statistically significant.  In addition, the positive association observed between parity and all of 
our case groups was attenuated and no longer statistically significant.  Due to a small sample size, we 
were unable to examine the association between parity and DPBOC in women born after 1960. 
In order to examine differences between women who developed two primary cancers (BR-OV 
and OV-BR) and women who developed one primary cancer (BR and OV), and to minimize possible 
survivor bias, we ran case-case analyses for our main exposures (Supplemental Table 3.17).  There was 
a non-statistically significant inverse association between ever OC use and risk of BR-OV versus BR but 
no association versus OV.  There was a non-statistically significant inverse association between ever OC 
use and risk of OV-BR versus OV, and OV-BR versus BR.  We observed a positive association between 
having two or more live births and all of the double primary cancer groups compared to the single primary 
cancer groups, but it was only statistically significant for the BR-OV versus BR and versus OV 
comparisons.   Lastly, we observed a non-statistically significant inverse association between ever 
breastfed and all of the double primary cancer groups compared to the single primary cancer groups. 
3.5. Discussion 
 In our study of women with a familial risk of breast or ovarian cancer we were able to examine the 
association between hormonal and reproductive risk factors and risk of DPBOC by cancer diagnosis 
order and risk profile.  We observed a lower risk of developing DPBOC (regardless of cancer diagnosis 
order) with ever OC use; however, when we stratified by BRCA1/2 mutation status we only observed 
these associations in the BRCA1/2 mutation negative group.  As most women with a family history of 
breast or ovarian cancer do not carry mutations in BRCA1/2 (approximately 75% for breast [24-26] and 
56% for ovarian [27]), we further examined our findings by 10-year risk of breast and ovarian cancer and 
observed a similar inverse association between ever OC use and DPBOC for women at average risk.  
While there was still a lower risk of DPBOC with ever OC use in the high risk group, it was not statistically 
significant; however we were limited by a small sample size.  We observed a positive association 
between having two or more children compared to being nulliparous and risk of BR-OV, OV-BR, and 
DPBOC overall.  Additionally, we found an inverse association between later age at first parity and 






Our finding of an inverse association between OC use and BR-OV compared to controls 
contrasts the finding by Trentham-Diaz and colleagues that showed no association with OC use and risk 
of BR-OV compared to BR [86]; however our reference groups differed.  In order to compare our findings 
using the same reference group we evaluated the association between OC use and BR-OV compared to 
BR, a case-case analysis, and observed a suggestion of a lower risk but it was not statistically significant 
(OR=0.63, 95% CI: 0.36, 1.10) (Supplemental Table 3.17).  Similar results to our main findings were also 
found for the BR and OV groups.  OC use has been consistently shown to reduce the risk of ovarian 
cancer in both the general population [142] and in women at high risk [47,143,144] and our findings in 
women with OV are consistent with this.  In contrast, OC use in the general population has been shown to 
slightly increase the risk of breast cancer, particularly among current or recent users [145]; however 
findings in high risk women have been inconsistent [47,144].  We observed a lower risk of BR with OC 
use; however this association only remained in the BRCA1/2 mutation negative and average risk groups.  
While our finding of a reduced risk of BR with ever OC use is not consistent with most studies, one study 
found a reduced risk of breast cancers in women with a BRCA1/2 mutation [146] and one study found a 
reduced risk of mucinous breast cancer with ever OC use [4]. 
Our findings of a positive association between having two or more children compared to being 
nulliparous and risk of BR-OV and OV-BR contradict findings by Trentham-Diaz et al. [86] and Bergfeldt 
et al. [87] who found an inverse association between parity and BR-OV and OV-BR, respectively; 
however their results were not statistically significant.  For a more accurate comparison of their findings, 
we examined our results using similar reference groups, a case-case analysis, and observed a more than 
2-fold increased risk of BR-OV compared to BR (OR=2.68, 95% CI: 1.19, 6.73) and OV-BR compared to 
OV (OR=2.34, 95% CI: 0.64, >999) with two or more children (Supplemental Table 3.17).  We also 
observed a positive association between parity and BR.  Parity has been shown to reduce the risk of 
breast cancer in the general population after age 40 years [49,115,122]; however, results in high risk 
women have been less consistent.  A lower risk of breast cancer has been observed in BRCA1 mutation 
carriers with 4 or more children [115,122] and parous women with a family history of breast cancer 
compared to parous women with no family history [147], while in BRCA2 mutation carriers being parous 





associations in less common histologic subtypes of breast cancer and observed that having a greater 
number of children was positively associated with medullary breast cancer, which is more commonly 
found in women with BRCA1/2 mutations [4].   
Since our parity results disagreed with our hypothesis of an inverse association between parity 
and DPBOC, we conducted additional post hoc analyses to further explore our findings.  We found that 
women with 10 to less than 20 years since last parity had an increased risk of DPBOC compared to 
women with 20 years or more since last parity and women with 10 to less than 20 years and less than 10 
years since last parity had an increased risk of BR compared to women with 20 year or more since last 
parity.  These results suggest that our parity findings may partly be driven by cancers diagnosed closer to 
pregnancy, which supports prior literature showing a transient increase in breast cancer risk following 
pregnancy [148,149].  Lastly, for women born prior to 1930 and exposed to high oestrogen OC 
formulations, there was no association between OC use and DPBOC and the inverse association 
between OC use and BR was attenuated and no longer statistically significant.  In addition, the positive 
association observed between parity and BR was attenuated and no longer statistically significant for one 
child and null for two or more children, suggesting a possible birth cohort effect. 
It can be difficult to disentangle the independent effects of OC use and parity as trends have 
shown decreasing parity with increasing OC use [150].  To address this issue we conducted two 
additional analyses.  Supplemental Table 3.18 shows our results looking at duration of OC use in parous 
women in relation to their first pregnancy.  We observed an inverse association between OC use and all 
of our case groups for women who used OCs only prior to first pregnancy and women who used OCs 
after first pregnancy.  Supplemental Table 3.19 shows our results looking at parity in women who have 
used OCs by duration of use.  We still observed a positive association between parity and risk of DPBOC 
and BR regardless of duration of OC use.  This suggests that the increased risk observed for parous 
women is not due to a shorter duration of OC use. 
Russo and colleagues have shown that the breast tissue architectural pattern of parous women at 
high risk of breast cancer (either a BRCA1 mutation or a family history of breast cancer) was similar to 





breast cancer [151]; suggesting that the influence of parity on breast cancer risk may have differential 
effects based on genetic or familial risk status. However, in the present study, we observed an increased 
risk of DPBOC and BR regardless of BRCA1/2 mutation status and breast and ovarian risk score, 
although the associations were stronger in the higher risk groups (BRCA1/2 mutation positive and risk 
score ≥20%). 
Our finding of an inverse association between later age at first parity and DPBOC also contradicts 
findings by Trentham-Diaz et al. [86] and Bergfeldt et al. [87] who observed a positive association 
between later age at first parity and BR-OV and OV-BR, respectively; however their results were not 
statistically significant.  We again examined our results using matching reference groups and observed 
similar findings to our main analyses (data not shown).  Earlier age at first birth has been associated with 
a reduced risk of breast cancer in average risk women [152], while studies in high risk women have been 
mixed.  For familial breast cancer, one study observed a reduced risk with an earlier age at first parity 
[147], while a study in BRCA1/2 mutation carriers observed no statistically significant association [62].  
The association between age at first parity and ovarian cancer in average risk women is less clear, with 
studies showing positive [45,46,153-162], inverse [45,46,53,163-165], and null associations [45,166], 
whereas an inverse association [62] and no association [58] have been reported for ovarian cancer in 
high risk women.  
We observed an inverse association between breastfeeding and DPBOC which contradicts the 
finding of Cvelbar et al. [88] of no association.  This inverse association remained in stratified analyses of 
women with a breast/ovarian cancer risk ≥20%, which is consistent to what others have observed in high 
risk women (BRCA1 mutation carriers) [122-124].  When we stratified by BRCA1/2 mutation status, we 
did observe a stronger inverse association between breastfeeding and DPBOC in the mutation positive 
group, but it did not reach statistical significance.  Further, we observed some differences by study site.  
Specifically, there was a statistically significant inverse association between breastfeeding and DPBOC in 
the Philadelphia and Utah sites, but not the New York site, highlighting potential differences in the women 





Although pathology collection was attempted on all cases, complete information was not obtained 
on all due to the use of proxies for deceased cases and availability of pathology for cases diagnosed 
many years prior.  Without confirmation on all cancers, we were unable to confirm that all self-reported 
cancers in the DPBOC group were primary tumors rather than metastases.  However, research has 
shown that ovarian metastases to the breast are an uncommon event [167,168] and ovarian cancer in a 
woman with prior breast cancer is more likely to be a second primary cancer than a breast metastasis 
[169,170].  Additionally, breast metastases to the ovary occur more commonly with lobular than ductal 
breast carcinomas which are less common [170].  Further, in order to address this concern we excluded 
synchronous breast and ovarian cancers diagnosed within 12 months of each other and found minimal 
differences in our results (Supplemental Table 3.9).  We were also unable to examine our breast and 
ovarian cancers by molecular or histological subtype due to incomplete pathology information on our 
cases.  In order to address some of these concerns we ran our analyses limited to only confirmed cases 
(Supplemental Table 3.6), to only epithelial ovarian cancers (Supplemental Table 3.7) and excluding in 
situ breast cancers (Supplemental Table 3.8) and observed minimal differences in our results, suggesting 
that these cases were representative of all cases. 
Treatment data were collected via self-report in this study and we had missing information on 
20.5% of our BR cases, 56.1% of our OV cases, and 30.2% of our DPBOC cases regarding treatment for 
the first cancer.  As some studies have reported an association between treatment and risk of BR-OV and 
OV-BR we performed a sensitivity analysis with our available data.  Specifically, we stratified by any 
chemotherapy, radiotherapy, or hormone therapy and surgery only.  Overall we observed minimal 
differences in our results with the exception that there was no association between ever breastfeeding 
and DPBOC in the surgery only stratum (Supplemental Table 3.20).  We only had tumor stage data on a 
limited number of cases so we were unable to assess this.  One study found differences in ovarian tumor 
stage depending on whether the cancer was a first primary or second primary.  Specifically the OV-BR 
group had a higher proportion of stage I and II ovarian tumors compared to the BR-OV group.  In contrast 





Another limitation of this study was the potential role of selection and information bias.  First, our 
analyses included prevalent cases, which may have led to survivor bias.  In order to address this concern 
we conducted pseudo-incident analyses where we stratified by time between diagnosis and interview and 
examined only cases diagnosed within 2 years of the baseline interview (Supplemental Table 3.21) and 
within 5 years of the baseline interview (Supplemental Table 3.22).  Most of our DPBOC cases were 
diagnosed more than 5 years before the baseline interview so we had very little power to examine this 
outcome in these analyses.  With the limited number of pseudo-incident DPBOC cases, this analysis only 
suggested a possible attenuated association for OC use and parity in the pseudo-incident cancers 
compared to the prevalent cancers.  However, as both the first and second primary cancers were 
retrospective, stratifying by time between diagnosis and interview for both cancers also stratifies by time 
between diagnosis of the first primary cancer and diagnosis of the second primary cancer.  One study has 
shown that risk of ovarian cancer following ER negative breast cancer, but not ER positive breast cancer, 
increases with time since the breast cancer diagnosis [38].  Therefore, by stratifying by time between 
breast and ovarian cancer diagnosis, this analysis could also be stratifying by breast and ovarian cancers 
with different molecular characteristics and underlying risk of second primary cancer.  To address this 
concern we limited the analysis to just one cancer diagnosed ≤2 years before baseline versus one cancer 
diagnosed >2 years before baseline and we similarly observed an attenuated association for OC use and 
parity in the pseudo-incident group compared to the prevalent group (data not shown).  When we 
examined survivor bias in our BR and OV findings, OC use was not associated with pseudo-incident BR 
or OV but the inverse association remained in the prevalent BR and OV cases.  While the positive 
association between parity and BR remained, it was attenuated in the pseudo-incident case group.  When 
examining differences between our pseudo-incident and prevalent BR and OV cases we found that the 
pseudo-incident BR and OV cases were more likely to be ever OC users compared to the prevalent 
cases.  Further, the pseudo-incident BR cases were more likely to be pre-menopausal and the pseudo-
incident OV cases were more likely to be BRCA1/2 mutation positive compared to the prevalent cases.  
Lastly, there were a higher proportion of high risk women with pseudo-incident DPBOC and OV 
compared to prevalent DPBOC and OV which could have contributed to some of these observed 





that selection bias through the selection of controls may have influenced our results.  Specifically, cases 
were recruited from various hospitals, clinics, and centers and their family members were subsequently 
enrolled.  Therefore, cases and controls were not necessarily recruited from the same source population 
which could have introduced selection bias into the study.  Furthermore, without a defined source 
population we were unable to perform alternative analytic techniques, such as inverse probability 
weighting, to evaluate the presence of selection bias.  However, we were able to replicate the established 
protective effect of OC use on ovarian cancer risk which reduces the likelihood of strong selection bias.  
Also, we observed minimal differences between the Utah site, where families in the study are larger and 
more likely to live locally, and the New York and Philadelphia sites.  One way to avoid these selection 
bias concerns with a case-control design is to conduct a case-case analysis which removes the potential 
for bias in the selection of controls (women unaffected with breast or ovarian cancer).  In this study we 
also conducted case-case analyses comparing the double primary cancer groups to the single primary 
cancer groups, and overall we observed similar results to our main findings using controls with no breast 
or ovarian cancer with the exception of the finding of no association between ever OC use and risk of BR-
OV versus OV.  However, while these case-case analyses limited the potential for survivor bias as both 
the case and referent groups had prevalent breast and/or ovarian cancer, the double primary groups had 
a longer time between first cancer diagnosis and baseline interview (12 and 18 years for BR-OV and OV-
BR, respectively) compared to the single primary groups (2 and 4 years for OV and BR, respectively), 
suggesting that this analysis was not able to entirely rule out survivor bias. 
Information bias may have also influenced our results.  Recall bias is a concern in case-control 
studies as exposure information is collected after the outcome and exposure information may be 
differentially recalled by cases and controls.  Parity and breastfeeding are major life events and less 
susceptible to recall bias.  Furthermore, for breastfeeding we used a crude ever/never categorization 
which would have minimized any information bias.  Taking oral contraceptives, on the other hand, may be 
more susceptible to recall bias compared to parity and breastfeeding.  However, oral contraceptive use 
was also defined as ever/never which would have limited exposure misclassification.  Providing further 
support of minimal information bias in our study parity [172], breastfeeding [173], and OC use [174,175] 





bias as both the case and referent groups were individuals with a cancer diagnosis; however differences 
in the time between cancer diagnosis and entry into the study between groups suggest that this analysis 
was not able to entirely rule out recall bias. 
Unlike prior studies, our study was uniquely able to examine risk factor associations for DPBOC 
by cancer diagnosis order and risk profile.  We observed similar associations between OC use, parity, 
and breastfeeding and BR-OV and OV-BR, suggesting that these exposures similarly affect the risk of a 
second primary breast cancer in women with ovarian cancer as with a second primary ovarian cancer in 
women with breast cancer.  Further, we observed some differences in our risk factor associations 
between women who developed DPBOC and women who developed BR or OV.  Specifically, later age at 
first birth and breastfeeding showed stronger inverse associations with DPBOC, while parity showed a 
stronger positive association with DPBOC than BR and OV.  Given the conflicting literature on parity and 
breast and ovarian cancer in high risk women, further work is needed to provide clear clinical guidelines 
to women at greatest risk of developing these cancers.  Our findings suggest there may be modifiable 






Table 3.1. Demographic, reproductive and behavioral differences between ovarian and/or breast 
cancer cases and controls in the Breast Cancer Family Registry 
Characteristic BR-OV (n = 68) 
OV-BR 




(n = 214) 
All Controls 











Age at dx/interview or 
death (yr) 








































Age at menarche (yr) 




































Missing n (%) 
  1.6 (0.1) 
0 




  1.6 (0.1) 
1 (0.5) 
  1.6 (0.1) 
32 (0.9) 
BMI (kg/m2) 

























































































Age at first birth (yrs) 










7  (0.3) 
Age at last birth (yrs) 




































High school or less 


































































































Table 3.2. Risk of developing both breast and ovarian cancer, only breast cancer, and only ovarian cancer using unordered 
polytomous logistic regression with clustered bootstrapping, Breast Cancer Family Registry 



































































































































































































































































































































































































 (0.42, 1.70) 
0.57 











































 (0.08,  0.37) 
0.87 


















 (0.56, 1.87) 
0.67 

















 (0.33, 0.51) 
0.90 


















 (0.60, 1.37) 
1.04 














































































*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main 
exposures 
Table 3.3. Risk of developing both breast and ovarian cancer, only breast cancer, and 
only ovarian cancer using unordered polytomous logistic regression with clustered 
bootstrapping stratified by BRCA1/2 status and age at diagnosis/interview, Breast 
Cancer Family Registry 
BRCA1/2 Mutation Negative
 DPBOC BR OV 





 OR (95% CI) OR (95% CI) OR (95% CI) 





0.21 (0.10, 0.41) 
 
1.0 
0.59 (0.52, 0.67) 
 
1.0 







2.48 (<0.01, 9.99) 
3.90 (1.35, 13.14) 
 
1.0 
2.27 (1.76, 2.90) 
2.27 (1.87, 2.80) 
 
1.0 
1.10 (0.44, 2.20) 





0.77 (0.39, 1.77) 
1.0 
0.81 (0.70, 0.94) 
1.0 
0.80 (0.55, 1.24) 
BRCA1/2 Mutation Positive










0.82 (0.40, 1.88) 
 
1.0 
1.02 (0.69, 1.47) 
 
1.0 







2.17 (<0.01, 14.95) 
7.03 (2.34, 44.16) 
 
1.0 
2.56 (1.17, 5.36) 
3.14 (1.55, 5.62) 
 
1.0 
1.84 (0.35, 8.01) 






0.35 (0.14, 1.09) 
 
1.0 
0.73 (0.52, 1.33) 
 
1.0 
1.18 (0.49, 4.17) 
Age at Diagnosis/Interview ≤40










0.28 (0.13, 0.68) 
 
1.0 
0.67 (0.53, 0.85) 
 
1.0 







2.86 (<0.01, 10.67) 
2.92 (0.79, 12.66) 
 
1.0 
2.14 (1.41, 3.28) 
1.94 (1.36, 2.78) 
 
1.0 
2.67 (0.68, 7.39) 






0.39 (0.18, 1.52) 
 
1.0 
0.64 (0.46, 0.92) 
 
1.0 
0.43 (0.16, 1.23) 
Age at Diagnosis/Interview >40










0.35 (0.18, 0.57) 
 
1.0 
0.48 (0.40, 0.55) 
 
1.0 







1.07 (<0.01, 7.24) 
4.16 (1.78, 21.79) 
 
1.0 
1.54 (1.15, 2.00) 
1.55 (1.22, 1.90) 
 
1.0 
0.67 (0.25, 1.46) 






0.51 (0.26, 0.91) 
 
1.0 
0.80 (0.69, 0.94) 
 
1.0 




Chapter 4. Hormonal and Reproductive Risk Factors for Single and Double Primary Breast and 
Ovarian Cancer in a Cohort Enriched for Increased Familial Risk, ProF-SC 
 
4.1. Abstract 
Background:  With enhancements in screening and treatment, breast cancer survivors make up the 
largest group of cancer survivors in the U.S.  Developing a second primary cancer is one of the most 
severe long-term outcomes of a cancer diagnosis, particularly if the second primary cancer lacks an 
effective screening tool as with ovarian cancer.  Limited research has been done to assess risk factors for 
second primary ovarian cancer following a breast cancer diagnosis and even more limited are prospective 
studies that minimize information and selection bias.  Using data from a family-based cohort enriched for 
increased familial risk, we evaluated the association between hormonal and reproductive factors and risk 
of second primary ovarian cancer following a breast cancer diagnosis. 
Methods:  Using data from The Breast Cancer Prospective Family Study Cohort (ProF-SC) we evaluated 
the association between oral contraceptive (OC) use, number of full-term (FT) pregnancies, and 
breastfeeding and risk of second primary ovarian cancer following breast cancer (BR-OV), risk of first 
primary ovarian cancer (OV), and risk of first primary breast cancer (BR) using Cox proportional hazards.  
We evaluated effect measure modification by predicted lifetime risk of breast and ovarian cancer to 
evaluate differences in these associations across the risk spectrum.  
Results:  OC use was associated with a non-statistically significant greater risk of BR-OV (HR=1.62, 95% 
CI: 0.91, 2.90) and the risk was stronger and statistically significant in women with a lifetime risk of breast 
and ovarian cancer ≥20% (high risk) (HR=3.05, 95% CI: 1.02, 9.13).  However, when we stratified by time 
between breast cancer diagnosis and the baseline interview, the positive association between OC use 
and BR-OV was only seen in the prevalent cancers (breast cancer diagnosis >2 years before baseline) 
and not in the pseudo-incident cancers (breast cancer diagnosis ≤2 years before baseline).  OC use was 
associated with a borderline statistically significant lower risk of OV (HR=0.59, 95% CI: 0.34, 1.00) and 
this association was stronger in women at high risk (HR=0.33, 95% CI: 0.13, 0.86).  OC use was not 




risk in older women (HR=1.39, 95% CI: 1.11, 1.73).  Having two or more FT pregnancies was associated 
with a lower risk of BR-OV (HR=0.47, 95% CI: 0.22, 0.97).  While number of FT pregnancies was not 
associated with OV or BR, later age at first pregnancy was associated with an increased risk of OV for 
women aged 25-29 years versus <20 years (HR=3.51, 95% CI: 1.08, 11.40) and an increased risk of BR 
for women aged ≥30 years versus <20 years (HR=1.49, 95% CI: 1.09, 2.04).  We observed no 
association between breastfeeding and any of our outcomes. 
Conclusion:  This study suggests that OC use may have a discordant effect on ovarian cancer depending 
on whether it is a first primary or a second primary cancer, and on underlying risk of breast or ovarian 
cancer.  Being able to identify potentially modifiable risk factors for second primary cancers is critical for 





 Improvements in the detection and treatment of cancer have led to an increasing number of 
people surviving a cancer diagnosis.  According to the American Cancer Society, as of January 1, 2016 
there were more than 15.5 million children and adults living with a history of cancer.  More than half this 
group (67%) was diagnosed 5 or more years ago and 17% were diagnosed 20 or more years ago.  By 
January 2026 it is estimated that there will be 20.3 million cancer survivors [176].  According to SEER, 
cancer survivors have a 14% increased risk of developing a second primary cancer compared to the 
general population [177].  With the growing population of cancer survivors, research is needed to better 
understand the etiology of second primary cancers and to identify potential means of prevention. 
Many factors may contribute to the development of second primary cancers including shared risk 
factors, shared genetics, and treatment of the first cancer.  Breast and ovarian cancer share multiple risk 
factors (e.g., parity and breastfeeding), and genetics (e.g. BRCA1/2), and have been found to co-occur 
[34-41].  The bi-directional nature of primary and secondary breast and ovarian cancer suggests that 
shared risk factors and genetics, rather than treatment, are the main contributors of this association [86].  
Developing a second primary cancer is a serious adverse event for cancer survivors and research has 
shown that women with breast cancer who develop a second primary cancer have worse survival 
[178,179].  Research into double primary breast and ovarian cancer (DPBOC) has shown that diagnosis 
order matters in terms of survival.  Liou and colleagues found that women with ovarian cancer following 
breast cancer (BR-OV) had worse survival than women with breast cancer following ovarian cancer (OV-
BR).  Contributing to this finding, ovarian cancers in the BR-OV group were higher stage, higher grade, 
and more likely to be serous versus other histologic subtypes, compared to ovarian cancers in the OV-BR 
group [171].  High-grade serous carcinoma is the most common type of ovarian cancer and has the worst 
survival [180]. 
 Few studies have examined potentially modifiable risk factors for DPBOC; one prospective cohort 
study examining  risk of BR-OV [86] and three retrospective case-control studies, assessing OV-BR [87], 
DPBOC combined [88], and BR-OV and OV-BR (Chapter 3).  While retrospective case-control studies are 




such as second primary cancers, they are susceptible to information and selection bias.  Recall bias is a 
concern in case-control studies as recall may be influenced by disease status; a minimal concern for 
exposures such as parity and breastfeeding, which are major life events, but possibly a greater concern 
for exposures such as oral contraceptive (OC) use.  In addition, selection bias is a concern in case-
control studies with the selection of controls, particularly if the source population is difficult to define.  
Prospective cohort studies, on the other hand, avoid many forms of information and selection bias but 
identifying a sufficient number of cases may be a challenge.  Therefore, prospective studies which are 
potentially more valid are less efficient.  In order to address these gaps we conducted a prospective 
cohort study using a family-based cohort of breast and ovarian cancer families enriched for increased 
familial risk to examine the association between OC use, parity, and breastfeeding and three outcomes: 
1) second primary ovarian cancer following a breast cancer diagnosis (BR-OV), 2) single primary ovarian 
cancer (OV), and 3) single primary breast cancer (BR).  
4.3. Methods 
 We conducted a prospective cohort study using participants from The Breast Cancer Prospective 
Family Study Cohort (ProF-SC) who were enrolled in the six sites of the Breast Cancer Family Registry 
(BCFR).  ProF-SC has been described in detail elsewhere [181].  Briefly, ProF-SC includes all female 
participants from the BCFR [126] who were enrolled before June 30, 2011.  There are three population-
based sites (Australia, Northern California, and Ontario) and three clinic-based sites (New York, 
Philadelphia, and Ontario).  The three population-based sites recruited case families through cancer 
registries and control families via random digit dialing in the same catchment area as the local cancer 
registry.  Australia over-sampled cases with an early age at diagnosis whereas Northern California and 
Ontario over-sampled cases with an early age at diagnosis and/or having a family history or other genetic 
predisposition.  The three clinic-based sites enrolled case families through local hospitals, organizations, 
and breast cancer support groups.  Further details of recruitment at the three clinic-based sites are 
described in Chapter 3. 
 Exposure information: Starting in 1996 the BCFR administered baseline epidemiologic 




other behavioral factors such as alcohol consumption and cigarette smoking.  Beginning in 2007 the 
BCFR initiated a follow-up study to update information on vital status, personal and family history of 
cancer, and breast cancer risk factors that were collected at baseline.  The BCFR has sought 
biospecimen collection on all cases and blood or buccal samples on most participants. Screening for 
BRCA1 and BRCA2 germline mutations was conducted on the proband or the youngest affected family 
member and if a deleterious mutation was found then screening was performed on family members.  In 
order to assess underlying risk of breast and ovarian cancer in participants included in this analysis, we 
obtained predicted breast and ovarian cancer risk scores using the Breast and Ovarian Analysis of 
Disease Incidence and Carrier Estimation Algorithm (BOADICEA) [138].  We stratified by lifetime risk of 
breast or ovarian cancer ≥20% versus <20% as this cutpoint has been used by the National 
Comprehensive Cancer Network to identify women at high risk [21].  As a sensitivity analysis we used the 
continuous measure of predicted 1-year risk of breast or ovarian cancer. 
Outcome information: For our double primary cancer groups, the first primary cancer was 
prevalent (cancer diagnosed prior to baseline interview) and the second primary cancer was incident 
(cancer diagnosed after the baseline interview).  The single primary groups were incident cancers.  Figure 
4.1 displays the exclusion criteria and sample size for our four initial analytic groups.  For the affected 
breast group (followed prospectively for BR-OV) and unaffected group (followed prospectively for OV) we 
excluded women with a prior bilateral oophorectomy, and for the affected ovarian group (followed 
prospectively for OV-BR) and unaffected group (followed prospectively for BR) we excluded women with 
a prior bilateral mastectomy.  For all of the groups we excluded women who were 80 years of age or older 
at the baseline interview and anyone missing the age at censor variable.  Our final sample sizes were as 
follows: 1) affected breast group: n = 8,969, 2) affected ovarian group: n = 298, 3) Unaffected  group 
(followed for OV): n = 11,870, 4) Unaffected group (followed for BR): n = 12,974.  Cancer confirmation 
was sought on all cases.  The Australia, Ontario, and Utah sites of the BCFR regularly link to local 
population-based cancer registries to confirm cases at their sites and all BCFR sites link to the National 
Death Index or other death registries to update vital status.  Additionally, pathology and medical reports 
were sought for all cases.  While cancer confirmation is ongoing, we have confirmation of both cancers 




32 (47.1%) of our OV cases, and 559 (74.7%) of our BR cases.  Cancer treatment was self-reported 
using a validated questionnaire that collected information on cancer stage and type of initial breast or 
ovarian treatment (e.g. surgery, chemotherapy, radiotherapy).  We currently have breast treatment data 
on 53 (77.9%) of our BR-OV cases. 
4.3.1. Statistical Analysis 
While we initially established four analytic groups of interest: 1) affected breast followed for 
ovarian (BR-OV), 2) affected ovarian followed for breast (OV-BR), 3) unaffected followed for ovarian (OV), 
and 4) unaffected followed for breast (BR), we only observed 2 cases of OV-BR and were unable to 
examine this group in a multivariable model.  Therefore, we only present the baseline data for the OV-BR 
group.  We examined mean and percent differences between baseline measures of our covariates of 
interest and our three main exposures (OC use, parity, and breastfeeding) for each of our four initial 
analytic groups.  As we had data at two time points (baseline and follow-up) we created time-varying 
covariates for our exposures and covariates of interest that could change over time using a simple update 
method.  If a value was only available at one time point then that value was used for the entire study 
period.  The variables for height and BMI at baseline and follow-up were evaluated and outliers were 
removed in the following two-step process: 1) Heights greater than three standard deviations away from 
the mean were removed (n = 75 (1 BR case) for baseline, n = 33 (1 case) for follow-up) and 2) BMIs 
greater than 50kg/m2 and less than or equal to 14kg/m2 were removed (n = 72 (2 BR cases) for baseline, 
n = 31 (0 cases) for follow-up).  In order to test the robustness of our height and BMI variables we ran 
analyses with the cleaned time-varying covariates, the original time-varying covariates, and the baseline 
variables.  As we observed minimal differences in our results with these three sets of height and BMI 
variables, we used the cleaned time-varying covariates in our final models.  We used Cox proportional 
hazards models to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association 
between OC use, parity, and breastfeeding and risk of BR-OV, OV, and BR using age as the time-scale.  
Person-time was calculated differently for the three analytic groups we were able to examine in a 
multivariable model.  For the BR-OV group we calculated person-time from age at breast cancer 
diagnosis until the earliest of the following ages: age at ovarian cancer diagnosis, age at bilateral 




calculated person-time from age at the baseline interview until the earliest of the following ages: age at 
ovarian cancer diagnosis, age at bilateral prophylactic oophorectomy, age at death, age at last follow-up, 
or age 80 years.  For the BR group we calculated person-time from age at the baseline interview until the 
earliest of the following ages: age at breast cancer diagnosis, age at bilateral prophylactic mastectomy, 
age at death, age at last follow-up, or age 80 years.  We tested the proportional hazards assumption for 
our main exposures using an interaction between our main exposures and the natural log of age and by 
examining the cumulative sums of martingale residuals over attained age [182].  We used a robust 
sandwich estimator to account for the family-based nature of the cohort.  We developed directed acyclic 
graphs (DAGs) to identify confounders of our proposed causal effects.  Additionally, we assessed the 
following variables for confounding using the 10% change-in-beta criterion: race/ethnicity (white vs. non-
white), education level (>high school degree vs. ≤high school degree), cigarette use (ever vs. never), 
alcohol consumption (ever vs. never), age at menarche (years), menopausal status (pre- vs. post-
menopausal), hormone replacement therapy use (ever vs. never), height (meters), and BMI (kg/m2).  If a 
covariate was identified as a potential confounder using either the DAG method or the statistical method 
then it was included in our multivariable model.  Based on these two approaches all of the covariates 
were included in our multivariable models.  We stratified our models by birth cohort (<1950, 1950-1959, 
1960-1969, ≥1970) to account for secular changes in our exposures and outcomes over time.  We dealt 
with missing covariate data (less than 3% for all covariates) by including a missing indicator variable for 
those covariates with missing data.  We conducted a sensitivity analysis where individuals missing 
covariate data were excluded from the multivariable models and observed minimal differences in our 
results; therefore we included the missing indicators to maximize our statistical power.  To test the 
robustness of our Cox proportional hazards model we ran parallel models using Poisson regression. 
 In order to evaluate whether the associations between our main exposures and outcomes varied 
by predicted risk of breast and ovarian cancer, we examined effect measure modification (interaction) on 
the multiplicative and additive scale.  Interaction on the multiplicative scale was assessed by including an 
interaction term in our multivariable models between our main exposures and predicted risk and using 
either the Wald Test of the Likelihood Ratio Test.  Interaction on the additive scale was determined using 




The following sensitivity analyses were performed to test the robustness of our results: 1) 
Multivariable models using baseline variables rather than time-varying covariates (Supplemental Table 
4.1); 2) Exposures truncated to the age of diagnosis of the first primary breast cancer for the BR-OV 
group (Supplemental Table 4.2); 3) Excluding in situ breast cancers for the BR-OV and BR groups 
(Supplemental Table 4.3).  We observed minimal differences in our results across sensitivity analyses 
and therefore retained our time-varying covariates and included all cancers to enhance our statistical 
power. 
All analyses were conducted using SAS version 9.4. 
4.4. Results 
 Table 4.1a reports baseline differences in our exposed and unexposed groups for OC use, parity, 
and breastfeeding by our covariates of interest for the BR-OV group.  In this group, 0.48% were missing 
OC use, 0.06% were missing parity, and 0.36% were missing breastfeeding data.  Compared to never 
OC users, ever OC users were more likely to be younger at baseline, pre-menopausal, to have ever 
smoked cigarettes, and to have ever consumed alcohol.  Compared to nulliparous women, parous 
women were more likely to be post-menopausal, to have never consumed alcohol, to have a high school 
degree or less, and to have been born before 1950.  Compared to parous women who never breastfed, 
parous women who ever breastfed were more likely to be from the Australia site, pre-menopausal, and to 
have been born in 1950 or later. 
 Table 4.1b reports baseline differences for the OV-BR group.  In this group, 1.34% were missing 
OC use, 0.00% were missing parity, and 0.34% were missing breastfeeding data.  Compared to never 
OC users, ever OC users were more likely to be from the Philadelphia site but less likely to be from the 
New York site, more likely to have ever smoked cigarettes, to have ever consumed alcohol, to have more 
than a high school degree, to have ever used HRT, and to be born in 1950 or later.  Compared to 
nulliparous women, parous women were more likely to have a high school degree or less, and to have 
been born before 1950.  Compared to parous women who never breastfed, parous women who ever 
breastfed were more likely to be from the Utah site, non-white, to have never smoked cigarettes, to have 




 Table 4.1c reports baseline differences for the OV group.  In this group, 0.51% were missing OC 
use, 0.03% were missing parity, and 0.76% were missing breastfeeding data.  Compared to never OC 
users, ever OC users were younger at baseline, more likely to be pre-menopausal, to have ever smoked 
cigarettes, to have ever consumed alcohol, to have more than a high school degree, and to be born in 
1950 or later.  Compared to nulliparous women, parous women were older at baseline and at censor, 
more likely to be post-menopausal, to have a high school degree or less, to have ever used HRT, to have 
been born before 1950, and to have a higher BMI.  Compared to parous women who never breastfed, 
parous women who ever breastfed were more likely to be from the Australia site, pre-menopausal, to 
have more than a high school degree, and to have been born in 1950 or later. 
Table 4.1d reports baseline differences for the BR group.  In this group, 0.49% were missing OC 
use, 0.03% were missing parity, and 0.77% were missing breastfeeding data.  Compared to never OC 
users, ever OC users were younger at baseline, more likely to be pre-menopausal, to have ever smoked 
cigarettes, to have ever consumed alcohol, to have more than a high school degree, and to be born in 
1950 or later.  Compared to nulliparous women, parous women were older at baseline and at censor, 
more likely to be post-menopausal, to have a high school degree or less, to have ever used HRT, to have 
been born before 1950, and to have a higher BMI.  Compared to parous women who never breastfed, 
parous women who ever breastfed were more likely to be from the Australia site, pre-menopausal, to 
have more than a high school degree, and to have been born in 1950 or later. 
Table 4.2 reports the multivariable results of our Cox proportional hazards regression analyses 
for the BR-OV, OV, and BR groups.  We observed a non-statistically significant greater risk of BR-OV for 
ever OC use versus never use (HR=1.62, 95% CI: 0.91, 2.90) but a borderline statistically significant 
lower risk of OV (HR=0.59, 95% CI: 0.34, 1.00).  There was no association between OC use and risk of 
BR; however, the proportional hazards assumption was violated for OC use in this group.  Therefore, we 
stratified by an attained age of 52 years after review of the cumulative distribution of the martingale 
residuals.  For those with an attained age greater than 52 years, ever OC use was associated with an 
increased risk of BR (HR=1.31, 95% CI: 1.05, 1.65).  For those with an attained age less than or equal to 




number of full-term (FT) pregnancies, we observed a statistically significant lower risk of BR-OV for those 
with two or more FT pregnancies compared to nulliparous women (HR=0.47, 95% CI: 0.22, 0.97).  We 
observed a statistically significant lower risk of BR in our crude model (HR=0.77, 95% CI: 0.61, 0.98); 
however the association became attenuated and no longer statistically significant after adjustment for 
potential confounders.  There was no association between number of FT pregnancies and risk of OV.  We 
found no association between later age at first FT pregnancy and risk of BR-OV.  In contrast, we 
observed a statistically significant greater risk of OV for women with a first FT pregnancy 25-29 years 
compared to less than 20 years (HR=3.51, 95% CI: 1.08, 11.40) and a statistically significant greater risk 
of BR for women with an age at first FT pregnancy 30 years or later compared to less than 20 years 
(HR=1.49, 95% CI: 1.09, 2.04).  We found no association between years since last FT pregnancy and risk 
of BR-OV, OV, and BR.  However, the proportional hazards assumption was violated for this variable in 
the OV group so we stratified by an attained age of 52 years based on the cumulative distribution of the 
martingale residuals.  While we did not observe any statistically significant associations between years 
since last FT pregnancy and risk of OV, there was a suggestion of a greater risk in younger women and a 
lower risk in older women for 0-5 years since last FT pregnancy versus nulliparous (data not shown).  
Lastly, we observed no association between breastfeeding or breastfeeding and pregnancy combined 
and BR-OV, OV, and BR.  In order to test the robustness of our results we ran Poisson regression and 
compared these results to our main findings using Cox proportional hazards (Supplemental Table 4.4).  
We observed minimal differences in the results of the two models suggesting our findings are robust to 
model specification. 
Figures 4.2a, 4.2b, and 4.2c show our multivariable results stratified by lifetime risk of breast or 
ovarian cancer greater than or equal to 20% (high risk) compared to less than 20% (average risk) for OC 
use, number of FT pregnancies, and breastfeeding, respectively.  For ever versus never OC use we 
observed a greater risk of BR-OV in those at high risk (HR=3.05, 95% CI: 1.02, 9.13) but this finding was 
attenuated and not statistically significant for those at average risk (HR=1.21, 95% CI: 0.60, 2.43).  In 
contrast, for ever OC use we observed a lower risk of OV in those at high risk (HR=0.33, 95% CI: 0.13, 
0.86); however, this finding was attenuated and not statistically significant in those at average risk 




women at high or average risk, but when we stratified by attained age 52 years to account for the 
proportional hazards violation there was a suggestion of a greater risk in older women in the high risk 
group (HR=1.54, 95% CI: 0.79, 3.01), but not in younger women in the high risk group (HR=1.07, 95% CI: 
0.70, 1.63).  Overall we found no association between number of FT pregnancies and risk of BR-OV, OV, 
and BR in either the high or average risk groups; however there was a borderline inverse association 
between having 2 or more FT pregnancies and BR-OV in the average risk group (HR=0.46, 95% CI: 0.20, 
1.08).  Lastly, there was no association between breastfeeding and risk of BR-OV, OV, and BR when we 
stratified by lifetime risk.  Despite these differences in our risk factor associations between women at high 
and average risk, we did not observe any statistically significant interactions on either the multiplicative or 
additive scale for lifetime risk. 
In order to determine whether our exposures had a differential effect on risk of first primary 
ovarian cancer (OV) versus second primary ovarian cancer (BR-OV), we combined our OV and BR-OV 
analytic groups and assessed interaction on the multiplicative and additive scale between our exposures 
and pre-baseline breast cancer status.  We observed a borderline statistically significant multiplicative 
interaction between OC use and pre-baseline breast cancer status (p=0.07) but no additive interaction.  
When we stratified by lifetime risk we observed a statistically significant multiplicative interaction in 
women at high risk between OC use and pre-baseline breast cancer status (p<0.05) and breastfeeding 
and pre-baseline breast cancer status (p<0.05), but no additive interaction. 
We further examined our results stratified by BRCA1/2 mutation status (Supplemental Table 4.5).  
Due to a small number of events in the BRCA1/2 mutation positive stratum in the OV group we were 
unable to obtain multivariable estimates.  In the BRCA1/2 mutation positive group, there was a 
suggestion of a greater risk of BR-OV for ever OC users versus never users (HR=2.10, 95% CI: 0.80, 
5.48), however it was not statistically significant.  Overall there was no association between OC use and 
risk of BR in either BRCA1/2 mutation group, but when we stratified by attained age 52 years there was a 
statistically significant greater risk for older women in both BRCA1/2 mutation positive and negative 
groups (HR=3.10, 95% CI: 1.04, 9.25) and (HR= 1.27, 95% CI: 1.01, 1.61), respectively.  We observed 




positive and negative groups; however they did not reach statistical significance.  Similarly, in the 
BRCA1/2 mutation negative group there was an inverse association between one FT pregnancy versus 
nulliparous and OV, however the results were not statistically significant.  In contrast, for BRCA1/2 
positive women we observed a statistically significant positive association between having 1 FT 
pregnancy versus nulliparous and risk of BR (HR=2.66, 95% CI: 1.19, 5.91), but no association in 
BRCA1/2 negative women (multiplicative interaction p<0.05).   
In order to evaluate survivor bias in the BR-OV group we conducted a sensitivity analysis 
stratifying by breast cancers diagnosed within 2 years of the baseline interview (pseudo-incident cancers) 
and breast cancers diagnosed more than 2 years from the baseline interview (prevalent cancers) 
(Supplemental Table 4.6).  The positive association between OC use and risk of BR-OV was only seen in 
the prevalent breast cancers and there was no association between OC use and risk of BR-OV in the 
pseudo-incident breast cancers. 
4.5. Discussion 
In this prospective cohort study of breast cancer families representing women across the risk 
spectrum, we examined the association between hormonal and reproductive risk factors and the risk of 
BR-OV, OV, and BR.  For women who had ever used OCs compared to women who had never used 
OCs, we observed a non-statistically significant greater risk of BR-OV.  Further, when we stratified by 
lifetime risk of breast and ovarian cancer, this association became stronger and statistically significant in 
women at high risk compared to women at average risk.  In contrast, we observed an inverse association 
between OC use and risk of OV.  When we stratified by lifetime risk of breast or ovarian cancer this 
association only remained in the high risk group.  These findings suggest that OC use may have a 
differential effect on ovarian cancer risk depending on whether it is a first primary or second primary 
cancer, and whether a woman is at high or average risk.  We observed a positive association between 
OC use and BR but this association was limited to women with an attained age of 52 years or more.  
Further, when we stratified by lifetime risk this association appeared stronger in the high risk group. 
Our finding of an increased risk of BR-OV with ever OC use contradicts a study by Trentham-Diaz 




limited number of events (n=36) in their study.  Additionally, this result contradicts our case-control 
findings of an inverse association between OC use and BR-OV.  It is possible that there were differences 
between the BR-OV cases from our case-control study compared to this cohort study that could have 
contributed to these discordant OC use findings.  We had limited tumor characteristic data for our cases, 
particularly in the case-control study, so we were unable to investigate whether differences in tumor 
histology or molecular characteristics contributed to the observed differences.  Two studies have 
observed differences in the association between OC use and ovarian cancer by histology and molecular 
characteristics with one study showing a non-statistically significant greater risk for mucinous and clear 
cell cancers [183] and one study showing no association with mucinous cancers and with well-
differentiated serous cancers [184].  While the median age at breast cancer diagnosis was the same 
between studies (44 years), the median time between the breast and ovarian cancer diagnoses was 7 
years in the case-control study and 11 years in this cohort study, suggesting possible differences in 
participant or tumor characteristics.  Lastly, differences in study design could have contributed to these 
discordant findings as retrospective case-control studies are more susceptible to recall and selection bias 
compared to prospective cohort studies.  However, survivor bias may have affected the results of our 
case-control and cohort study as both studies included pseudo-incident cancers (diagnosed ≤2 years 
before baseline) and prevalent cancers (diagnosed >2 years before baseline).  When the cohort study 
was restricted to the pseudo-incident cancers, we observed no association between OC use and BR-OV.  
In order to explore this finding, we examined baseline differences between the prevalent and pseudo-
incident cases.  Women with prevalent first primary breast cancer were more likely to be older, post-
menopausal, to have ever smoked cigarettes, to have ever consumed alcohol, to have been born before 
1950, and to be at high risk (BRCA1/2 mutation carriers and ≥20% lifetime risk of breast or ovarian 
cancer).  It is possible that women born before 1950 were exposed to OCs with higher estrogen 
formulations compared to women born after 1950 which could have contributed to the discrepant findings; 
however all of our models were stratified by birth cohort.  Further, our multivariable models were adjusted 
for menopausal status, cigarette smoking, and alcohol consumption.  When we stratified by risk based on 
BRCA1/2 mutation status or BOADICEA lifetime risk, the positive association was only seen in the high 




cancers.  So it is possible that the positive association between OC use and BR-OV in high risk women 
was partially driven by there being more prevalent cancers in this group.  Lastly, it is possible that 
information bias may have contributed to the discrepant OC use findings between prevalent and pseudo-
incident cases.  Parity and breastfeeding, which are major life events, may be easier to recall than OC 
use, and their findings were not discordant between the prevalent and pseudo-incident cases.  Recall of 
OC use, on the other hand, may have been less accurate for the prevalent cases as they were older and 
more likely to be post-menopausal; however, OC use has been shown to be reliably recalled [174,175] 
and using a crude ever versus never categorization of OC use should improve recall. 
Our finding of an inverse association between OC use and OV is consistent with the literature 
(reviewed in [45]).  Additionally, our finding of an increased risk of BR in older women is consistent with 
much of the literature (reviewed in [45]) and some studies have similarly observed differences in the 
association between OC use and BR by age of breast cancer diagnosis with some studies showing 
higher risks [145,185] and one study reporting a lower risk [186] in women diagnosed at older ages.  
While our models were stratified by birth cohort, a possible explanation of our finding of an increased risk 
of BR in older women could be related to differences in OC formulations over time.  A study by Work and 
colleagues observed an increased risk of ER/PR negative breast cancer with OC use before 1975 but not 
in 1975 or later [5].  While we were missing ER/PR data on 55.9% of our BR cases, we ran a sensitivity 
analysis stratifying by known ER status and our results suggested a positive association between OC use 
and ER negative BR, but not ER positive BR, regardless of attained age; however the results were not 
statistically significant (data not shown). 
We observed a lower risk of BR-OV with two or more FT pregnancies which is consistent with the 
study by Trentham-Diaz and colleagues which showed a non-statistically significant lower risk of BR-OV 
with four or more children [86], but not consistent with Cvelbar and colleagues who observed no 
association with DPBOC [88], or our case-control study showing an increased risk of BR-OV with two or 
more children (Chapter 3).  We found no association between parity and OV or BR in our multivariable 
models which is not consistent with the literature showing a protective effect of parity on risk of OV and 




throughout sensitivity analyses.  We did not observe an association between age at first FT pregnancy 
and BR-OV.  While the study by Trentham-Diaz and colleagues suggested a positive association between 
older age at first FT pregnancy and BR-OV, their finding was not statistically significant [86].  Older age at 
first FT pregnancy was associated with an increased risk of OV and BR.  While these results are 
consistent with the breast cancer literature, the ovarian cancer literature has been mixed (reviewed in 
[45]).  Further, we observed no association between age at first FT pregnancy and OV and BR in our 
case-control study. 
We found no association between breastfeeding or pregnancy and breastfeeding combined with 
BR-OV, OV, or BR.  While this null finding for BR-OV is consistent with the study by Cvelbar and 
colleagues [88], our findings for OV and BR are not consistent with the literature suggesting a protective 
effect of breastfeeding on OV [187,188] and BR (reviewed in [45]). Additionally, these results for BR-OV 
and BR are not consistent with our case-control study which observed an inverse association between 
breastfeeding and BR-OV and BR. 
In order to test the robustness of our predicted measure of lifetime risk of breast and ovarian 
cancer using a 20% cutoff, we conducted sensitivity analyses using a continuous measure of predicted 1-
year risk.  While our results were similar between the two risk measures there were a few differences 
worth noting.  While we did not observe interaction on either the multiplicative or additive scale for the 
association between OC use and BR-OV by lifetime risk, we observed a borderline statistically significant 
multiplicative interaction using the continuous measure of 1-year risk (p=0.06), but no additive interaction.  
In addition, while we did not observe interaction on either the multiplicative or additive scale for the 
association between OC use and BR by lifetime risk and attained age 52 years, we observed 
multiplicative interaction by 1-year risk (p<0.05), but no additive interaction. 
Our study had several limitations including a limited number of OV-BR cases which prevented us 
from examining risk factor associations with this group and comparing to the BR-OV group to assess the 
importance of diagnosis order.  However, our case-control study observed similar risk factor associations 
for the BR-OV and OV-BR groups.  Information bias may have contributed to our observed findings due 




the affected cohort.  We had limited treatment data on our BR-OV cases (22.1% missing) to evaluate 
interaction between our main exposures and treatment.  We had 46 BR-OV events with any 
chemotherapy, radiotherapy, or hormone therapy and when we examined our results limited to these 
cases we observed minimal differences in our results.  We only had 7 BR-OV events with surgery only or 
no treatment and were therefore unable to examine this stratum.  However, since women with breast 
cancer have an increased risk of ovarian cancer and women with ovarian cancer have an increased risk 
of breast cancer, it is unlikely that treatment is the predominant cause [86].  We had a limited number of 
confirmed BR-OV (45.6%) and OV (47.1%) cases and were unable to assess our results limited to 
confirmed cases.  There could be some concern that a non-confirmed ovarian cancer following a breast 
cancer diagnosis is a metastasis rather than a second primary cancer, however this has been shown to 
be an unlikely event [169,170].  To further address this concern we ran our analyses removing 
synchronous cancers diagnosed within 1 year of each other (n=2) and observed minimal differences in 
our results with the exception being the positive association between OC use and BR-OV became 
stronger and statistically significant (HR = 1.93, 95% CI:1.06, 3.51).  We may have had information bias 
through misclassification of our exposures; however, parity and breastfeeding, which are major life 
events, are less susceptible to misclassification and have been shown to be reliably reported [172,173].  
Further, we used crude measures of these variables (ever versus never for breastfeeding and nulliparous 
versus parous defined as 1 or ≥2 for parity) which minimizes exposure misclassification.  OC use, on the 
other hand, may be more subject to misclassification compared to breastfeeding and parity.  However, 
OC use has also been shown to be reliably reported [174,175], and we similarly used a crude measure 
(ever versus never) which would have minimized any misclassification.  For the affected cohort, exposure 
information was collected after their breast cancer diagnosis whereas for the unaffected cohort, exposure 
information was collected prior to a cancer diagnosis; therefore recall bias in the affected cohort could 
have influenced the results.  Selection bias may have influenced our results through loss to follow-up.  In 
the overall ProF-SC cohort 18.1% have been lost to follow-up; however those lost to follow-up had similar 
baseline proportions of OC use and parity as the total cohort [181].  Therefore, any misclassification due 
to loss to follow-up would likely be non-differential.  While our cohort contained women across the risk 




without a family history (sporadic cases) or the general population of women at average risk.  Lastly, we 
were likely underpowered to assess interaction on both the multiplicative and additive scale in the BR-OV 
and OV groups.  For example, while we did not find a statistically significant interaction by lifetime risk for 
the association between OC use and OV on either the multiplicative or additive scale, we would expect 
interaction on one scale as both OC use and lifetime risk were statistically significantly associated with 
risk of OV. 
Our study also had many strengths.  The BCFR recruited probands with breast or ovarian cancer 
and their relatives in the mid-1990s, thus establishing a family-based cohort representing women across 
the continuum of breast and ovarian cancer risk.  Therefore, this study was uniquely able to examine 
established risk factors for breast and ovarian cancer in women across the spectrum of risk.  This is 
particularly critical as studies have already shown differences in breast and ovarian cancer risk factors 
between average and high risk women [189,190], including our case-control study.  ProF-SC was then 
established to follow these women prospectively extending the cohort and allowing for updated exposure 
and outcome information and alternative analytic designs.  Further, having breast and ovarian cancer 
cases recruited at baseline allowed us to follow these women prospectively for the development of a 
second primary cancer.  Therefore, we were able examine differences in risk factor associations between 
first primary and second primary ovarian cancer in the same study.  Our study had extensive risk factor 
data which is often limited in large population-based registries, insurance claims databases, and clinic 
databases.  Lastly, having data at two time points allowed us to create time-varying covariates to more 
accurately account for changes in covariates over time. 
In the U.S. there are over 3.5 million breast cancer survivors; the largest group of cancer 
survivors in the country [176].  As developing a second primary cancer is one of the most severe 
sequelae of a cancer diagnosis, identifying cancer survivors at greatest risk is critical.  While there is no 
established screening tool for ovarian cancer, identifying women with a breast cancer diagnosis at 
greatest risk of developing a second primary ovarian cancer could help inform clinical recommendations 
for prophylactic surgery.  Our study contributes to the sparse epidemiologic literature on risk of second 




breast and ovarian cancer risk factors.  As many of our findings were not consistent between our case-
control and cohort studies regarding risk of BR-OV, additional studies are needed to replicate our 
findings.  In particular, as oral contraceptives also function as a chemopreventive agent often prescribed 
to women at high risk of ovarian cancer, further work is needed to understand whether they similarly 





4.6. Tables and Figures 
 








Table 4.1a. Demographic, reproductive, and behavioral differences between exposed and unexposed for the BR-OV group, ProF-SC (n = 
8,969) 
                        
Total 
 
Ever OC Use Never OC Use 
 
Parous Nulliparous 




  N/Mean %/SD 
 
N/Mean %/SD N/Mean %/SD  N/Mean %/SD N/Mean %/SD  N/Mean %/SD N/Mean %/SD 
Age at Baseline 50.63 10.95 
 
48.84 9.93 55.06 12.01  51.57 10.78 46.90 10.83  50.50 10.91 53.95 10.04 
Age at Censure   58.23 12.06 
 
56.81 11.42 61.79 12.78  59.05 11.96 54.97 11.89  58.11 12.08 61.14 11.42 





Philadelphia 546 6.09 
 
339 5.34 186 7.21  434 6.06 110 6.11  250 5.09 169 7.62 
New York 904 10.08 
 
543 8.56 355 13.76  709 9.90 194 10.77  420 8.55 289 13.04 
Utah 188 2.10 
 
130 2.05 57 2.21  169 2.36 19 1.05  135 2.75 33 1.49 
Australia 1615 18.01 
 
1326 20.90 288 11.16  1295 18.08 320 17.77  1090 22.18 202 9.11 
Ontario 1906 21.25 
 
1374 21.65 522 20.23  1541 21.51 365 20.27  1020 20.76 514 23.18 
California 3810 42.48 
 
2634 41.51 1172 45.43  3015 42.09 793 44.03  1999 40.68 1010 45.56 





White 5485 61.16 
 
4090 64.45 1376 53.33  4350 60.73 1133 62.91  3075 62.58 1255 56.61 
Other 3444 38.40 
 
2238 35.27 1190 46.12  2789 38.94 652 36.20  1826 37.16 951 42.90 
Missing 40 0.45 
 
18 0.28 14 0.54  24 0.34 16 0.89  13 0.26 11 0.50 
Menopausal 
Status   
 
    
 
    
 
    
Pre 3768 42.01 
 
2985 47.04 763 29.57  2821 39.38 945 52.47  2140 43.55 665 30.00 
Post 5201 57.99 
 
3361 52.96 1817 70.43  4342 60.62 856 47.53  2774 56.45 1552 70.00 





Ever 3741 41.71 
 
2889 45.52 844 32.71  3014 42.08 727 40.37  1957 39.82 1041 46.96 
Never 5188 57.84 
 
3439 54.19 1728 66.98  4139 57.78 1045 58.02  2952 60.07 1173 52.91 
Missing 40 0.45 
 
18 0.28 8 0.31  10 0.14 29 1.61  5 0.10 3 0.14 





Ever 3837 42.78 
 
3045 47.98 786 30.47  2927 40.86 908 50.42  2008 40.86 911 41.09 
Never 5077 56.61 
 
3270 51.53 1785 69.19  4216 58.86 860 47.75  2901 59.04 1293 58.32 
Missing 55 0.61 
 
31 0.49 9 0.35  20 0.28 33 1.83  5 0.10 13 0.59 
 
Education   
 
    
 
    
 




> High school 6137 68.42 
 
4512 71.10 1612 62.48  4667 65.15 1467 81.45  3388 68.95 1262 56.92 
≤ High school 2778 30.97 
 
1809 28.51 954 36.98  2468 34.45 309 17.16  1507 30.67 946 42.67 
Missing 54 0.60 
 
25 0.39 14 0.54  28 0.39 25 1.39  19 0.39 9 0.41 





Ever 2001 22.31 
 
1441 22.71 556 21.55  1672 23.34 328 18.21  1059 21.55 611 27.56 
Never 6861 76.50 
 
4855 76.50 1987 77.02  5434 75.86 1425 79.12  3826 77.86 1587 71.58 
Missing 107 1.19 
 
50 0.79 37 1.43  57 0.80 48 2.67  29 0.59 19 0.86 





<1950 4463 49.76 
 
2859 45.05 1584 61.40  3769 52.62 691 38.37  2354 47.90 1398 63.06 
1950 - 1959 2788 31.08 
 
2132 33.60 649 25.16  2202 30.74 585 32.48  1619 32.95 578 26.07 
1960 - 1969 1477 16.47 
 
1176 18.53 290 11.24  1056 14.74 420 23.32  832 16.93 215 9.70 
≥1970 241 2.69 
 
179 2.82 57 2.21  136 1.90 105 5.83  109 2.22 26 1.17 





Positive 595 6.63 
 
448 7.06 146 5.66  468 6.53 127 7.05  339 6.90 126 5.68 
Negative 8374 93.37 
 
5898 92.94 2434 94.34  6695 93.47 1674 92.95  4575 93.10 2091 94.32 
Age at 
Menarche 12.68 1.58 
 
12.66 1.56 12.74 1.64  12.69 1.58 12.67 1.62  12.69 1.56 12.67 1.61 
Missing 122 1.36 
 
51 0.80 51 1.98  88 1.23 32 1.78  51 1.04 35 1.58 
BMI, kg/m2 26.03 5.67 
 
25.97 5.68 26.17 5.66  26.27 5.68 25.05 5.54  25.95 5.43 26.95 6.13 
Missing 234 2.61 
 
139 2.19 85 3.29  186 2.60 46 2.55  127 2.58 56 2.53 
Height, M 1.63 0.07 
 
1.63 0.07 1.61 0.07  1.62 0.07 1.63 0.07  1.63 0.07 1.62 0.07 
Missing 95 1.06 
 





Table 4.1b. Demographic, reproductive, and behavioral differences between exposed and unexposed for the OV-BR group, ProF-SC (n = 
298) 






N/Mean %/SD N/Mean %/SD 
 
N/Mean %/SD N/Mean %/SD 
 
N/Mean %/SD N/Mean %/SD 
Age at Baseline 54.53 11.86  51.23 10.52 58.28 12.33  55.68 11.70 49.44 11.29  54.71 12.23 57.33 10.71 
Age at Censure   63.09 12.48  59.76 11.49 66.96 12.62  64.13 12.40 58.51 11.88  63.31 12.78 65.62 11.67 
Study Site   
   
Philadelphia 46 15.44  32 20.38 13 9.49  36 14.81 10 18.18  17 11.33 18 19.57 
New York 161 54.03  70 44.59 89 64.96  128 52.67 33 60.00  75 50.00 53 57.61 
Utah 31 10.40  22 14.01 9 6.57  28 11.52 3 5.45  25 16.67 3 3.26 
Australia 15 5.03  7 4.46 7 5.11  14 5.76 1 1.82  10 6.67 4 4.35 
Ontario 13 4.36  9 5.73 4 2.92  11 4.53 2 3.64  7 4.67 4 4.35 
California 32 10.74  17 10.83 15 10.95  26 10.70 6 10.91  16 10.67 10 10.87 
Race   
   
White 214 71.81  118 75.16 94 68.61  172 70.78 42 76.36  100 66.67 72 78.26 
Other 80 26.85  37 23.57 42 30.66  68 27.98 12 21.82  48 32.00 19 20.65 
Missing 4 1.34  2 1.27 1 0.73  3 1.23 1 1.82  2 1.33 1 1.09 
Menopausal 
Status   
 
    
 
    
 
    
Pre 25 8.39  16 10.19 9 6.57  17 7.00 8 14.55  14 9.33 3 3.26 
Post 273 91.61  141 89.81 128 93.43  226 93.00 47 85.45  136 90.67 89 96.74 
Cigarette Use   
   
Ever 122 40.94  75 47.77 47 34.31  98 40.33 24 43.64  55 36.67 43 46.74 
Never 174 58.39  81 51.59 90 65.69  144 59.26 30 54.55  94 62.67 49 53.26 
Missing 2 0.67  1 0.64 . .  1 0.41 1 1.82  1 0.67 . . 
Alcohol Use   
   
Ever 102 34.23  63 40.13 38 27.74  83 34.16 19 34.55  52 34.67 31 33.70 
Never 192 64.43  93 59.24 97 70.80  158 65.02 34 61.82  97 64.67 61 66.30 
Missing 4 1.34  1 0.64 2 1.46  2 0.82 2 3.64  1 0.67 . . 
 
Education   
 
    
 
    
 




> High school 211 70.81  122 77.71 87 63.50  165 67.90 46 83.64  105 70.00 59 64.13 
≤ High school 84 28.19  33 21.02 50 36.50  76 31.28 8 14.55  44 29.33 32 34.78 
Missing 3 1.01  2 1.27 . .  2 0.82 1 1.82  1 0.67 1 1.09 
HRT Use   
   
Ever 169 56.71  100 63.69 69 50.36  141 58.02 28 50.91  77 51.33 64 69.57 
Never 124 41.61  56 35.67 66 48.18  99 40.74 25 45.45  71 47.33 28 30.43 
Missing 5 1.68  1 0.64 2 1.46  3 1.23 2 3.64  2 1.33 . . 
Year of birth   
   
<1950 187 62.75  83 52.87 102 74.45  161 66.26 26 47.27  92 61.33 68 73.91 
1950 - 1959 73 24.50  52 33.12 19 13.87  55 22.63 18 32.73  37 24.67 18 19.57 
1960 - 1969 29 9.73  15 9.55 14 10.22  21 8.64 8 14.55  16 10.67 5 5.43 
≥1970 9 3.02  7 4.46 2 1.46  6 2.47 3 5.45  5 3.33 1 1.09 
BRCA1/2 Status   
   
Positive 60 20.13  33 21.02 26 18.98  51 20.99 9 16.36  34 22.67 17 18.48 
Negative 238 79.87  124 78.98 111 81.02  192 79.01 46 83.64  116 77.33 75 81.52 
Age at 
Menarche 12.49 1.57 
 12.45 1.66 12.54 1.47  12.46 1.61 12.61 1.37  12.62 1.70 12.23 1.43 
Missing 5 1.68  2 1.27 1 0.73  4 1.65 1 1.82  2 1.33 2 2.17 
BMI, kg/m2 26.35 6.12  26.19 6.63 26.55 5.56  26.42 5.63 26.06 7.98  26.28 5.54 26.66 5.82 
Missing 5 1.68  3 1.91 1 0.73  4 1.65 1 1.82  3 2.00 1 1.09 
Height, M 1.62 0.06  1.63 0.06 1.61 0.06  1.62 0.06 1.63 0.07  1.62 0.06 1.62 0.06 










Ever OC Use Never OC Use 
 
Parous Nulliparous 




  N/Mean %/SD 
 
N/Mean %/SD N/Mean %/SD 
 
N/Mean %/SD N/Mean %/SD 
 
N/Mean %/SD N/Mean %/SD 
Age at Baseline 45.93 15.00  43.31 12.97 52.91 17.64  49.93 13.46 34.37 13.11  49.10 13.63 52.88 12.46 
Age at Censure   56.67 14.84  54.62 13.45 62.19 16.83  60.55 13.16 45.46 13.65  59.92 13.33 62.83 12.31 
Study Site   
   
Philadelphia 826 6.96  614 7.13 193 6.03  586 6.65 239 7.83  347 5.19 175 8.60 
New York 1810 15.25  1157 13.44 639 19.96  1172 13.30 638 20.90  826 12.35 346 16.99 
Utah 693 5.84  536 6.23 155 4.84  483 5.48 210 6.88  435 6.51 45 2.21 
Australia 3756 31.64  2767 32.15 975 30.45  2801 31.78 954 31.25  2438 36.46 349 17.14 
Ontario 2210 18.62  1713 19.90 492 15.37  1613 18.30 597 19.55  1156 17.29 450 22.10 
California 2575 21.69  1820 21.15 748 23.36  2158 24.49 415 13.59  1485 22.21 671 32.96 
Race   
   
White 8807 74.20  6580 76.45 2196 68.58  6353 72.09 2452 80.31  4948 73.99 1319 64.78 
Other 2972 25.04  1978 22.98 979 30.57  2403 27.27 567 18.57  1697 25.38 702 34.48 
Missing 91 0.77  49 0.57 27 0.84  57 0.65 34 1.11  42 0.63 15 0.74 
Menopausal 
Status   
 
    
 
    
 
    
Pre 7740 65.21  6258 72.71 1442 45.03  5084 57.69 2655 86.96  4068 60.83 948 46.56 
Post 4130 34.79  2349 27.29 1760 54.97  3729 42.31 398 13.04  2619 39.17 1088 53.44 
Cigarette Use   
   
Ever 4775 40.23  3710 43.10 1052 32.85  3690 41.87 1083 35.47  2671 39.94 986 48.43 
Never 7025 59.18  4860 56.47 2137 66.74  5096 57.82 1928 63.15  4009 59.95 1048 51.47 
Missing 70 0.59  37 0.43 13 0.41  27 0.31 42 1.38  7 0.10 2 0.10 
Alcohol Use   
   
Ever 5365 45.20  4288 49.82 1065 33.26  3818 43.32 1545 50.61  2961 44.28 826 40.57 
Never 6412 54.02  4262 49.52 2120 66.21  4949 56.16 1462 47.89  3710 55.48 1200 58.94 
Missing 93 0.78  57 0.66 17 0.53  46 0.52 46 1.51  16 0.24 10 0.49 
Education   




> High school 8019 67.56  6195 71.98 1798 56.15  5446 61.80 2570 84.18  4335 64.83 1049 51.52 
≤ High school 3779 31.84  2377 27.62 1384 43.22  3330 37.79 448 14.67  2328 34.81 975 47.89 
Missing 72 0.61  35 0.41 20 0.62  37 0.42 35 1.15  24 0.36 12 0.59 
HRT Use    
Ever 2187 18.42  1565 18.18 612 19.11  1950 22.13 237 7.76  1366 20.43 581 28.54 
Never 9450 79.61  6895 80.11 2535 79.17  6717 76.22 2731 89.45  5262 78.69 1432 70.33 
Missing 233 1.96  147 1.71 55 1.72  146 1.66 85 2.78  59 0.88 23 1.13 
Year of birth   
   
<1950 4460 37.57  2637 30.64 1796 56.09  4050 45.95 408 13.36  2863 42.81 1159 56.93 
1950 - 1959 2889 24.34  2312 26.86 564 17.61  2392 27.14 496 16.25  1845 27.59 508 24.95 
1960 - 1969 2509 21.14  2119 24.62 381 11.90  1781 20.21 728 23.85  1470 21.98 295 14.49 
≥1970 2012 16.95  1539 17.88 461 14.40  590 6.69 1421 46.54  509 7.61 74 3.63 
BRCA1/2 Status   
   
Positive 558 4.70  414 4.81 140 4.37  367 4.16 190 6.22  302 4.52 56 2.75 
Negative 11312 95.30  8193 95.19 3062 95.63  8446 95.84 2863 93.78  6385 95.48 1980 97.25 
Age at 
Menarche 12.86 1.58 
 12.82 1.55 12.95 1.63  12.88 1.59 12.78 1.55  12.89 1.56 12.87 1.67 
Missing 182 1.53  110 1.28 37 1.16  107 1.21 74 2.42  81 1.21 24 1.18 
BMI, kg/m2 25.63 5.64  25.57 5.67 25.77 5.55  26.10 5.62 24.28 5.48  25.83 5.39 26.95 6.21 
Missing 282 2.38  194 2.25 74 2.31  205 2.33 75 2.46  147 2.20 54 2.65 
Height, M 1.63 0.07  1.64 0.07 1.62 0.07  1.63 0.07 1.65 0.07  1.63 0.07 1.62 0.07 





Table 4.1d. Demographic, reproductive, and behavioral differences between exposed and unexposed groups for the BR group, ProF-SC 
(n = 12,974) 
                        
Total 
 
Ever OC Use Never OC Use 
 
Parous Nulliparous 




  N/Mean %/SD  N/Mean %/SD N/Mean %/SD  N/Mean %/SD N/Mean %/SD  N/Mean %/SD N/Mean %/SD 
Age at Baseline 47.06 15.13  44.21 13.16 54.29 17.28  50.91 13.49 35.19 13.66  50.03 13.72 53.85 12.34 
Age at Censor   57.74 14.85  55.47 13.51 63.53 16.42  61.46 13.08 46.25 14.06  60.79 13.30 63.77 12.08 
Study Site   
   
Philadelphia 909 7.01  666 7.19 224 6.14  653 6.67 255 8.03  376 5.14 206 8.67 
New York 1900 14.64  1198 12.93 687 18.84  1247 12.73 653 20.56  872 11.92 375 15.78 
Utah 787 6.07  604 6.52 181 4.96  570 5.82 217 6.83  511 6.98 56 2.36 
Australia 4003 30.85  2902 31.33 1086 29.78  3028 30.92 974 30.67  2627 35.90 387 16.28 
Ontario 2405 18.54  1817 19.61 583 15.99  1786 18.24 619 19.49  1263 17.26 514 21.62 
California 2970 22.89  2077 22.42 886 24.29  2510 25.63 458 14.42  1668 22.80 839 35.30 
Race   
   
White 9569 73.76  7029 75.87 2508 68.77  7031 71.79 2536 79.85  5405 73.87 1531 64.41 
Other 3310 25.51  2184 23.58 1110 30.44  2703 27.60 605 19.05  1868 25.53 830 34.92 
Missing 95 0.73  51 0.55 29 0.80  60 0.61 35 1.10  44 0.60 16 0.67 
Menopausal 
Status   
 
    
 
    
 
    
Pre 7764 59.84  6276 67.75 1447 39.68  5104 52.11 2659 83.72  4080 55.76 951 40.01 
Post 5210 40.16  2988 32.25 2200 60.32  4690 47.89 517 16.28  3237 44.24 1426 59.99 
Cigarette Use   
   
Ever 5246 40.43  4016 43.35 1216 33.34  4113 42.00 1131 35.61  2927 40.00 1150 48.38 
Never 7651 58.97  5204 56.17 2418 66.30  5649 57.68 2001 63.00  4380 59.86 1225 51.54 
Missing 77 0.59  44 0.47 13 0.36  32 0.33 44 1.39  10 0.14 2 0.08 
Alcohol Use   
   
Ever 5789 44.62  4553 49.15 1224 33.56  4187 42.75 1600 50.38  3198 43.71 953 40.09 
Never 7083 54.59  4647 50.16 2404 65.92  5554 56.71 1528 48.11  4100 56.03 1412 59.40 
Missing 102 0.79  64 0.69 19 0.52  53 0.54 48 1.51  19 0.26 12 0.50 
Education   
   




≤ High school 4286 33.04  2639 28.49 1628 44.64  3803 38.83 482 15.18  2620 35.81 1153 48.51 
Missing 77 0.59  37 0.40 23 0.63  41 0.42 36 1.13  27 0.37 13 0.55 
HRT Use   
   
Ever 3030 23.35  2117 22.85 902 24.73  2703 27.60 327 10.30  1848 25.26 851 35.80 
Never 9692 74.70  6987 75.42 2684 73.59  6929 70.75 2761 86.93  5404 73.86 1499 63.06 
Missing 252 1.94  160 1.73 61 1.67  162 1.65 88 2.77  65 0.89 27 1.14 
Year of birth   
   
<1950 5300 40.85  3088 33.33 2184 59.88  4811 49.12 487 15.33  3356 45.87 1425 59.95 
1950 - 1959 3098 23.88  2471 26.67 614 16.84  2566 26.20 531 16.72  1947 26.61 574 24.15 
1960 - 1969 2562 19.75  2164 23.36 388 10.64  1826 18.64 736 23.17  1505 20.57 303 12.75 
≥1970 2014 15.52  1541 16.63 461 12.64  591 6.03 1422 44.77  509 6.96 75 3.16 
BRCA1/2 Status   
   
Positive 619 4.77  458 4.94 157 4.30  424 4.33 194 6.11  345 4.72 67 2.82 
Negative 12355 95.23  8806 95.06 3490 95.70  9370 95.67 2982 93.89  6972 95.28 2310 97.18 
Age at 
Menarche 12.85 1.58 
 12.81 1.56 12.96 1.64  12.88 1.59 12.78 1.56  12.88 1.57 12.87 1.67 
Missing 191 1.47  114 1.23 40 1.10  113 1.15 77 2.42  84 1.15 27 1.14 
BMI, kg/m2 25.82 5.68  25.75 5.71 25.98 5.59  26.28 5.66 24.40 5.52  25.99 5.44 27.13 6.18 
Missing 299 2.30  202 2.18 83 2.28  220 2.25 77 2.42  159 2.17 57 2.40 
Height, M 1.63 0.07  1.64 0.07 1.62 0.07  1.62 0.07 1.65 0.07  1.63 0.07 1.62 0.07 






Table 4.2. Hormonal and reproductive factors and risk of BR-OV, OV, and BR using Cox proportional hazards, ProF-SC 
 BR-OV OV BR 
 Model 1* Model 2**  Model 1* Model 2**  Model 1* Model 2** 
Exposure No. Events 
Events (n = 68) 
Person-time*** 
(111,152 py) 





Events (n = 68) 
Person-time*** 
(133,712 py) 





Events (n = 748)
Person-time*** 
(145,052) 
Events (n = 748)
Person-time*** 
(145,052) 




         
Never 17 1.00 (Ref) 1.00 (Ref) 24 1.00 (Ref) 1.00 (Ref) 182 1.00 (Ref) 1.00 (Ref) 
Ever 51 1.33 (0.75, 2.36) 1.62 (0.91, 2.90) 44 0.66 (0.39, 1.12) 0.59 (0.34, 1.00) 566 1.17 (0.97, 1.41) 1.14 (0.95, 1.38) 
     
Number of FT 
Pregnancies          
Nulliparous 18 1.00 (Ref) 1.00 (Ref) 14 1.00 (Ref) 1.00 (Ref) 145 1.00 (Ref) 1.00 (Ref) 
1 10 0.63 (0.25, 1.55) 0.64 (0.26, 1.62) 4 0.46 (0.15, 1.43) 0.56 (0.17, 1.81) 88 0.89 (0.66, 1.19) 0.98 (0.72, 1.32) 
≥2 40 0.50 (0.24, 1.05) 0.47 (0.22, 0.97) 50 0.78 (0.35, 1.74) 1.02 (0.44, 2.38) 515 0.77 (0.61, 0.98) 0.88 (0.68, 1.13) 
     
Age at 1st FT 
Pregnancy          
Nulliparous 18 2.00 (0.81, 4.98) 1.95 (0.79, 4.81) 14 3.88 (0.93, 16.19) 1.98 (0.50, 7.83) 145 1.56 (1.15, 2.12) 1.35 (0.98, 1.87) 
<20 7 1.00 (Ref) 1.00 (Ref) 3 1.00 (Ref) 1.00 (Ref) 81 1.00 (Ref) 1.00 (Ref) 
20 - 24 20 1.19 (0.50, 2.83) 1.10 (0.48, 2.51) 29 3.70 (1.15, 11.96) 2.94 (0.68, 12.78) 243 1.26 (0.98, 1.61) 1.22 (0.94, 1.58) 
25 - 29 13 0.90 (0.36, 2.28) 0.80 (0.32, 2.02) 16 3.17 (0.95, 10.60) 3.51 (1.08, 11.40) 164 1.28 (0.98, 1.66) 1.20 (0.91, 1.60) 
≥30 10 1.11 (0.42, 2.93) 1.05 (0.42, 2.63) 6 2.13 (0.56, 8.09) 2.87 (0.84, 9.77) 115 1.59 (1.19, 2.12) 1.49 (1.09, 2.04) 
     
Year Since Last 
FT Pregnancy          
Nulliparous 18 2.08 (0.98, 4.43) 2.17 (1.02, 4.63) 14 1.39 (0.62, 3.10) 1.09 (0.48, 2.46) 145 1.21 (0.94, 1.56) 1.06 (0.81, 1.38) 
0 - 5 1 1.02 (0.12, 8.69) 1.00 (0.11, 8.69) 2 1.56 (0.29, 8.46) 1.75 (0.29, 10.51) 20 1.03 (0.62, 1.70) 1.01 (0.61, 1.68) 
6 - 20 16 1.44 (0.71, 2.91) 1.38 (0.68, 2.80) 12 0.89 (0.41, 1.93) 0.90 (0.41, 1.98) 156 0.88 (0.68, 1.15) 0.86 (0.66, 1.12) 
≥21 33 1.00 (Ref) 1.00 (Ref) 40 1.00 (Ref) 1.00 (Ref) 427 1.00 (Ref) 1.00 (Ref) 
     
Breastfeeding    
Never  31 1.00 (Ref) 1.00 (Ref) 27 1.00 (Ref) 1.00 (Ref) 288 1.00 (Ref) 1.00 (Ref) 
 Ever 37 1.34 (0.71, 2.52) 1.37 (0.74, 2.56) 41 1.01 (0.54, 1.90) 1.05 (0.56, 1.98) 460 1.07 (0.88, 1.29) 1.05 (0.86, 1.27) 




Number  of FT 
Pregnancies & 
Breastfeeding 
         
Nulliparous 18 1.00 (Ref) 1.00 (Ref) 14 1.00 (Ref) 1.00 (Ref) 145 1.00 (Ref) 1.00 (Ref) 
Any FTP/Never 
Breastfed 13 0.53 (0.26, 1.10) 0.51 (0.24, 1.05) 13 0.72 (0.33, 1.55) 0.92 (0.41, 2.08) 143 0.80 (0.63, 1.01) 0.90 (0.71, 1.15) 
Any FTP/Ever 
Breastfed 37 0.70 (0.40, 1.24) 0.68 (0.38, 1.22) 41 0.75 (0.40, 1.39) 1.00 (0.52, 1.92) 460 0.84 (0.69, 1.02) 0.93 (0.76, 1.14) 
*Regression models conditional on birth cohort; hazard ratios include all main exposures (OC use, number of FT pregnancies, and breastfeeding) 
**Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, age at menarche, menopausal status, BMI, 
height, education, cigarette use, alcohol consumption, hormone replacement therapy, and all main exposures 




Figure 4.2a. Oral contraceptive use and risk of BR-OV, OV, and BR by risk profile, ProF-SC 
 
*Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, age at menarche, menopausal status, BMI, 
height, education, cigarette use, alcohol consumption, hormone replacement therapy, and all main exposures 
**Age is the time-scale 




Figure 4.2b. Number of full-term pregnancies and risk of BR-OV, OV, and BR by risk profile, ProF-SC 
 
*Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, age at menarche, menopausal status, BMI, 
height, education, cigarette use, alcohol consumption, hormone replacement therapy, and all main exposures 




Figure 4.2c. Breastfeeding and risk of BR-OV, OV, and BR by risk profile, ProF-SC 
 
 
*Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, age at menarche, menopausal status, BMI, 





Chapter 5. Methodological Considerations in the Study of Double Primary Breast and Ovarian 
Cancer 
 
In 1889 Dr. Theodore Billroth first described cases of multiple primary tumors in patients with skin 
cancer without metastases who later developed cancers of the stomach and bowel [191,192].  Since that 
first report, cases of multiple primary tumors were increasingly documented and in 1932 Warren and 
Gates developed the following criteria for multiple malignancies which are generally still followed today: 1) 
each tumor must be malignant, 2) each tumor must be distinct, and 3) one tumor cannot be the 
metastasis of the other [193-195].  Over time, research moved from identification of multiple primary 
tumors to understanding their etiology and research has suggested the following groups of factors to be 
associated with the development of second primary cancers including 1) treatment of the first cancer, 2) 
shared genetics, 3) shared risk factors, and 4) interactions between these factors.  Breast and ovarian 
cancer have shared risk factors and genetics and have been found to co-occur [34-41].  As of January 1, 
2016, there were approximately 3.5 million breast cancer survivors living in the U.S., the largest group of 
cancer survivors in the country [176].  Individuals with cancer are at an increased risk of developing a 
second primary cancer compared to individuals without cancer [196] and developing a second primary 
cancer increases the morbidity and mortality of cancer survivors, particularly when there is no effective 
screening tool to detect the second cancer at an early stage as with ovarian cancer.  Identifying 
potentially modifiable risk factors for double primary breast and ovarian cancer (DPBOC) could have a 
large impact on the health of cancer survivors and women at increased risk of breast and ovarian cancer.  
Therefore, the overall goals of this dissertation were to summarize the literature on DPBOC and to 
evaluate the contribution of shared risk factors, genetics/underlying risk, and their interaction, to the 
development of DPBOC, while considering possible treatment effects.  However, understanding the 
etiology of DPBOC is challenging due to the complexity of second cancers and methodological limitations 
of epidemiological studies.  This chapter summarizes the results of my dissertation in light of these 
complexities and methodological concerns. 
Chapter 2 was a comprehensive review of the literature to identify studies assessing risk factors 
for DPBOC.  The review focused on 1) epidemiologic risk factors (yielding 18 studies), 2) genetic risk 
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factors (yielding 13 studies), and 3) epigenetic risk factors (yielding 0 studies).  The first part of this 
comprehensive review assessed epidemiologic risk factors and DPBOC.  The majority of studies 
identified assessed the role of treatment in the development of DPBOC.  Only three studies were 
identified that assessed the association between oral contraceptive (OC) use, parity, or breastfeeding and 
risk of DPBOC; two were case-control studies [87,88] and one was a cohort study [86].  However, these 
studies were limited due to power (small number of events in each study ranging from 31 to 72 DPBOC 
cases) and assessment of crude associations only [88], and comparison across studies was difficult due 
to the use of different outcomes (ovarian cancer following breast cancer (BR-OV) [86], breast cancer 
following ovarian cancer (OV-BR) [87], and DPBOC combined [88]) and control groups (women with 
single primary breast cancer (BR) [86] and women with single primary ovarian cancer (OV) [87,88]).  It is 
important to note that none of the studies observed any statistically significant associations between OC 
use, parity, or breastfeeding and their outcomes which may have been due to limited power.  Results 
from this portion of the comprehensive review highlighted the need for more studies assessing the 
association between OC use, parity, and breastfeeding and risk of DPBOC.  The second part of this 
comprehensive review assessed genetics and risk of DPBOC and most of the studies identified focused 
on BRCA1/2 mutations or family history.  While differences in study design and outcome definitions made 
direct comparison across studies challenging, all studies reported an association between mutations in 
BRCA1/2 and risk of DPBOC [90,102-111,197].  Similarly, the majority of the studies identified supported 
an association between family history and risk of DPBOC [86,87,112,113]; however most only considered 
a dichotomous variable representing family history or no family history and did not take degree of the 
relative into account.  Results from this portion of the comprehensive review showed that BRCA1/2 and 
family history play a role in the development of DPBOC and these variables should be considered in 
epidemiologic studies of DPBOC.  The third part of the comprehensive review did not identify any studies 
assessing DNA methylation and risk of DPBOC, revealing the need for research in this area.  Overall, 
results from this comprehensive review not only highlight the dearth of research on risk factors for 
DPBOC, but also how differences in outcome (diagnosis order), study design, and small sample size may 
contribute to discordant or null findings. 
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To address these gaps we conducted a case-control study (Chapter 3), where we had more 
cases of DPBOC and could examine associations by diagnosis order, and a prospective cohort study 
(Chapter 4), where we could reduce information and selection bias, to examine OC use, parity, and 
breastfeeding and risk of BR-OV, OV-BR, OV, and BR using data from a study enriched for increased 
familial risk of breast and ovarian cancer.  In the case-control study we used data from the three clinic-
based sites of the Breast Cancer Family Registry (BCFR).  We ran unordered polytomous logistic 
regression with a clustered bootstrap to adjust our standard errors given the correlated nature of our 
family-based data in order to examine the association between our main exposures and our four 
outcomes: 1) BR-OV (n = 68 cases), 2) OV-BR (n = 18 cases), 3) BR (n = 2,136 cases), and 4) OV (n = 
214 cases).  We observed a statistically significant inverse association between OC use and risk of BR-
OV (OR=0.40, 95% CI: 0.22, 0.69) and OV-BR (OR=0.30, 95% CI: 0.05, 0.70).  Similarly, we observed a 
statistically significant inverse association between breastfeeding and BR-OV (OR=0.49, 95% CI: 0.28, 
0.84) and a suggestive non-statistically significant inverse association with OV-BR (OR=0.63, 95% CI: 
0.20, 2.74).  In contrast we observed a positive association between parous women with two or more 
children versus nulliparous and risk of BR-OV (OR=6.42, 95% CI: 2.80, 16.42) and OV-BR (OR=3.98, 
95% CI: 1.01, >999).  As the study cohort was enriched for increased familial risk we were able to 
examine whether our observed associations differed between women at high risk versus women at 
average risk.  When we stratified by lifetime risk of breast or ovarian cancer, estimated using BOADICEA, 
the inverse association with OC use only remained in the average risk group while the inverse association 
with breastfeeding only remained in the high risk group.  The positive association with parity remained in 
both the high and average risk groups.  Overall we observed similar findings when we examined our 
exposures with risk of OV and BR; however, the inverse association with OC use and positive association 
with parity was stronger for the double primary cancer groups compared to the single primary cancer 
groups.  As the positive association between parity and DPBOC disagreed with our original hypothesis, 
and the positive association with OV and BR disagree with much of the literature, we ran several 
sensitivity analyses to see if we could explain this association; however the positive association remained 
throughout.  As case-control studies are subject to information and selection bias due to exposures being 
collected after the outcome and the challenge of identifying appropriate controls, it is possible that these 
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forms of bias contributed to these unexpected findings.  We evaluated the impact of survivor bias by 
stratifying our results by pseudo-incident cases (cancers diagnosed ≤2 years prior to baseline) and 
prevalent cases (cancers diagnosed >2 years prior to baseline).  As this type of stratification in the 
DPBOC group also stratifies by time between diagnosis of the first and second primary cancers, we 
performed an additional analysis stratifying by only one of the cancers being diagnosed ≤2 years or >2 
years before baseline.  While we were limited by a small sample size for the DPBOC group, these results 
suggested the inverse association with OC use and the positive association with parity only remained in 
the prevalent group.  While both the inverse association with OC use and the positive association with 
parity were attenuated in the pseudo-incident group, the parity finding was still statistically significant.  
Further, the inverse association between OC use and BR and OV only remained in the prevalent group 
and there was no association with the pseudo-incident cases.  Unequal exposure distribution between the 
pseudo-incident and prevalent groups and possible differential recall bias, particularly for OC use, may 
have contributed to this potential survivor bias.  The results of this aim are summarized in Table 5.1. 
Table 5.1. Summary of findings for Aim 2: Case-Control Study* 
 
* The ↑ symbol represents a positive association; the ↓ symbol represents an inverse association; 





To address concerns of information and selection bias in our case-control study, we conducted a 
prospective cohort study to examine the association between OC use, parity, and breastfeeding and risk 
of BR-OV, OV, and BR (Chapter 4).  Our study included data on participants from The Breast Cancer 
Prospective Family Study Cohort (ProF-SC) who were enrolled in the six sites of the BCFR starting in 
1996 and prospectively followed (median follow-up time = 11.8 years).  We used Cox proportional 
hazards models with a robust sandwich estimator to account for the correlated nature of our family-based 
data to examine the association between our main exposures and four outcomes: 1) BR-OV (n = 68 
events), 2) OV-BR (n = 2 events), 3) OV (n = 68 events), and 4) BR (n = 748 events).  As we only had 2 
OV-BR events we were unable to examine this outcome in a multivariable model.  In this study we 
observed a non-statistically significant positive association between OC use and risk of BR-OV (HR = 
1.62, 95% CI: 0.91, 2.90) and when we stratified by BOADICEA lifetime risk of breast or ovarian cancer 
this result became stronger and statistically significant in women at high risk (HR = 3.05, 95% CI: 1.02, 
9.13) compared to women at average risk (multiplicative interaction using continuous 1-year risk measure 
p = 0.06).  In contrast we observed an inverse association between OC use and risk of OV.  Similar to our 
BR-OV findings we found a positive association between OC use and risk of BR but only in older women 
(>52 years).  Since our BR-OV group included prevalent breast cancer cases who were prospectively 
followed for ovarian cancer, these results may have also been influenced by survivor and recall bias.  To 
address this concern we again stratified by time between breast cancer diagnosis and baseline interview 
using a two-year cutpoint.  The positive association between OC use and BR-OV was only seen in the 
prevalent cancers and there was no association with the pseudo-incident cancers.  While baseline 
differences between the pseudo-incident and prevalent cases may have contributed to these discordant 
findings, recall bias may have also played a role with differential recall of OC use.  The results of this aim 






Table 5.2. Summary of findings for Aim 3: Cohort Study* 
 
* The ↑ symbol represents a positive association; the ↓ symbol represents an inverse association; 




In conclusion, when restricted to the pseudo-incident cases, the case-control and cohort studies 
were consistent in the finding of no association between OC use and risk of DPBOC.  In contrast, the 
studies were contradictory in the parity and breastfeeding findings with the case-control study suggesting 
a positive association with parity but an inverse association with breastfeeding, and the cohort study 
suggesting an inverse association with parity but no association with breastfeeding.  Since the pseudo-
incident analysis in the cohort study was better able to mimic a cohort analysis with only the first cancer 
being prevalent and the second cancer being incident, and thus was able to minimize selection and 
information bias better than the case-control study, the findings from this analysis may be more valid. 
The results from this dissertation highlight the benefits and limitations of different epidemiologic 
study designs in research on second primary cancers.  Case-control studies, while ideal for including a 
sufficient number of cases, a particular concern for rare outcomes with long latency periods such as 
second primary cancer, are subject to information and selection bias.  Recall bias, a type of information 
bias, is a concern in case-control studies as exposure information is collected after the outcome and 
reporting of exposure history may differ between cases and controls.  This may be a particular problem if 
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having the disease results in more accurate recall of exposures or if the disease or its treatment affects 
memory and thus limits the accurate recall of exposures.  In addition, with retrospective exposure 
collection in case-control studies, identifying the appropriate exposure window for a disease may be 
challenging.  While recall of crude measures of certain exposures, such as ever versus never, may be 
more accurate for participants, and thus less susceptible to exposure misclassification, lack of detail on 
dosage or duration and timing of the exposure may result in null findings if data cannot be captured on 
critical periods of development when the exposure has its greatest impact on disease risk.  However, in 
our studies we were able to observe associations with ever versus never OC use suggesting that this 
exposure measure was sufficient to capture an effect on disease risk.  Information bias is also a concern 
if detailed data on these prevalent cases are unable to be obtained.  While parity [172], breastfeeding 
[173], and OC use [174,175] have been shown to be reliably self-reported, information that requires 
retrieval from hospitals or registries, such as medical records, pathology reports, or tissue samples, may 
be more difficult to obtain for prevalent cancers, particularly if they were diagnosed long before entry into 
the study.  Cancer confirmation is important in studies of second primary cancers in order to entirely rule 
out the cancer being a metastasis of the first cancer.  While all of our cases were not confirmed in our 
case-control study, when we limited our analysis to the confirmed cases we observed minimal differences 
in our results.  In addition, research has shown differences in histology, molecular characteristics, and 
survival between BR-OV and OV-BR cancers [171]; however, we were unable to examine differences by 
tumor histology or molecular characteristics given our small number of cases and missing pathology data.  
It is likely that given the rarity of second primary cancers, only large consortia will have enough power to 
assess risk of DPBOC by histology and molecular characteristics.  While they did not assess risk of 
second cancer, the Ovarian Cancer Association Consortium (OCAC) examined ovarian cancer risk 
factors by histology and showed an inverse association between OC use and serous (the largest 
histologic subtype) and clear cell ovarian cancers, but no association between OC use and endometriod 
and mucinous ovarian cancers.  While they observed an inverse association between higher parity and all 
histologic subtypes of ovarian cancer, it was most strongly associated with endometriod and clear cell 
tumors.  Lastly they observed no association between duration of breastfeeding and any histologic 
subtype of ovarian cancer [184]. 
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Selection bias is also a concern in case-control studies.  First, the selection of an appropriate 
control group can be a challenge, particularly if the source population is not clearly defined.  A proper 
control group should be a representative sample of the source population that gave rise to the cases.  In 
our case-control study the controls were unaffected family members of the cases.  While both the cases 
and controls came from families with breast and ovarian cancer, these families ranged in terms of both 
family size and number and degree of affected family members.  Additionally, family members may have 
lived in different regions of the country which may have influenced the exposure distribution between 
cases and controls.  Therefore, it is possible that the controls were not representative of the source 
population which gave rise to the cases leading to selection bias.  For example, the positive association 
between parity and DPBOC and BR in this study could have resulted from the cases joining the study due 
to a concern about the health of their children which would have led to an imbalance in the distribution of 
the exposure, parity, between cases and controls.  Second, case-control studies that use prevalent cases 
may be influenced by survivor bias if cases diagnosed farther from the baseline interview, and thus had 
longer survival before study entry, differed in the distribution of the exposure compared to cases 
diagnosed close to the baseline interview and thus had shorter survival before study entry.  Survivor bias 
may have influenced the results of our case-control study as we observed differences in our OC use and 
parity findings between the pseudo-incident and prevalent cancers. 
In the study of second primary cancers, a case-case design may limit some of the selection and 
information bias concerns common to case-control designs discussed above.  For example, using a case-
case design in our study, both the case groups (BR-OV and OV-BR) and referent groups (OV and BR, 
respectively) were recruited from the same source population, and were both prevalent cancers 
diagnosed before the baseline interview.  Therefore, selection bias resulting from the control group not 
being representative of the source population which gave rise to the cases, as well as survivor bias, 
would be minimized.  In addition, differential recall bias would be minimized as the exposure information 
was collected after a cancer diagnosis for both the case and referent groups.  In Chapter 3, case-case 
analyses were conducted as a sensitivity analysis which assessed risk of our double primary cancer 
groups compared to our single primary cancer groups.  While these findings were consistent with most of 
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our main case-control findings (an inverse association with OC use and breastfeeding, and a positive 
association with parity), there was no association between ever OC use and risk of BR-OV versus OV. 
While cohort studies are still subject to some forms of information bias, they are less likely to be 
differential with respect to the exposure and outcome as exposures are collected prior to the outcome.  
Therefore, any misclassification is likely to be non-differential which would, in general, result in estimates 
being biased towards the null.  However, in the study of second primary cancers where the cohort 
consists of women with single primary cancer being followed for the development of second primary 
cancer, such as is the case with our affected group (women with BR being followed for BR-OV), the 
exposure is collected after the first cancer diagnosis.  Therefore, recall bias may be a concern, particularly 
with varying lengths of time between cancer diagnosis and entry into the study.  In our cohort study we 
used crude measures of exposure (ever versus never for OC use and breastfeeding, and nulliparous 
versus 1 or ≥2 for parity) which would have minimized exposure misclassification but may have missed 
critical levels where exposure has the greatest impact on disease risk.  For instance, we were unable to 
replicate the finding of an inverse association between parity and breast cancer risk which may have 
been detected if we were able to include more categories of full-term births (e.g., ≥4 full-term births).  With 
prospective cohort studies, the ability to collect updated exposure and outcome data can reduce 
information bias, specifically for exposures and outcomes that can change over time, and it may be easier 
to examine specific exposure windows of disease risk if exposures are able to be updated prospectively.  
In the study of second primary cancers, exposure assessment can be a challenge as there are several 
times at which exposures can be assessed, such as at baseline, before the first cancer, or over time.  In 
our cohort study we had baseline and follow-up data and were able to create time-varying covariates for 
our exposures that could change over time.  To evaluate the influence of exposure assessment at 
different time points we conducted sensitivity analyses looking at just the baseline values and, for our BR-
OV group, we truncated our exposures to the age of breast cancer diagnosis, rather than the age at 
baseline interview used in our main analyses; overall we observed minimal differences in our results.   
 Selection bias in cohort studies can occur with loss to follow-up.  If individuals who are lost to 
follow-up differ in terms of the distribution of the exposure and outcome compared to individuals who 
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remain in the study, then the results will be biased either towards or away from the null.  In the study of 
second primary cancers, cohort studies are also subject to survivor bias if the cohort consists of cancer 
survivors who are being followed prospectively for the development of a second primary cancer with 
varying lengths of time between diagnosis of the first cancer and the baseline interview.  We observed 
differences in the association between OC use and risk of BR-OV when we stratified by pseudo-incident 
versus prevalent cancers, suggesting that survivor bias may have influenced these results.  One way 
cohort studies examining second primary cancers can avoid this is to enroll newly-diagnosed cancers so 
that the baseline interview can be conducted close to the diagnosis for all participants. 
Another challenge for cohort studies examining second primary cancers is to determine the 
appropriate follow-up start time.  Follow-up start time could occur from birth, age of the first primary 
cancer diagnosis, or age at the baseline interview, and may be analysis-specific.  For instance, if the 
study is designed to assess risk of second primary cancer in a cohort of women with a first primary 
cancer, then age at first primary cancer diagnosis may be the appropriate follow-up start time.  However, 
if the study is designed to assess risk of a particular cancer (either first primary or second primary) in a 
cohort of women with our without a first primary cancer, then birth or age at interview may be the 
appropriate follow-up start time as everyone in the cohort will not have an age at diagnosis to start from.  
In our study we used different follow-up start times for our different analytic groups.  For the BR-OV group 
we used age at breast cancer diagnosis but for the OV and BR groups we used age at baseline interview.  
In our sensitivity analysis where we combined the BR-OV and OV cohorts we used age at baseline 
interview as not everyone had an age at breast cancer diagnosis.  Therefore, it is important to consider 
the follow-up start time when comparing results across studies. 
The main challenge of cohort studies with examining second primary cancers is the ability to 
collect a sufficient number of cases with this outcome which has a long latency period.  Therefore, the 
decision to design a case-control or a cohort study is often a question of precision versus validity.  While 
case-control studies can capture more cases thus allowing for examination of a wider exposure range, 
and ultimately improving precision, information and selection bias may question their validity.  Cohort 
studies, on the other hand, are less subject to information and selection bias which improves validity, but 
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may lack a sufficient number of cases affecting their precision, or lack detailed exposure data.  However, 
as the exposures are collected prior to the outcome, temporality can be established and recall bias is less 
of a concern.  While national population-based cancer registries, such as those in Denmark and Sweden, 
are ideal for capturing a large number of events, they often lack detailed exposure data.  The ProF-SC 
study was uniquely designed to circumvent this lack of precision issue that cohort studies often face by 
enrolling breast and ovarian cancer families enriched for increased family risk.  This cohort design 
enhances the potential for rare events, thereby increasing precision, while still capturing detailed 
exposure data.  However, we still had an insufficient sample of OV-BR cases to assess this outcome and 
were likely underpowered to evaluate effect measure modification by lifetime risk.   
Following the results of this dissertation, future work will focus on clarifying the discordant findings 
we observed between OC use, parity, and breastfeeding and risk of DPBOC in our studies by trying to 
replicate findings in another cohort where women are enrolled soon after their first cancer diagnosis, as 
well as examining the relation between other potentially modifiable risk factors and risk of DPBOC.  In 
addition, future directions of this research will examine DNA methylation and risk of DPBOC as no studies 
were identified in this area.  Breast and ovarian cancer have been found to have a 38% overlap in 
hypermethylated genes [76], showing that in addition to shared risk factors and genetics, breast and 
ovarian cancer also have shared epigenetics.  Being able to identify epigenetic changes in the blood of 
women before they develop cancer could improve risk prediction models and clinical recommendations.  
We have already begun data collection in the BCFR to examine DNA methylation in the plasma of women 
affected with breast cancer who prospectively develop ovarian cancer (BR-OV) and unaffected women 
who prospectively develop ovarian cancer (OV). 
With a growing population of cancer survivors, identifying women at greatest risk of developing a 
second primary cancer is critical.  As breast cancer survivors are the largest group of cancer survivors in 
the country, understanding risk factors for the development of a second primary ovarian cancer is 
necessary as ovarian cancer has a high fatality rate.  As there is no effective screening tool for ovarian 
cancer, being able to identify women at greatest risk of a second primary ovarian cancer may impact 
prophylactic surgery recommendations.  Further, if potentially modifiable risk factors are identified, clinical 
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recommendations can be made for these women to improve primary prevention.  As we identified a 
potential discordant effect of OC use on risk of second primary ovarian cancer versus first primary ovarian 
cancer, further work is needed to replicate this finding as OCs are commonly prescribed as a 
chemopreventive agent to women at high risk of ovarian cancer.  Our results also suggest differences in 
risk factor associations by underlying risk of breast and ovarian cancer.  Identifying risk factors for second 
primary cancer that may differ for women at high risk versus women at average risk is important for 
accurate clinical recommendations and personalized medicine.  The results of this dissertation highlight 
the challenges of studying second primary cancers and methodological limitations of different study 
designs.  Some of our results may have been influenced by survivor bias and future cohort studies should 
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Appendix A: Supplemental Tables for Chapter 3 
  
Supplemental Table 3.1.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping excluding cancer diagnoses prior to date of breast/ovarian cancer 
diagnosis for cases and date of interview for controls, Breast Cancer Family Registry 
 DPBOC BR OV 




























2.37 (0.46, 7.93) 
6.15 (3.01, 16.53) 
 
1.0 
2.21 (1.74, 2.76) 
2.30 (1.88, 2.73) 
 
1.0 
1.53 (0.74, 2.86) 










0.80 (0.70, 0.92) 
 
1.0 
0.79 (0.55, 1.13) 






*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main exposures 
  
Supplemental Table 3.2.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping excluding proxies, Breast Cancer Family Registry 
 DPBOC BR OV 




























2.44 (0.37, 7.00) 
4.47 (1.73, 11.31) 
 
1.0 
2.31 (1.84, 2.94) 
2.31 (1.89, 2.80) 
 
1.0 
1.35 (0.63, 2.72) 










0.76 (0.66, 0.88) 
 
1.0 





*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main exposures  
  
Supplemental Table 3.3.  Risk of developing both breast and ovarian cancer, only breast cancer, 
and only ovarian cancer using unordered polytomous logistic regression with clustered 
bootstrapping excluding imputed menopausal status values, Breast Cancer Family Registry 
 DPBOC BR OV 












0.57 (0.33, 1.04) 
 
1.0 
0.77 (0.68, 0.87) 
 
1.0 







2.55 (0.40, 7.40) 
4.39 (1.70, 11.14) 
 
1.0 
2.37 (1.87, 3.05) 
2.26 (1.84, 2.74) 
 
1.0 
1.40 (0.66, 2.93) 










0.76 (0.66, 0.88) 
 
1.0 
0.83 (0.51, 1.26) 
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Supplemental Table 3.4. Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping excluding BOADICEA-imputed BRCA1/2 mutation values, Breast 
Cancer Family Registry 
BRCA1/2 Status Negative 
 DPBOC BR OV 












0.54 (0.23, 1.41) 
 
1.0 
0.77 (0.66, 0.91) 
 
1.0 







2.68 (0.00, 20.24) 
1.83 (0.30, 13.73) 
 
1.0 
2.28 (1.72, 3.04) 
2.03 (1.64, 2.57) 
 
1.0 
1.10 (0.30, 2.68) 





0.99 (0.30, 4.69) 
1.0 
0.75 (0.64, 0.90) 
1.0 
0.63 (0.34, 1.16) 
BRCA1/2 Status Positive 











0.95 (0.43, 2.42) 
 
1.0 
0.99 (0.69, 1.50) 
 
1.0 







2.39 (0.00, 13.90) 
7.19 (2.34, 42.92) 
 
1.0 
2.52 (1.15, 5.47) 
3.06 (1.54, 5.93) 
 
1.0 
2.26 (0.40, 10.45) 






0.39 (0.14, 1.08) 
 
1.0 
0.74 (0.51, 1.33) 
 
1.0 
1.15 (0.50, 4.26) 
 






Supplemental Table 3.5.  Risk of developing both breast and ovarian cancer, only breast cancer, 
and only ovarian cancer using unordered polytomous logistic regression with clustered 
bootstrapping excluding bilateral oophorectomies and mastectomies occurring prior to the date 
of breast/ovarian diagnosis for cases and date of interview for controls, Breast Cancer Family 
Registry 
 DPBOC BR OV 












0.39 (0.23, 0.63) 
 
1.0 
0.65 (0.57, 0.74) 
 
1.0 







2.64 (0.57, 7.34) 
6.00 (2.67, 14.24) 
 
1.0 
2.33 (1.83, 2.94) 
2.40 (1.95, 2.85) 
 
1.0 
1.31 (0.61, 2.44) 










0.79 (0.69, 0.93) 
 
1.0 
0.84 (0.58, 1.23) 





Supplemental Table 3.6.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping including only confirmed cases, Breast Cancer Family Registry 
 DPBOC** BR OV 












0.99 (0.35, 3.74) 
 
1.0 
0.86 (0.73, 1.00) 
 
1.0 







<0.01 (<0.01, 3.67) 
10.80 (2.39, >999) 
 
1.0 
2.21 (1.66, 2.89) 
2.27 (1.77, 2.80) 
 
1.0 
1.36 (0.35, 3.80) 










0.75 (0.64, 0.89) 
 
1.0 
1.04 (0.55, 1.91) 
*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main exposures 





Supplemental Table 3.7. Risk of developing both breast and ovarian 
cancer and only ovarian cancer using unordered polytomous logistic 
regression with clustered bootstrapping including only epithelial 
ovarian cancer cases, Breast Cancer Family Registry 
 DPBOC OV 
Exposure Multivariable model* (Cases n=30) 
Multivariable model* 
(Cases n=70) 







0.84 (0.32, 2.23) 
 
1.0 







<0.01 (<0.01, <0.01) 
10.56 (2.79, 66.46) 
 
1.0 
1.38 (0.34, 4.12) 






0.34 (0.12, 0.88) 
 
1.0 
1.10 (0.56, 2.02) 
*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and 
other main exposures 
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Supplemental Table 3.8. Risk of developing both breast and ovarian 
cancer and only breast cancer using unordered polytomous logistic 
regression with clustered bootstrapping excluding in situ breast 
cancers, Breast Cancer Family Registry 
 DPBOC BR 
Exposure Multivariable model* (Cases n=84) 
Multivariable model* 
(Cases n=2,008) 



















2.05 (0.39, 6.29) 
5.59 (2.68, 13.60) 
 
1.0 
2.38 (1.84, 3.01) 






0.51 (0.31, 0.90) 
 
1.0 
0.79 (0.69, 0.92) 
*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and 















*Adjusted for age, menopausal status, alcohol consumption, BCFR 
site, and other main exposures
Supplemental Table 3.9.  Risk of developing both breast 
and ovarian cancer using unordered polytomous logistic 
regression with clustered bootstrapping excluding 
synchronous cases, Breast Cancer Family Registry 
 DPBOC 
Exposure Multivariable model* (Cases n=72) 
 OR (95% CI) 












3.35 (0.59, 13.92) 






0.54 (0.31, 1.04) 
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Supplemental Table 3.10.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping, Breast Cancer Family Registry 
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 (1.95, 2.80) 
1.89 






 (0.99, 2.54) 
1.44 
 (0.94, 2.16) 




*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main exposures 
 
Supplemental Table 3.11.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping stratified by 10-year risk of breast and ovarian cancer, Breast 
Cancer Family Registry 
Breast/Ovarian Cancer Risk <20% 
 DPBOC BR OV 




























1.73 (<0.01, 8.05) 
3.69 (1.39, 13.32) 
 
1.0 
2.08 (1.62, 2.73) 
1.97 (1.68, 2.57) 
 
1.0 
1.15 (0.46, 2.45) 










0.99 (0.75, 1.03) 
 
1.0 
1.09 (0.63, 1.38) 
Breast/Ovarian Cancer Risk ≥20% 
 DPBOC BR OV 




























5.19 (<0.01, 43.50) 
11.42 (4.28, 84.53) 
 
1.0 
2.98 (1.33, 5.67) 
3.77 (1.97, 6.34) 
 
1.0 
1.46 (0.16, 5.85) 










0.51 (0.35, 0.85) 
 
1.0 




Supplemental Table 3.12. Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping stratified by tertiles of number of first and second degree relatives, 
Breast Cancer Family Registry 
<14 First and Second Degree Relatives 
 DPBOC BR OV 












0.77 (0.30, 2.65) 
 
1.0 
1.03 (0.80, 1.31) 
 
1.0 







0.74 (<0.01, 5.42) 
2.03 (0.41, 8.53) 
 
1.0 
2.08 (1.41, 3.19) 
1.79 (1.25, 2.64) 
 
1.0 
1.51 (0.25, 5.56) 





0.54 (0.11, 2.63) 
1.0 
0.84 (0.63, 1.19) 
1.0 
0.75 (0.27, 2.07) 
14-20 First and Second Degree Relatives 











0.53 (0.17, 1.64) 
 
1.0 
0.74 (0.59, 0.91) 
 
1.0 







10.71 (0.01, >999) 
10.19 (2.07, >999) 
 
1.0 
2.19 (1.42, 3.08) 
1.81 (1.30, 2.41) 
 
1.0 
0.79 (0.15, 2.31) 






0.55 (0.18, 1.74) 
 
1.0 
0.74 (0.58, 0.97) 
 
1.0 
0.94 (0.50, 2.51) 
>20 First and Second Degree Relatives 











0.42 (0.16, 0.97) 
 
1.0 
0.53 (0.40, 0.64) 
 
1.0 







<0.01 (<0.01, 3.46) 
4.26 (0.59, >999) 
 
1.0 
2.10 (1.30, 3.76) 
2.97 (1.96 4.58) 
 
1.0 
1.97 (0.49, 10.79) 






0.54 (0.17, 2.35) 
 
1.0 
0.67 (0.52, 0.85) 
 
1.0 
0.64 (0.33, 1.05) 







Supplemental Table 3.13. Risk of developing both breast and ovarian cancer, only 
breast cancer, and only ovarian cancer using unordered polytomous logistic regression 
with clustered bootstrapping stratifying by center, Breast Cancer Family Registry 
Philadelphia 
 DPBOC BR OV 












0.20 (0.07, 0.46) 
 
1.0 
0.47 (0.37, 0.59) 
 
1.0 







4.92 (0.71, 30.91) 
3.90 (1.29, 21.21) 
 
1.0 
2.14 (1.36, 3.45) 
2.54 (1.79, 3.62) 
 
1.0 
1.38 (0.36, 4.61) 





0.36 (0.12, 0.88) 
1.0 
0.85 (0.67, 1.09) 
1.0 
0.57 (0.33, 1.01) 
New York 











0.42 (0.19, 0.86) 
 
1.0 
0.72 (0.62, 0.85) 
 
1.0 







0.59 (<0.01, 3.72) 
3.74 (1.06, 17.91) 
 
1.0 
2.13 (1.59, 2.77) 
2.10 (1.66, 2.65) 
 
1.0 
1.25 (0.43, 2.71) 






1.06 (0.48, 2.80) 
 
1.0 
0.83 (0.70, 1.00) 
 
1.0 
1.31 (0.78, 2.33) 
Utah 











0.60 (0.15, 3.09) 
 
1.0 
0.54 (0.34, 0.70) 
 
1.0 







<0.01 (<0.01, 31.01) 
25.44 (5.75, >999) 
 
1.0 
3.92 (1.89, 9.59) 
3.77 (1.80, 7.46) 
 
1.0 
<0.01 (<0.01, 1.47) 






0.18 (0.05, 0.81) 
 
1.0 
0.62 (0.39, 1.04) 
 
1.0 
0.70 (0.29, 4.48) 
















Supplemental Table 3.14.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping by time since last parity, Breast Cancer Family Registry 















































 (<0.01, 1.83) 
0.55 









 (0.32, 2.71) 
3.28 







 (1.20, 1.92) 
2.23 















*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main exposures 
  
Supplemental Table 3.15. Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping by time between menarche and first parity, Breast Cancer Family 
Registry 








































































 (0.37, 0.54) 
0.91 











 (0.52, 1.55) 
1.24 








Supplemental Table 3.16. Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping stratified birth cohort, Breast Cancer Family Registry 
 Born before 1930 (aged ≥45 in 1975) 
 DPBOC BR OV 












1.26 (0.23, 4.42) 
 
1.0 
0.87 (0.50, 1.51) 
 
1.0 







1.40 (<0.01, >999) 
2.82 (0.63, >999) 
 
1.0 
1.34 (0.56, 3.28) 
0.99 (0.48, 1.97) 
 
1.0 
0.74 (<0.01, 4.95) 






0.80 (0.26, 2.28) 
 
1.0 
1.46 (1.01, 2.12) 
 
1.0 
1.53 (0.81, 3.27) 
 Born between 1930 and 1960 (aged 15 to 45 in 1975) 











0.69 (0.36, 1.45) 
 
1.0 
0.73 (0.61, 0.86) 
 
1.0 







1.93 (0.30, 8.35) 
3.37 (1.51, 10.62) 
 
1.0 
1.77 (1.32, 2.35) 
1.82 (1.41, 2.26) 
 
1.0 
0.98 (0.41, 2.06) 






0.39 (0.21, 0.79) 
 
1.0 
0.61 (0.51, 0.73) 
 
1.0 
0.72 (0.47, 1.15) 
 Born after 1960 (≤15 in 1975) 











0.06 (<0.01, >999) 
 
1.0 
0.91 (0.63, 1.24) 
 
1.0 







<0.01 (<0.01, 3.12) 
<0.01 (<0.01, <0.01) 
 
1.0 
1.81 (0.96, 2.91) 
1.44 (0.81, 2.15) 
 
1.0 
1.66 (<0.01, 7.61) 






0.50 (<0.01, 902.96) 
 
1.0 
0.83 (0.57, 1.44) 
 
1.0 
0.42 (0.08, 2.71) 





Supplemental Table 3.17. Risk of developing both breast and ovarian cancer compared to 
only breast cancer or only ovarian cancer using unordered polytomous logistic regression 
with clustered bootstrapping stratified birth cohort, Breast Cancer Family Registry 















































  1.50 (0.33, 4.39) 
2.68 (1.19, 6.73) 
 
1.0 
2.69 (0.52, 10.05) 







<0.01 (<0.01, 1.66) 






0.61 (0.35, 1.06) 
 
1.0 






0.79 (0.25, 3.45) 




Supplemental Table 3.18. Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping in parous women by duration of OC use pre- and post-first parity, 
Breast Cancer Family Registry 
OC use pre-pregnancy only 
 DPBOC BR OV 





 OR (95% CI) OR (95% CI) OR (95% CI) 








0.24 (0.06, 0.48) 




0.50 (0.41, 0.61) 




0.28 (0.13, 0.47) 
0.23 (0.04, 0.44) 
OC use post-pregnancy 
 DPBOC BR OV 





 OR (95% CI) OR (95% CI) OR (95% CI) 








0.33 (0.11, 0.64) 




0.51 (0.40, 0.60) 




0.25 (0.11, 0.43) 
0.35 (0.18, 0.52) 
 
*Adjusted for age, breastfeeding, menopausal status, alcohol consumption, and BCFR site  
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Supplemental Table 3.19. Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping in women who have used oral contraceptives by duration of use, 
Breast Cancer Family Registry 
OC use ≥ 5 years 
 DPBOC BR OV 












3.24 (<0.01, >999) 
3.63 (1.05, >999) 
 
1.0 
2.23 (1.45, 3.33) 
1.80 (1.21, 2.55) 
 
1.0 
2.31 (0.38, 19.03) 
2.07 (0.51, 14.87) 
OC use < 5 years 
 DPBOC BR OV 











2.67 (<0.01, >999) 
3.37 (<0.01, >999) 
 
1.0 
2.46 (1.63, 3.86) 
3.06 (2.06, 4.30) 
1.0 
0.65 (<0.01, 2.95) 
0.80 (0.23, 2.73) 
 





*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main exposures 
 
Supplemental Table 3.20.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping stratified by treatment, Breast Cancer Family Registry 
Any chemotherapy, radiotherapy, hormone therapy 
 DPBOC BR OV 












0.51 (0.25, 1.08) 
 
1.0 
0.87 (0.74, 1.00) 
 
1.0 







1.00 (<0.01, 8.44) 
5.18 (1.41, 43.57) 
 
1.0 
2.44 (1.86, 3.19) 
2.27 (1.80, 2.85) 
 
1.0 
1.21 (0.32, 3.29) 






0.78 (0.33, 2.39) 
 
1.0 
0.72 (0.61, 0.86) 
 
1.0 
0.82 (0.45, 1.44) 
Surgery only 
 DPBOC BR OV 












0.31 (0.10, 0.82) 
 
1.0 
0.45 (0.36, 0.53) 
 
1.0 







1.23 (<0.01, 9.84) 
4.71 (0.86, 49.97) 
 
1.0 
2.13 (1.36, 3.21) 
3.20 (2.14, 4.58) 
 
1.0 
0.83 (<0.01, 3.59) 






0.91 (0.31, 3.26) 
 
1.0 
1.00 (0.78, 1.29) 
 
1.0 
1.18 (0.51, 4.95) 
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Supplemental Table 3.21.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping stratified by time since diagnosis, Breast Cancer Family Registry 
Time Between Diagnosis and Interview ≤2 years** 
 DPBOC BR OV 




























2.43 (0.09, 64.26) 
0.90 (0.04, 20.32) 
 
1.0 
1.44 (1.05, 1.97) 
1.33 (1.02, 1.74) 
 
1.0 
1.24 (0.48, 3.18) 






0.73 (0.06, 8.73) 
 
1.0 
0.98 (0.79, 1.20) 
 
1.0 
0.83 (0.46, 1.49) 
Time Between Diagnosis and Interview >2 years** 
 DPBOC BR OV 




























2.39 (0.68, 8.45) 
5.10 (2.05, 12.68) 
 
1.0 
3.29 (2.49, 4.36) 
3.38 (2.68, 4.28) 
 
1.0 
1.51 (0.56, 4.08) 






0.55 (0.30, 1.00) 
 
1.0 
0.65 (0.55, 0.77) 
 
1.0 




*Adjusted for age, menopausal status, alcohol consumption, BCFR site, and other main exposures 
**Non-proxies only 
 
Supplemental Table 3.22.  Risk of developing both breast and ovarian cancer, only breast 
cancer, and only ovarian cancer using unordered polytomous logistic regression with 
clustered bootstrapping stratified by time since diagnosis, Breast Cancer Family Registry 
Time Between Diagnosis and Interview ≤5 years** 
 DPBOC BR OV 












0.97 (0.24, 7.25) 
 
1.0 
0.99 (0.84, 1.16) 
 
1.0 







0.98 (<0.01, 6.43) 
1.14 (<0.01, 10.27) 
 
1.0 
1.87 (1.40, 2.45) 
1.55 (1.20, 1.93) 
 
1.0 
1.10 (0.40, 2.51) 






0.53 (0.07, >999) 
 
1.0 
0.93 (0.78, 1.11) 
 
1.0 
0.89 (0.50, 1.52) 
Time Between Diagnosis and Interview >5 years** 
 DPBOC BR OV 












0.47 (0.25, 0.84) 
 
1.0 
0.49 (0.40, 0.58) 
 
1.0 







3.65 (<0.01, 18.27) 
7.50 (2.46, 31.60) 
 
1.0 
3.10 (2.27, 4.73) 
4.22 (3.12, 5.79) 
 
1.0 
2.28 (0.42, 9.19) 






0.55 (0.27, 1.22) 
 
1.0 
0.58 (0.47, 0.71) 
 
1.0 
0.76 (0.35, 1.56) 
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Supplemental Figure 3.1. Percent of both breast and ovarian cancer cases, only breast cancer 
cases, and only ovarian cancer cases at high risk versus low risk of breast or ovarian cancer by 




*High risk defined as having a 10-year breast or ovarian cancer risk greater than or equal to 20% 






Supplemental Table 3.23. Number of cases per group for Table 2 









Exposure N Cases N Cases N Cases N Cases N Cases 






































































































































Appendix B: Supplemental Tables for Chapter 4 
 
Supplemental Table 4.1. Hormonal and reproductive factors and risk of BR-OV, OV, and BR using 
Cox proportional hazards with baseline variables, ProF-SC 
  
 BR-OV OV BR 
 Model 1* Model 2** Model 1* Model 2** Model 1* Model 2** 

































  HR (95% CI) 
HR (95% 
CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Oral 
Contraceptive 
Use       
Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 












Number of FT 
Pregnancies       
Nulliparous 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
























Never  1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 











*Regression models conditional on birth cohort; hazard ratios include all main exposures (OC use, 
number of FT pregnancies, and breastfeeding) 
**Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, 
age at menarche, menopausal status, BMI, height, education, cigarette use, alcohol consumption, 
hormone replacement therapy, and all main exposures 
***Age is the time-scale 
 141 
 
Supplemental Table 4.2. Hormonal and reproductive factors and risk of BR-OV using Cox 
proportional hazards with variables truncated to the age at diagnosis of the first primary breast 
cancer, ProF-SC  
BR-OV 
Model 1* Model 2** 
Exposure Events (n = 68) Person-time*** (111,152 py) 
Events (n = 68) 
Person-time*** (111,152 py) 
HR (95% CI) HR (95% CI) 
Oral Contraceptive 
Use   
Never 1.00 (Ref) 1.00 (Ref) 
Ever 1.32 (0.75, 2.33) 1.57 (0.88, 2.80) 
Number of FT 
Pregnancies   
Nulliparous 1.00 (Ref) 1.00 (Ref) 
1 0.84 (0.36, 1.98) 0.88 (0.37, 2.11) 
≥2  0.63 (0.31, 1.30) 0.59 (0.29, 1.21) 
Breastfeeding 
Never 1.00 (Ref) 1.00 (Ref) 
Ever 1.27 (0.70, 2.30) 1.25 (0.70, 2.23) 
*Regression models conditional on birth cohort; hazard ratios include all main exposures (OC use, 
number of FT pregnancies, and breastfeeding) 
**Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, 
age at menarche, menopausal status, BMI, height, education, cigarette use, alcohol consumption, 
hormone replacement therapy, and all main exposures 




Supplemental Table 4.3. Hormonal and reproductive factors and risk of BR-OV and BR using Cox 
proportional hazards excluding in situ breast cancers, ProF-SC  
  BR-OV BR 
  Multivariable Model* Multivariable Model* 
Exposure 
Events (n = 64) 
Person-time** (103,539 py) 
Events (n = 646) 
Person-time** (145,052 py) 
  HR (95% CI) HR (95% CI) 
Oral Contraceptive 
Use     
Never 1.00 (Ref) 1.00 (Ref)
Ever 1.51 (0.84, 2.72) 1.17 (0.96, 1.43)
      
Number of FT 
Pregnancies     
Nulliparous 1.00 (Ref) 1.00 (Ref)
1 Child 0.59 (0.23, 1.56) 0.96 (0.68, 1.35)
≥2 Children 0.45 (0.21, 0.94) 0.96 (0.73, 1.26)
      
Breastfeeding     
Never  1.00 (Ref) 1.00 (Ref)
 Ever 1.40 (0.74, 2.68) 1.01 (0.82, 1.24)
 
*Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, 
age at menarche, menopausal status, BMI, height, education, cigarette use, alcohol consumption, 
hormone replacement therapy, and all main exposures 






Supplemental Table 4.4. Comparison of Cox proportional hazards and Poisson regression results, ProF-SC 
  
BR-OV OV BR 
  Cox PH Poisson Cox PH Poisson Cox PH Poisson 












Events (n = 68) 
Person-time** 
(111,152 py) 
Events (n = 68) 
Person-time** 
(111,152 py) 
Events (n = 68)
Person-time** 
(133,712 py) 
Events (n = 68) 
Person-time** 
(133,712 py) 
Events (n = 748)
Person-time** 
(145,052 py) 
Events (n = 748)
Person-time** 
(145,052 py) 
  HR (95% CI) RR (95% CI) HR (95% CI) RR (95% CI) HR (95% CI) RR (95% CI) 
Oral Contraceptive Use  
Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Ever 1.62 (0.91, 2.90) 1.53 (0.85, 2.74) 0.59 (0.34, 1.00) 0.56 (0.15, 2.14) 1.14 (0.95, 1.38) 1.04 (0.54, 2.02) 
  
Number of FT 
Pregnancies       
Nulliparous 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
1 0.64 (0.26, 1.62) 0.65 (0.26, 1.62) 0.56 (0.17, 1.81) 0.68 (0.03, 15.15) 0.98 (0.72, 1.32) 1.23 (0.40, 3.77) 
≥2 0.47 (0.22, 0.97) 0.49 (0.22, 1.06) 1.02 (0.44, 2.38) 1.33 (0.16, 10.99) 0.88 (0.68, 1.13) 1.21 (0.47, 3.11) 
  
Breastfeeding 
Never  1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
 Ever 1.37 (0.74, 2.56) 1.38 (0.72, 2.65) 1.05 (0.56, 1.98) 0.98 (0.19, 5.01) 1.05 (0.86, 1.27) 0.98 (0.48, 2.01) 
 
*Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, age at menarche, menopausal status, BMI, 
height, education, cigarette use, alcohol consumption, hormone replacement therapy, and all main exposures 





Supplemental Table 4.5. Hormonal and reproductive factors and risk of BR-OV, OV, and BR by 
BRCA1/2 status, ProF-SC 
BRCA1/2 Positive 
BR-OV OV BR 
Exposure Multivariable Model* Multivariable Model** Multivariable Model* 
  
Events (n = 23) 
Person-time**  
(6,550 py) 
Events (n = 17) 
Person-time**  
(4,188 py) 
Events (n = 101) 
Person-time**  
(5,457 py) 
  HR (95% CI) HR (95% CI) HR (95% CI) 
Oral Contraceptive 
Use    
Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Ever 2.10 (0.80, 5.48) - 1.23 (0.68, 2.22) 
  
Number of Full-
Term Pregnancy    
Nulliparous 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
1 0.50 (0.07, 3.86) - 2.66 (1.19, 5.91) 
≥2 0.25 (0.05, 1.19) - 1.17 (0.65, 2.14) 
  
Breastfeeding 
Never  1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
 Ever 3.12 (0.82, 11.80) - 0.68 (0.39, 1.18) 
BRCA1/2 Negative 
  Events (n = 45) 
Person-time** 
(104,602 py) 
Events (n = 51) 
Person-time**  
(129,524 py) 
Events (n = 647) 
Person-time**  
(139,595 py) 
  HR (95% CI) HR (95% CI) HR (95% CI) 
Oral Contraceptive 
Use    
Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Ever 1.33 (0.66, 2.70) 0.79 (0.43, 1.45) 1.16 (0.95, 1.42) 
  
Number of Full-
Term Pregnancy    
Nulliparous 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
1 0.60 (0.20, 1.75) 0.28 (0.06, 1.31) 0.92 (0.66, 1.27) 
≥2 0.48 (0.20, 1.12) 0.70 (0.27, 1.79) 0.84 (0.64, 1.10) 
  
Breastfeeding 
Never  1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
 Ever 1.02 (0.48, 2.15) 1.30 (0.59, 2.87) 1.06 (0.87, 1.30) 
*Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, 
age at menarche, menopausal status, BMI, height, education, cigarette use, alcohol consumption, 
hormone replacement therapy, and all main exposures 
**Age is the time-scale 
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Supplemental Table 4.6. Hormonal and reproductive factors and risk of BR-OV stratified by time 






















*Regression models conditional on birth cohort; hazard ratios adjusted for study center, race/ethnicity, 
age at menarche, menopausal status, BMI, height, education, cigarette use, alcohol consumption, 
hormone replacement therapy, and all main exposures 
**Age is the time-scale 
Time Between Diagnosis and Interview ≤2 years* 
 BR-OV 
Exposure Multivariable model* 
 (Events n=40) Person-time** (60,084 py) 
 HR (95% CI) 





1.07 (0.51, 2.25) 






0.85 (0.26, 2.80) 






1.43 (0.59, 3.48) 
  
Time Between Diagnosis and Interview >2 years* 
 BR-OV 
Exposure Multivariable model* 
  (Events n=28) Person-time** (51,068 py) 
 HR (95% CI) 





2.82 (1.16, 6.88) 






0.34 (0.06, 1.88) 






1.38 (0.55, 3.51) 
